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Cancer’s a Funny Thing*
I wish I had the voice of Homer
To sing of rectal carcinoma,
Which kills a lot more chaps, in fact,
Than were bumped off when Troy was sacked.
Yet, thanks to modern surgeon’s skills,
It can be killed before it kills
Upon a scientific basis
In nineteen out of twenty cases…
JBS Haldane, 1964
*the complete 72 line poem is in this thesis on page 169
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tage is Set: 
Now the Screenplay
Colorectal cancer is a major public health problem. In the Netherlands in 2005 
colorectal cancer was newly diagnosed in 10,851 persons, ranking it third after 
prostate and lung cancer in males and second after breast cancer in females and the 
incidence is still rising (www.ikcnet.nl). In 2003 colorectal cancer was responsible 
for more than 56,000 life years lost and for 70,000 disability adjusted life years in 
the Netherlands. Total annual costs for management of colorectal cancer patients 
amounted to 230 million euros.1 
Survival for colorectal cancer is dependent on the stage of the tumour and ranges 
from over 90% to as little as 10%. Without mass screening, colorectal cancer is usually 
detected as a result of symptoms, with a rather poor average 5-year survival of 
50% to 60% (www.ikcnet.nl). Studies from different countries have confirmed that 
colorectal cancer screening reduces mortality at favourable costs compared with 
breast cancer and cervical cancer screening.2-4 
In 2001 the Dutch Health Council recommended the design of studies to investigate 
the feasibility of colorectal cancer screening in the Netherlands.5 In 2003 the European 
Commission wrote a council recommendation for colorectal cancer screening.6 In the 
same year, a number of research questions for the Dutch situation were formulated 
in the COCAST report.7 In 2006 the Minister of Health promulgated a policy letter to 
inform the government of his planning for the actual implementation of a nationwide 
colorectal cancer screening programme.8 At a consensus meeting in 2005, it was 
concluded that colorectal cancer fulfils almost all major requirements to allow 
population-based screening in the Netherlands according to the Wilson & Jugner 
guidelines.9 However before a nationwide screening programme could be implemented 
still several questions needed to be answered, to a certain extent specifically for the 
Dutch situation. 
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Outline
In this thesis 11 questions comprised in 6 chapters are addressed 
Chapter 1: Willingness-to-be-screened.
Question 1. Are the Dutch aware of colorectal cancer and screening? 
Question 2. Are the Dutch ‘willing-to-be-screened’ for colorectal cancer? 
Question 3. Do willing subjects participate and what about the unwilling?
Chapter 2: Which tests and why. 
Question 4. Which tests are available for population-based colorectal cancer 
screening and what is the performance of these tests?
Question 5. What is the performance of the Hemoccult-II®, guaiac based faecal 
occult blood test, compared with the OC-Sensor®, immunochemical faecal occult 
blood test, in a screening population?
Chapter 3: Mortality. 
Question 6. Is colorectal cancer mortality expected to decrease by FOBT screening 
compared with no screening? 
Question 7. Is colorectal cancer mortality expected to decrease more by iFOBT 
screening than by gFOBT screening compared with no screening?
Chapter 4: Cost-effectiveness. 
Question 8. Is screening with FOBT cost-effective compared with no screening?
Question 9. Is screening with iFOBT cost-effective compared with gFOBT screening?
Chapter 5: Cut-off value for iFOBT positivity.
Question 10. How does the performance of the iFOBT relate to the cut-off value?
Chapter 6: Quality control.
Question 11. Is stability of haemoglobin in the faecal sample of the iFOBT 
sufficient?
Stage is Set: Now the Screenplay
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Chapter 1: 
illingness-to-be-
screened
Question 1.
Are the Dutch aware of colorectal cancer and screening?
Question 2.
Are the Dutch ‘willing-to-be-screened’ for colorectal cancer?
Question 3.
Do willing subjects participate and what about the unwilling?
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Abstract
Introduction To assess future attendance, the association between willingness-to-
be-screened and subsequent participation in colorectal cancer screening should be 
clear. We have studied previously reported willingness-to-be-screened followed by 
participation in population-based colorectal cancer screening.
Methods In October 2005, randomly 500 Dutch subjects aged 50-75 years received 
a questionnaire with concerning willingness-to-be-screened for colorectal cancer with 
a ‘simple faecal test’. One year later they were invited for colorectal cancer screening. 
The association between willingness-to-be-screened and actual participation was 
calculated with risk ratios and 95% confidence intervals(95%CI).
Results Of 500 subjects, 42 were not invited for screening; 25 were too old, 3 had 
colorectal cancer, 3 died, 4 had a colonoscopy and 7 for other reasons. Eventually 
338(74%) filled-out the questionnaire and were invited for screening of whom 86% 
participated in screening. Participation was 89% in willing-to-be-screened compared 
with 76% in unwilling-to-be-screened (RR 1.2 95%CI 1.0-1.3) and much lower but still 
quite substantial with 41% in 120 non-responders to the survey (RR 2.2; 95%CI 1.8-2.7). 
Conclusion Participation was higher in subjects willing-to-be-screened compared 
with subjects unwilling-to-be-screened. Participation of non-responders was significantly 
lower compared with responders, however quite considerable. Therefore unresponsive 
subjects should not be excluded from screening. 
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Introduction
The participation in colorectal cancer screening is lower than participation in mass 
screening for other forms of cancer.1 Several countries have already implemented 
colorectal cancer screening or population-based studies on colorectal cancer screening, 
and participation in screening can differ quite extensively between countries and 
depends on the methods of screening.2-6 The participation rates in these studies hardly 
ever exceed 60% of the population, which is far from optimal and only achieved with 
immunochemical faecal occult blood tests.2 To increase the uptake of colorectal 
cancer screening new approaches are needed, which might focus on individual 
characteristics and preferences by means of tailored interventions.7,8 Preceding the 
design and implementation of these new approaches to improve participation in 
screening, the base line support of screening in the population should be assessed as 
well as health characteristics that might determine the uptake of colorectal cancer 
screening. With this information subgroups with less uptake can be identified, to 
assist in personally tailored interventions and to focus on groups with the least 
anticipated uptake. 
However the evaluation of baseline colorectal cancer screening support, by measuring 
actual participation in colorectal cancer screening in large population-based studies, 
consumes much time and draws many resources. The assessment of willingness-to-
be-screened instead of de facto participation seems a much more attractive approach 
to measure baseline support of colorectal cancer screening and the characteristics 
associated with this support.9-13 Also it could enable to focus interventions to 
increase the uptake of colorectal cancer screening on subjects who will benefit most 
from these intervention.7 The advantages of evaluating willingness-to-be-screened 
before the invitation for actual screening are quite clear, still the association between 
willingness-to-be-screened and subsequent participation has never been determined. 
A few studies have been performed concerning willingness-to-be-screened and 
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participation.14,15 However in one of these studies willingness-to-be-screened was 
not assessed prior to inviting subjects to participate in screening.14 In the other study 
preferences for screening were assessed prior to screening, but no active invitation 
for colorectal cancer screening was performed and subjects not interested in 
screening were excluded from follow-up to enquire if colorectal cancer screening was 
performed after 6 months.15 Therefore the association between previously assessed 
willingness-to-be-screened and subsequent participation in colorectal cancer 
screening still remains unclear. We aimed to study willingness-to-be-screened and 
subsequent participation in colorectal cancer screening.
Methods
Population
In October 2005, randomly 500 Dutch subjects aged 50-75 years were invited to 
fill-out a questionnaire. One year later, in October 2006, independent of the response 
to the survey, all subjects were invited for colorectal cancer screening with a faecal 
occult blood test (FOBT). In the invitation we advised subjects with increased risk 
for colorectal cancer, like subjects with IBD or familiar risk of colorectal cancer, with a 
history of colorectal cancer, with a recent colonoscopy and with complaints indicating 
an increased risk of colorectal cancer (e.g. rectal bleeding), not to participate in 
colorectal cancer screening and to contact their physician. All subjects who had 
moved or had become 75 years or older after the survey was sent, were excluded 
from the final analysis. 
Questionnaire
The questionnaire consisted of 46 items respectively regarding: socio-economic 
status (3 items), general perceived health (1 item), awareness of colorectal cancer 
Chapter 1
~20~
and screening related issues (21 items), the main source of information for health 
developments (1 item), cancer related anxiety (2 items), willingness-to-be-screened 
for colorectal cancer with a ‘simple faecal test’ (1 item), possible reasons for being 
not or less willing-to-be-screened (1 item), treatment preferences (3 items). Subjects 
were considered relatively aware of colorectal cancer and screening related issues if 
they answered ≥14 (≥65%) of the 21 items concerning awareness of colorectal 
cancer and screening related issues correctly. The first item concerning willingness-
to-be-screened for colorectal cancer with a ‘simple faecal test’ had 4 options: ‘yes’, 
‘possibly’, ‘no’, ‘do not know’. A subject was defined willing-to-be-screened only if the 
answer was ‘yes’ and subsequently unwilling-to-be-screened if the answer was 
‘possibly’, ‘no’ or ‘do not know’. The second item concerned a multiple-choice item 
consisting of 13 possible non-excluding reasons why a subject might be less interested 
to be screened for colorectal cancer (mainly behaviour and test related issues). Non-
responders to the first invitation, received one single written reminder.
Screening with immunochemical faecal occult blood testing
All subjects who were sent the questionnaire, one year later also received an invitation 
to perform an immunochemical faecal occult blood test (iFOBT). Non-responders to 
the first invitation to participate in colorectal cancer screening with iFOBT, received 
one single written reminder. In this study the automated semi-quantitative iFOBT, 
OC-Sensor® (Eiken Chemical Co. Ltd., Tokyo, Japan), was used and the subjects were 
invited to take one faecal sample on a single day with bowel movement. The subjects 
were informed of the exclusion criteria and, if applicable, asked not to participate, to 
seek advice from their physician and to record the reason for not participating on 
their consent form. After taking the faecal sample they were asked to return the 
sample as soon as possible. The faecal samples, preserved in a plastic container in a 
liquid buffer, were processed with the OC-Micro instrument (Eiken Chemical Co. Ltd., 
Tokyo, Japan).16 All subjects gave written informed consent.
Willingness-to-be-screened
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Outcome measures and analysis
The association between willingness-to-be-screened and actual screening participation 
was calculated with risk ratios and 95% confidence intervals(95%CI). Influence of other 
health related characteristics were analysed with logistic regression: with a significance 
level of 0.15 possible risk factors were identified. Eventually a p-value <0.05 was 
accepted as statistically significant in multivariate logistic regression analysis to study 
risk factors associated with willingness-to-be-screened and participation in colorectal 
cancer screening.
Results
Survey
The 500 invited subjects had a mean age of 61.4 ± 7.1 years (SD), 50% (n=250) were 
male. The results of the responders to the survey are presented in table 1. Of the 366 
(73%) subjects who filled-out the questionnaire, 225 (61%) responded before the 
written reminder. Willingness-to-be-screened was reported by 270 (74%), whereas 
the 96 (26%) subjects unwilling-to-be-screened, comprised 12 (3%) who answered 
‘no’, 25 (7%) who answered ‘possibly’ and 59 (16%) who answered ‘do not know’. Of 
the subjects who reported willing-to-be-screened 66% responded before the written 
reminder compared with 48% of the subjects unwilling-to-be-screened (RR 1.4; 95%CI 
1.1-1.7). Of the subjects willing-to-be-screened 43% had a relatively high income 
compared with 31% of the subjects unwilling-to-be-screened (RR 1.4; 95%CI 1.0-1.9). 
Of the subjects willing-to-be-screened 26% was relatively aware of colorectal cancer 
and screening related issues compared with 15% of the subjects unwilling-to-be-
screened (RR 1.8; 95%CI 1.1-3.0). Of the subjects willing-to-be-screened 63% were 
worried about getting colorectal cancer compared with 34% of the subjects unwilling-
to-be-screened (RR 1.9; 95%CI 1.4-2.5). With multivariate logistic regression analysis 
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relative awareness (p=0.01), worry about getting cancer (p<0.0001) and quick 
responders to the survey (i.e. before the reminder) (p<0.05) were independent 
factors with statistically significantly increased willingness-to-be-screened. 
Table 1. Subject characteristics of all responders to the survey, by willingness-to-be-screened in 
colorectal cancer screening with iFOBT and relative risk ratios for willingness-to-be-screened. 
 Willing-to-be-screened Non-responders 
 Yes (N=270) No (N=96)   (N=134) 
 N (%)1 N (%)1 RR2 95%CI  
      
Responded before the reminder 179 (66%) 46 (48%) 1.4 1.1-1.7 n.a. 
      
Male gender 141 (52%) 40 (42%) 1.3 1.0-1.6 53% 
Above median age (>60 years) 137(51%) 50(52%) 1.0 0.8-1.2 60% 
Married or living together 226(84%) 77(80%) 1.0 0.9-1.2 n.a. 
High education 94 (35%) 29 (30%) 1.2 0.8-1.6 n.a. 
High income 117 (43%) 30 (31%) 1.4 1.0-1.9 n.a. 
Good Perceived health  185 (71%) 67 (71%) 1.0 0.9-1.2 n.a. 
      
Aware of colorectal cancer 70 (26%) 14 (15%) 1.8 1.1-3.0 n.a. 
      
Colorectal cancer anxiety 168 (63%) 31 (34%) 1.9 1.4-2.5 n.a. 
      
Excluded for screening 22(8%) 6(6%)   14(10%) 
      
Invited for screening 248 90   120 
      
Participation 222(90%) 68 (76%) 1.2 1.0-1.3 49(41%) 
n.a.= data not available 
1Percentages were calculated relative to all responders willing or unwilling-to-be-screened. 
2Statistically significant results are presented in bold type face 
Participation in colorectal cancer screening with iFOBT
Of the initially 500 subjects who were sent the survey 42 had to be excluded and 
therefore were not invited to participate in colorectal cancer screening: 25 were over 
75 years of age by October 2006, 5 had cancer (3 had colorectal cancer and 1 patient 
with colorectal cancer had died and 1 was terminal), 3 subjects died of other causes, 
4 had a colonoscopy and 2 subjects were incapable to participate and finally 3 had 
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moved (figure 1). Therefore 458 subjects were sent an iFOBT and an invitation to 
participate in colorectal cancer screening, of whom 338 (74%) had filled-out a 
questionnaire one year earlier and 339 (74%) participated by returning a faecal 
sample. Willingness-to-be-screened was reported by 248 (73%), and 90 (27%) 
subjects were unwilling-to-be-screened.
Screening participation was 86% in all subjects who filled-out the questionnaire. 
Participation was 90% in the willing-to-be-screened compared with 76% in the 
unwilling-to-be-screened (RR 1.2; 95%CI 1.0-1.3) (table 1). In the 90 subjects unwilling-
to-be-screened, 12 subjects had reported ‘not’ willing-to-be-screened but 83% (n=10) 
did actually participate in iFOBT screening, of the remaining 78 subjects who had 
reported ‘do not know’ or ‘possibly’ willing-to-be-screened 74% (n=58) participated 
in iFOBT screening. Compared with 41% participation in the non-responders the partici-
pation was higher in both the willing-to-be-screened (RR 2.2; 95%CI 1.8-2.7) and in the 
subjects who reported unwilling-to-be-screened ( RR 1.9; 95%CI 1.4-2.4). 
Screening population 50-75 years of age
Random selection: 500  
Yes: 366Response to the survey No: 134
Yes: 270Reported willing-to-be-screened: No: 96 Not applicable: 134
22Excluded for participation in 
l t l i
6 14
co orec a  cancer screen ng:
>75 years, died, moved, (colorectal) 
cancer, recent colonoscopy, incapable
248Invited to participate in colorectal 
cancer screening
90 120
Participation in colorectal 
cancer screening with iFOBT 222 68 49
Figure 1. Flow diagram for the two parts of the study.
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With univariate logistic regression analysis with a significance level of 0.15 we 
identified possible risk factors other than willingness-to-be-screened associated 
with participation: overall response to the survey (p<0.0001), quick response to the 
survey (p<0.001), awareness (p=0.06), relatively good or very good perceived 
health (p<0.05), and age (p=0.01). After multivariate logistic regression analysis with 
a significance level of 0.05 besides willingness-to-be-screened only quick response to 
the survey was identified to be independently associated with participation. Overall 
response to the survey could not be analysed with multiple logistic regression analysis 
as it became redundant after implementation of survey items such as willingness- 
to-be-screened into the model as survey items were only known for responders. 
Perceived health only just did not reach statistical significance (p=0.06). 
Discussion
In this study we present that previously reported willingness-to-be-screened is 
associated with subsequent participation in colorectal cancer screening. Participation 
in screening of subjects who previously reported willing-to-be-screened was higher 
compared with subjects who previously reported not or less willing-to-be-screened. 
There was no difference in participation in the subgroups who reported not or less 
willing-to-be-screened. Notably, the participation of subjects who previously reported 
not or less willing-to-be-screened was much higher than participation of subjects 
who did not respond to the survey at all. Several factors were either associated with 
willingness-to-be-screened or subsequent actual participation. In addition to willing-
ness-to-be-screened only quick response to the survey was independently associated 
with higher participation in colorectal cancer screening. Relatively good perceived 
health was also associated with higher participation in addition to willingness-to-be-
screened, but possibly due to lack of power just missed statistical significance.
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Many studies have been performed concerning either willingness-to-be-screened or 
participation.2-6,9-13 In some studies willingness-to-be-screened and participation 
were assessed, but the willingness-to-be-screened was not assessed prior to inviting 
subjects to actually participate in screening.14,17 In these studies subjects with general 
indifference for screening showed decreased participation. We can confirm that general 
indifference for screening seems associated with lower participation: compared with 
responders to the survey, non-responders to the survey had a much lower subsequent 
participation rate in colorectal cancer screening. Willingness-to-be-screened was deter-
mined by several factors, but most commonly lack of adequate knowledge about 
colorectal cancer was observed. We can confirm that willingness-to-be-screened is 
lower in subjects who are relatively less aware of colorectal cancer or screening related 
issues compared with more aware subjects. However, we did not observe an association 
between awareness and participation. This study was performed parallel to a much 
larger population-based colorectal cancer screening study in the same region.2 Over 
20,000 screening naïve subjects were invited for colorectal cancer screening in this study 
and randomly assigned either a guaiac faecal occult blood test (gFOBT) or an immuno-
chemical faecal occult blood test (iFOBT) identical to the one in the present study.2 Al-
though awareness of colorectal cancer and screening is lowest in the Netherlands of all 
the European countries,18 the participation in the guaiac arm of the study with 47% was 
according to intention-to-screen analysis almost identical to a large population-based 
study in France.19 In the study arm randomised to the immunochemical faecal occult 
blood test in the same rural region over 1,499 subjects were invited and the iFOBT 
participation rate was 68% (95%CI 65%-70%) compared with 74% (95%CI 70%-78%) 
in the present study. The difference was statistically significant and suggests that the 
questionnaire stimulated subsequent participation. This is substantiated by the apparent 
paradox, that 76% of subjects who previously reported less or not willing-to-be-screened 
eventually participated, which was relevantly higher than the overall participation 
with iFOBT in the larger population-based study without the preceding survey.
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Only non-responders to the survey participated much less than average. Obviously 
we lack detailed data from non-responders and the only data we have available are 
age and gender, which did not significantly differ compared with the responders. In 
the larger population-based study we sent all invited subjects a questionnaire a 
few weeks after the invitation for colorectal cancer screening.20 The subjects were 
explicitly informed that the questionnaire could be filled-out and returned indifferent 
of screening participation. However only 6% of subjects who did not participate in 
colorectal cancer screening did fill-out the questionnaire, compared with 82% of 
the subjects who did participate. Except for general unresponsiveness, we have no 
indication why non-responders participated less. Still 41% of the non-responders 
in the present study did eventually participate in colorectal cancer screening as did 
83% (n=10) of subjects who reported not willing-to-be-screened. Therefore subjects 
not interested in screening should not be excluded from follow-up, as in a study 
where preferences for screening were assessed prior to screening.15 In the larger 
population-based randomised study, we observed a difference of 13% in participation 
between the gFOBT and the iFOBT. Therefore the choice of test for colorectal cancer 
screening could very well influence participation, especially in difficult to reach 
subjects. Possibly by making the test and the test procedure even more user- 
friendly than this iFOBT (OC-Sensor®) already is, by making it less awkward and 
more hygienic e.g. with a disposable faecal collection device. Also with initiatives to 
tailor the invitation for colorectal cancer screening to individual characteristics and 
preferences, the uptake of colorectal cancer screening might be increased.7,8 
It might be argued that the lower than average participation in the non-responders 
to the survey compared with the responders, could be explained by unreported 
exclusion criteria for colorectal cancer screening. All subjects were asked to provide 
additional information about individual experiences with colorectal cancer or bowel 
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research in the section for remarks in the questionnaire. Additionally in the subse-
quent invitation for participation in screening with iFOBT, the subjects were informed 
specifically about exclusion criteria for participation in colorectal cancer screening. 
Subjects with exclusion criteria were asked not to participate and to record the reason 
for not being able to participate on their consent form. Eventually the assessment of 
exclusion criteria was only incomplete for subjects who did not respond to the survey 
and did not participate in the iFOBT screening and did not return their informed consent 
form. This number was very limited and the lower participation in iFOBT screening of 
the non-responders could not be explained by unreported exclusion criteria.
Conclusion
Willingness-to-be-screened is associated with subsequent participation. In addition to 
willingness-to-be-screened also quick response to the survey and possibly relatively 
good perceived health were associated with higher participation. Participation was 
higher in subjects who reported willing-to-be-screened compared with subjects who 
reported unwilling-to-be-screened and even higher compared with non-responders 
to the survey. However the participation of non-responders was far from negligible. 
Therefore to increase participation in population-based colorectal cancer screening, 
public health initiatives should probably focus more on generally unresponsive subjects, 
than on subjects who report not or less willing-to-be-screened. 
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 Abstract
Introduction Participation in screening should be the outcome of an informed 
decision. We evaluated whether invitees in the first Dutch colorectal cancer (CRC) 
screening programme were adequately informed after having received a detailed 
information leaflet.
Methods A total of 20,623 subjects aged 50-75 years were invited to the faecal 
occult blood test (FOBT) screening programme. All received a detailed information 
leaflet by mail between May 2006 and January 2007. After two weeks, a reminder 
letter was sent to all invitees, accompanied by a survey on CRC and screening.
Results The survey was completed by 9594 invitees (47%). Almost all responders 
(99%) found the leaflet clear and readable. Almost all indicated that CRC can be treated 
better if found early (99%). Only 20% of the responders answered all knowledge- 
related answers correctly. Almost half of the responders (47%) believed that a 
negative FOBT excludes the presence of CRC. Older age and having a positive family 
member for CRC were correctly identified as risk factors by 80%.
 
Conclusion This study demonstrates that although an information leaflet was 
reported as being clear and readable, the information provided in it was not always 
understood well. This suggests that other educational options should be investigated 
in order to improve general knowledge of CRC in screening invitees.
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Introduction
Colorectal cancer (CRC) has a high incidence in the western world and it is predicted 
that the incidence will increase in the future.1-4 CRC is known to have a long asymp-
tomatic phase, which makes early detection difficult, while early lesions are far better 
treatable and lead to better prognoses.5,6 Many countries have now initiated 
population-based screening programmes. An important dilemma in screening for CRC 
is the relatively low participation rate compared with screening programmes for 
breast cancer or cervical cancer.4,7-10
There are multiple possible reasons for low participation. For this study we focused 
on knowledge as an important factor for low participation. In order to participate in 
a screening programme, invitees should be provided with adequate information. For 
an individual to make an informed choice to participate in or decline screening, the 
potential benefits, limitations and consequences of screening should be clearly 
communicated.11 Previous research has shown that high levels of knowledge are 
positively associated with participation and that a common reason for nonpartici-
pation in a screening programme is lack of awareness.12,13 An earlier study reported 
low levels of knowledge throughout Europe and especially in the Netherlands.14 
Proper education, particularly through patient decision aids, may contribute to a 
better understanding of CRC.15 
For the first screening programme in the Netherlands a detailed information leaflet 
was developed, providing information for all the screening invitees. The leaflet 
contained information on CRC and on the benefits and consequences of screening. 
This study was undertaken to evaluate whether participants of the CRC screening 
programme were adequately informed after having received the detailed information 
leaflet.
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Methods
A total of 20,623 subjects aged 50-75 years were invited to the first Dutch CRC 
screening programme between May 2006 and January 2007 from two regions in 
the Netherlands (Amsterdam and Nijmegen) representative for the average Dutch 
population. Detailed information and the results of this randomised study are reported 
elsewhere.16 A screening package was sent by mail to all those invited for screening. 
The package consisted of an information leaflet, an invitation letter and a faecal 
occult blood test (FOBT).
The 18-page leaflet contained detailed information on CRC screening and the offered 
screening test. Table 1 provides translated excerpts from the leaflet on specific issues. 
The information provided in the leaflet was similar to leaflets designed of other 
European screening trials. The primary messages highlighted in the leaflet were the 
screening programme itself, the purpose, benefits and limitations of screening, the 
risk factors associated with CRC, and instructions on how to use the FOBT. A linguistic 
expert was involved to make the leaflet clear and readable for the level of under-
standing in an average Dutch population. The leaflet was provided in the Dutch 
language only. In the leaflet it was emphasized that participants with bowel 
complaints or recent rectal blood loss should consult their general practitioner and 
they were advised not to perform the FOBT. 
Two weeks after the initial invitation a reminder letter was sent. The reminder letter 
was accompanied by a two-page survey. This survey contained 36 statements designed 
for this screening programme. For the development of the survey, a qualitative interview 
took place to learn more about the views of potential screening invitees. A total of 32 
individuals aged between 52 and 73 years completed a 20-minute interview, in which 
issues regarding screening, CRC and the FOBT were explored. The interviews were 
recorded, fully transcribed and entered into a database. A number of items were 
identified by the literature search and the interviews to correspond with the 
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information provided in the leaflet and were converted into statements for the 
survey. The invitee could either ‘agree’ or ‘not agree’ or fill in ‘not applicable’.
In the analysis, we only included items from the questionnaire related to knowledge 
about CRC and CRC screening. The analysis included one self-reported knowledge 
statement, four knowledge-related statements and three advice-related statements. 
The definition of ‘adequate knowledge’ for this study was defined as being able to 
answer the knowledge related statements of the survey correctly (Table 1). All data 
collected were analysed with SPSS version 14.0.2 (SPSS Inc, Chicago, IL, USA).
Results
The overall participation rate for the FOBT screening was 53% (n = 10,993). The survey 
was completed by 9594 invitees (47%). Of these 9594 survey responders, a total of 
8989 also returned their FOBT (94%). The mean age of responders was 62 years and 
45% were men. 
Almost all responders (99%) reported that the information in the leaflet was clear and 
readable. Table 1 contains the knowledge-related and advice-related statements of 
the questionnaire, the number of responses and the number of positive and negative 
answers. Sixty-one percent reported that they knew little about the disease colorectal 
cancer. To test adequate knowledge we analysed how many individuals answered 
the four knowledge-related statements correctly (Table 1). Twenty percent of the 
responders answered all four knowledge-related statements correctly. Eighty-seven 
percent answered three out of four statements correctly and 61% answered two out 
of four statements correctly.
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Table1 Overview of the information given in the leaflet and the questions asked two weeks after the initial 
invitation 
Information given in the leaflet* Statement in 
survey 
Response
n 
Agree
Self-reported statement I know little about 
the disease 
colorectal cancer 
9093 61% 
Knowledge-related statements 
Better treatment is possible if colorectal cancer is 
detected in an early stage. If the disease is diagnosed in 
an early stage, the survival rate is 90%. If the cancer has 
spread to other organs (metastasis), the survival rate is 
only 40%. Early detection is the best way to decrease the 
number of individuals who die of colorectal cancer 
 
 
Better treatment is 
possible if colorectal 
cancer is detected in 
an early stage 
 
 
9317 
 
 
99% 
Many individuals have polyps, but they are usually not 
malignant. It is not known why some polyps develop into 
colorectal cancer and others do not. Research has shown 
that there are a number of risk factors associated with 
colorectal cancer. Both men and women can develop 
colorectal cancer, and the risk of developing cancer is 
higher:  
-When you are 50 years or over, because the risk 
increases with age  
-If a direct family member is or was diagnosed with 
colorectal cancer or polyps 
The risk of 
developing 
colorectal cancer 
increases after the 
age of 50 yrs 
7923 79% 
 
Colorectal cancer 
can be hereditary 
 
7698 
 
80% 
The result of the FOBT  
After you performed the FOBT and sent it to our 
laboratory, you will receive a result within two weeks 
- If the result shows no traces of blood we will not invite 
you for further investigation. A test without traces of blood 
does not mean that you can be absolutely sure you do not 
have colorectal cancer or that it is not possible to develop 
colorectal cancer in the future. So, stay alert and when 
complaints occur, please notify your general practitioner 
 
A negative FOBT 
means I do not have 
colorectal cancer 
 
7975 
 
47% 
Advice-related statements 
Many individuals have polyps. Most of the individuals do 
not know they have polyps because in a lot of cases 
polyps do not give any complaints. Even if polyps are 
malignant, it can still take a long time before individuals 
notice any complaints 
If complaints do occur, it can be associated with: 
-Blood and/or mucus in the stool or rectal blood loss 
-Changed bowel habits: constipation or diarrhoea 
-Recurrent bowel complaints, usually with cramps 
-Unexplained weight loss 
 
I have noticed blood 
in my stool in the last 
three months 
 
I have experienced 
bowel complaints in 
the last three months 
 
9292 
 
 
 
9252 
 
7% 
 
 
 
16% 
Please beware: If you recognize one of the above 
mentioned complaints, this does not mean you have 
colorectal cancer, but it is important that if you have 
experienced or are currently experiencing these 
complaints to discuss this with your general practitioner 
After reading the 
leaflet I consulted 
my general 
practitioner 
2185 2% 
*The information as provided verbatim in the leaflet translated from Dutch 
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Most participants correctly answered that CRC can be treated better if found early 
(99%). Of all responders, 47% incorrectly reported that a negative FOBT (no blood in 
the stool) excludes the presence of CRC. Age older than 50 years was correctly identified 
as a risk factor for CRC by 6278 of the responders (79%). A positive family history was 
also correctly identified as a risk factor by 6159 (80%). Of the 295 responders with a first-
degree family member with CRC, 221 (75%) acknowledged an increased risk for CRC.
The leaflet recommended invitees not to perform the FOBT in case of complaints, but 
to consult their general practitioner. However of all responders who reported a recent 
change in bowel habits (n = 1500) or rectal blood loss (n = 685), only 44 responders 
(2%) had consulted their general practitioner and almost all these invitees (96%), 
returned the FOBT in contrast with the advice.
Discussion
In this study, 99% of the responders reported that the information in the leaflet 
provided in this screening programme was clear and readable. Only 20% of the 
responders answered all knowledge-related answers correctly. Most of these partici-
pants answered correctly that CRC is better treatable if found early, an observation 
that corresponds well with the fact that most (94%) in this study also participated 
in this FOBT screening programme. Nevertheless, a disturbing high proportion (47%) 
believed that a negative FOBT excluded the possibility of having CRC. The fact that the 
FOBT detects blood, and that cancer does probably not always bleed enough to be 
detected, is apparently a difficult message. Poor understanding of the FOBT could be 
harmful. A false-negative result may convey in a false sense of health, which could 
lead to a delayed diagnosis of an underlying adenoma or early cancer. Reassurance of 
people with negative FOBT results may make them more resistant to general health 
recommendations because they might interpret the test result from screening as 
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showing that they are immune to the impact of unhealthy lifestyles: a phenomenon 
described as the ‘certificate of health’ effect.17
A limitation of this study is that there is no general agreement on the definition of 
being adequately informed.18 For this study, we focused on the level of knowledge 
and measured this by being able to answer four knowledge related statements 
correctly. We cannot exclude that participants were able to verify the answers in 
the information leaflet or guessed the right answer. This could have generated an 
overestimation of correctly given answers. It is thus possible that the true number of 
responders understanding the meaning of these statements is even lower.
This study also showed that only a few responders adhered to the recommendation 
in the leaflet not to perform the FOBT and to consult their general practitioner in 
case of rectal blood loss. This may also point to a misinterpretation of the significance 
of the test result. However, it is also possible that other reasons may have been of 
influence, e.g. lack of time to consult a general practitioner.
Conclusion
Despite the information in the leaflet most individuals who returned the questionnire 
of which most also participated in the screening programme,  misunderstood the fact 
that screening is for asymptomatic people and that there are limitations to the accuracy 
of FOBT. Providing an information leaflet is not enough to communicate the benefits 
and harms of screening to those invited to a population-based screening programme. 
Literature has shown that intensifying and extending the method of information supply 
for a FOBT screening programme contributes to higher levels of knowledge.19,20 
A recently published randomised trial also found that detailed risk and benefit infor-
mation about FOBT screening contributes higher levels of informed choice.21 A high 
participation rate should not be interpreted as proof of well-informed decision-making. 
We believe that our findings should encourage us and others responsible for screening 
to find better ways of informing screening invitees.
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Chapter 2: 
hich tests and why
Question 4.
Which tests are available for population-based colorectal cancer 
screening and what is the performance of these tests?
Question 5.
What is the performance of the Hemoccult-II®, guaiac based 
faecal occult blood test, compared with the OC-Sensor®, 
immunochemical faecal occult blood test, in a screening 
population?
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Evaluation of the available colorectal 
cancer screening tests.
Which tests and why
~43~
In the first part of this chapter several alternatives for colorectal cancer screening are 
evaluated. The list is not limitative. The focus is on tests developed and validated 
sufficiently to warrant consideration for implementation in population-based colorectal 
cancer screening: guaiac faecal occult blood tests (gFOBT), immunochemical FOBTs 
(iFOBT), colonoscopy, sigmoidoscopy and virtual colonoscopy (also CT-colonography 
or ‘CT-colonoscopy’). Each is described with general information about the test, the 
performance, advantages and limitations. In table 1 an overview of available data on 
population-based screening is reported. In the last paragraph a summary is given and 
conclusions are drawn. 
Guaiac Faecal Occult Blood Tests
Guaiac Faecal Occult Blood Tests (gFOBT) were the first tests to be used for colorectal 
cancer screening, starting in the nineteen seventies.1 Basically it is a biomarker test: 
peroxidase activity of haem in haemoglobin is shown on a card impregnated with 
guaiac resin and any blue discoloration serves as a proxy for possible blood in the 
stool. Normal colon mucosa does not bleed, colorectal cancer (and to a lesser extent 
adenoma) can bleed, therefore blue discoloration should suggest an increased 
risk of colorectal cancer (and adenoma). There are certain peroxidase-rich fruits 
and vegetables (e.g., broccoli, cauliflower, radishes, turnips, and some melons) and 
haem-rich animal meat (e.g. beef and lamb) that could in theory cause false positive 
test results, but in practice this does not seem a significant problem.2 When vitamin C 
is ingested in large quantities, much more than in a normal diet, false negative results 
can not be excluded.3 The amount of haem needed for a visible blue discoloration is 
quite high, which limits the sensitivity of the gFOBT. To increase sensitivity one 
complete gFOBT consists of three cards for consecutive days of bowel movement 
and on each card two faecal samples have to be applied.4,5 However, the number of 
testing days threatens the participation in screening and still the sensitivity is not 
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high. Although the positive predictive value is acceptable for screening, the detection 
rate per round of screening is low, due to the limited sensitivity. The main advantage of 
this test is the wide implementation in screening and the fact that only for the gFOBT, 
more specifically the Hemoccult®, evidence exists that colorectal cancer mortality can 
be decreased with screening.6 The performance of different gFOBTs varies and in 
table 1 we present data from the gFOBT, Hemoccult-II®.7
Table 1. Performance characteristics of a single round with alternative tests for population based 
colorectal cancer screening. 
Performance characteristic gFOBT iFOBT100 
Colono- 
scopy 
Sigmoido- 
scopy 
Virtual  
colono- 
scopy 
Mortality Decrease CRC (%) 15%6,35 22%35 18%31 12-15% 18% 
Participation (%) 47%14 60%14 25-30%19 25-35%19, 32 24%29 
Positivity (%) 2.4%14 5.5%14 100% 11% 13% 
Colonoscopy adherence (%) 85-99%14, 33 85-99%14, 33 - 90-100%19 90-97% 
Detection rate cancer  
per protocol (%) 0.23%
14 0.39%14 0.81%19 0.59%19 0.73%19, 34 
Detection rate advanced 
adenomas  
per protocol (%) 
1.0%14 2.0%14 6.3%19 4.6%19 5.7-6.4%19, 34 
Detection rate cancer  
intention-to-screen (%) 0.11%
14 0.23%14 0.21%19 0.19%19 0.2 
Detection rate advanced 
adenomas  
intention-to-screen (%) 
0.4%14 1.6%14 1.7%19 1.5%19 1.5 
PPV for cancer (%) 11%14 9%14 0.81%19 0.59%19 0.73%19, 34 
PPV for advanced adenomas (%) 45%14 43%14 6.3%19 4.6%19 5.7-6.4%19, 34 
Sensitivity cancer 28%14, 19 48%14, 19 95-100%15 85%19, 23 90-97%15, 34 
Specificity cancer 98%14 96%14 7019 85%19 65%19, 34 
Sensitivity advanced adenomas 17% 33% 90-100%16 70-80%16, 19 90-97%15, 34 
Specificity advanced adenomas 99%14 98%14 75%19 9019 70%19, 34 
Number Needed To Screen 
to find cancer intention-to-screen 936
14 43014 46319 55219 500 
Number Needed To Scope 
(Virtually) to find cancer 9
14 1214 12319 18719 154 
Costs estimate per CRC case # €7,986 €7,469 €55,181 €75,100 €46,366 
Population sensitivity impact^  
cancer (%) 13%
14, 19 29%14, 19 25%19 18%19 21% 
Population sensitivity impact^ 
advanced adenomas (%) 8%
14, 19 19%14, 19 20%19 20%19 18% 
Italic: completely no data available, (mostly) for virtual colonoscopy; data were estimated in 
accordance with endoscopy 
^Population Sensitivity Impact = Participation * Colonoscopy Adherence * Sensitivity (intention-to-
screen) 
#Colonoscopy costs set at €445, sigmoidoscopy costs set at €385, virtual colonoscopy €280 (Nza: 
http://ctg.bit-ic.nl/Nzatarieven/top.do), cost for gFOBT were €9.05 and for iFOBT €8.25 (chapter 4). 
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Immunochemical Faecal Occult Blood Tests
A new generation of faecal occult blood tests has been developed: immunochemical 
FOBTs (iFOBT). Basically the iFOBT also tests for the biomarker blood as a proxy for 
increased risk of colorectal cancer, but uses the globin part of haemoglobin enabling 
tests specific for human blood. The iFOBTs are more sensitive for blood compared 
with gFOBTs.8,9 Because of the higher sensitivity many iFOBTs can be limited to one 
day testing instead of 3 days with gFOBT, although many alternative iFOBTs exists with 
more days of consecutive testing. Usually the design of the test results in a more 
convenient test than the gFOBT card test.10 Combined with one day testing, the more 
convenient iFOBT could result in higher participation compared with both gFOBT 
screening and (virtual) endoscopy screening. The detection rate of colorectal cancer 
and precursor lesions (adenomas) is very good for an indirect test.11 The positive 
predictive value (PPV) of the iFOBT is equal to the gFOBT and the specificity is good. 
The performance between iFOBTs can vary extremely.12 In table 1 we present data 
from the iFOBTs, OC-Sensor® and Magstream®, which have been used in several 
countries and studies in population-based colorectal cancer screening.9,11,13 One of 
the great advantages of these iFOBTs is that they are semi-quantitative tests, allowing 
the choice of a cut-off value with optimal results serving local circumstances. Data 
presented are for the standard cut-off values as recommended by the manufacturer 
and used in most current literature.
Although in the literature the iFOBT seems to perform better compared with 
the gFOBT, randomised controlled trials in screening populations have not been 
performed. In this thesis a randomised trial, comparing the iFOBT, OC-Sensor®, with 
the gFOBT, Hemoccult-II® is presented in the next part of this chapter.14 Data from 
that study have already been applied in table 1 to achieve a more balanced idea of 
the available data.
Chapter 2
~46~
Colonoscopy
There is consensus that colonoscopy, although it is not perfect, should be considered 
the gold standard for diagnosis of colorectal cancer and to consider colonoscopy as 
primary screening test is understandable. The specificity of colonoscopy with biopsy 
is generally reported to be 99 percent or 100 percent: this assumes that all detected 
conditions and polyps represent true-positive results. Furthermore the sensitivity of 
colonoscopy for cancer and especially adenoma is not 100%.15,16 Colonoscopy is a 
very invasive test and, although most studies on complications for colonoscopy concern 
more vulnerable (older, symptomatic and clinical) patients compared with (presumed 
healthy) screening subjects, limited but sometimes serious complications and even 
death can occur.17,18 There are other reasons not to use colonoscopy as primary 
screening test as for example the high costs, but one of the most important reasons: 
participation is lower than all the screening alternatives described.19-21 Since colono-
scopies are performed with sedation, the low participation can partly be attributed to 
bowel preparation, which is experienced as a huge burden.22 Although one of the 
more frequent types of cancer, colorectal cancer is still quite rare and therefore many 
persons have to have a colonoscopy to find one person with cancer compared with 
colonoscopy in subjects with an abnormal FOBT. In addition, colonoscopy screening 
requires much more endoscopists than presently available in the Netherlands.
Sigmoidoscopy
Sigmoidoscopy is an endoscopic procedure similar to colonoscopy, with advantages 
and limitations. A sigmoidoscopy requires only limited bowel preparation, usually has 
fewer complications and can be performed quicker than a colonoscopy. By definition 
it is limited to the rectum, sigmoid and descending colon, but it is considered for primary 
screening because 60% of all colorectal cancers occur in that distal part of the colon 
(Dutch Cancer Registry Data). Adenomas in the distal part of the colon predict a higher 
risk of adenomas or cancer in the proximal part of the colon. However many patients 
Which tests and why
~47~
with proximal colorectal cancer have no adenomas in the distal part of the colon and 
would therefore be missed with sigmoidoscopy screening.23 Furthermore all subjects 
with (advanced) adenomas in the distal part of the colon still have to have a colonoscopy 
to examine the proximal colon. Therefore with sigmoidoscopy screening in total more 
persons will undergo endoscopy than in primary colonoscopy screening, with a rele-
vantly higher miss-rate for colorectal cancer and adenomas. In the Netherlands there 
is a slight difference in costs between sigmoidoscopy and colonoscopy. Therefore the 
costs of sigmoidoscopy screening are only little lower than primary colonoscopy 
screening. Furthermore participation in sigmoidoscopy screening is about as low as in 
colonoscopy screening.19
Virtual colonoscopy
Similar to sigmoidoscopy screening, virtual colonoscopy is considered for primary 
screening to decrease the number of colonoscopies and because bowel preparation can 
be limited. However, many of the disadvantages of sigmoidoscopy also hold true for 
virtual colonoscopy, but with an extra disadvantage: radiation.24 Although radiation can 
in the future be limited to as little as 2-3 mS, still virtual colonoscopy should be consi-
dered an invasive test and as such has limited use in primary screening.25 Furthermore 
between 7% and 30% of the patients still have to undergo a colonoscopy, depending 
on the extent of follow-up of lesions detected during virtual colonoscopy. The extra- 
colonic findings are another disadvantage of virtual colonoscopy, which can have 
considerable implications for the patient. This ethical dilemma has been debated only 
circuitously, and can also cause a considerable increase of costs with a low return.26,27
Conclusion
Although the sensitivity of colonoscopy and sigmoidoscopy and also virtual colonoscopy 
is quite high for screened persons, participation in colorectal cancer screening with 
colonoscopy, sigmoidoscopy and virtual colonoscopy is consistently low.19,28,29 
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Screening programmes with FOBTs have much better participation. Although different 
iFOBTs do not have identical performance, overall the iFOBT performs better than the 
gFOBT. The specificity of the iFOBT is slightly lower, but more importantly the sensitivity 
is much higher. Furthermore the participation in iFOBT screening can be much higher, 
because these tests can be designed to be used much more hygienic and can usually 
be limited to one day testing.10 
To account for misbalance between participation and sensitivity the population- 
sensitivity-impact statistic was designed, i.e. participation rate * adherence to 
colonoscopy * sensitivity. The population-sensitivity-impact (PSI) is an outcome that 
represents the proportion of the population with the condition of interest 
(i.e. cancer and/or advanced adenomas) that will be detected with one round 
of screening. The PSI of iFOBT screening for cancer is higher and for advanced 
adenomas is equal or higher compared with the alternatives (table 1). The other 
important outcome in colorectal cancer screening is the number-needed-to-scope 
which in this case means the number of colonoscopies that have to be performed to 
find one person with cancer (or advanced adenomas). All endoscopy alternatives 
require huge numbers of endoscopies (real or virtual), to be performed in comparison 
with iFOBT. Therefore also the costs of (virtual) endoscopy screening are extremely 
high compared with iFOBT. Also (virtual) endoscopy and gFOBT are qualitative 
tests and a great additional advantage of the iFOBTs (mainly OC-Sensor® and 
Magstream®) is that they are semi-quantitative. The optimal cut-off value to serve 
local circumstances can be chosen, which will be discussed in detail in chapter 5. In 
conclusion due to the issues of proportionality (i.e. the invasiveness of the procedure 
should be in proportion to the relevance of reaching the goal) and subsidiarity 
(i.e. no less invasive test may exist to reach the same result or goal) the iFOBT should 
be preferred over the other alternatives.30
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Abstract
Introduction Despite poor performance, guaiac based faecal occult blood tests (gFOBT) 
are most frequently implemented for colorectal cancer (CRC) screening. Immuno-
chemical faecal occult blood tests (iFOBT) are claimed to perform better, without 
randomised comparison in screening populations. Our aim was to randomly compare 
gFOBT with iFOBT in a screening population. 
 
Methods Population-based study on a random sample of 20,623 individuals 50-75 
years of age, randomised to either gFOBT (Hemoccult-II®) or iFOBT (OC-Sensor®). 
Tests and invitations were sent together. For iFOBT (OC-Sensor®) the standard cut-off 
of 100ng/ml was used. Positive FOBTs were verified with colonoscopy. Advanced 
adenomas were defined as ≥10mm, high grade dysplasia or ≥20% villous component.
Results 10,993 tests were returned: 4,836 (46.9%) gFOBTs and 6,157 (59.6%) iFOBTs. 
The participation rate difference was 12.7% (p<0.01). Of gFOBTs 117 (2.4%) were positive 
versus 339 (5.5%) of iFOBTs. The positivity rate difference was 3.1% (p<0.01). CRC and 
advanced adenomas were found in respectively 11 and 48 of gFOBTs and in 24 and 
121 of iFOBTs. Differences in positive predictive value (PPV) for CRC and, advanced 
adenomas and CRC were respectively -2.1% (p=0.4) and -3.6% (p=0.5). Differences in 
specificities favor gFOBT and were respectively -2.3% (p<0.01) and -1.3% (p<0.01). 
Differences in intention-to-screen detection rates favor iFOBT and were respectively 
0.1% (p<0.05) and 0.9% (p<0.01). 
Conclusions The positive predictive value for cancer was comparable between 
FOBTs. However, participation and detection rates for advanced adenomas and cancer 
were significantly higher for iFOBT. gFOBT significantly underestimates the prevalence 
of advanced adenomas and cancer in the screening population compared with iFOBT.
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Introduction
More than 30 years ago guaiac based faecal occult blood tests (gFOBT) to screen for 
colorectal cancer were introduced.1,2 A gFOBT is a relatively inexpensive test, easy to 
use, which can be carried out at home. However, gFOBTs are not specific for human 
blood and quality control on the evaluation of the tests, is hardly possible.3 Despite 
these disadvantages, the gFOBT is still the most implemented test for colorectal cancer 
(CRC) screening.4-9 
A promising alternative are the immunochemical faecal occult blood tests (iFOBTs), 
which are also cheap and not invasive, and easier to carry out than gFOBTs. Another 
advantage of iFOBTs is that they are specific for human blood. The most prominent 
advantage is that many iFOBTs make quality control possible. At least in theory they 
promise better diagnostic performance than gFOBTs. In several studies iFOBTs also 
seem to have higher specificity compared with gFOBTs.10-14
In order to demonstrate that iFOBTs have improved diagnostic performance, the tests 
should be compared with gFOBTs in a randomised design in a general screening popu-
lation. Up to now, direct comparison has only been performed in subjects 
at higher risk for CRC, like subjects with a positive gFOBT, symptomatic patients 
or patients already diagnosed with CRC.15-19 Also some studies focused on test 
performance parameters of both gFOBT and iFOBT by asking people to perform both 
tests at the same time, but such an approach may have negative impact on participation 
rates.20-23 Another study comparing gFOBT with iFOBT was performed in a non- 
randomised design and the specific iFOBT used (!nform®) was not semi-quantitative, 
did not allow quality control and had to be performed on two days with separate 
bowel motions.10 In the present study, we aimed to randomly compare the test 
performance parameters of the Hemoccult-II® gFOBT with the OC-Sensor® iFOBT in a 
screening population.
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Methods
Population
The population in this prospective study was a random selection of the general 
Dutch population between 50 and 75 years of age in Nijmegen and Amsterdam and 
surrounding areas. Population data with respect to date of birth, gender and postal 
area were provided by the civil service of the municipalities and updated every 
eight weeks to keep the database up to date with respect to moving, age, and death. 
Institutionalized and symptomatic people were excluded. Symptomatic people were 
advised to contact their physician. 
Randomization, invitation and participation
From the municipal databases, random samples were taken according to postal address 
and randomised to receive a gFOBT or an iFOBT. If more than one individual was listed 
on the same address they received the same test, to ensure relative blinding to the 
alternative test. Deviation from an equal distribution of the test allocation was 
prevented by an especially designed randomization program. From June 2006 to 
February 2007 randomised individuals received the allocated test, immediately with 
the invitation, an information brochure, a consent form and a freepost envelope. The 
information brochure was designed in accordance with brochures used in other 
countries and provided concise background information for CRC-screening and follow-
up examination in case of a positive FOBT. Phone numbers to help desks in the 
two screening areas were given as well as links to informative websites. The only 
intervention to raise participation was a single written reminder two weeks after 
the initial invitation. The time for adherence, i.e. the time between invitation and 
returning the test was unrestricted. Time for adherence was only restricted by closing 
of the study at May first 2007, after which time only follow-up was completed.
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Faecal Occult blood tests
In this study two FOBTs were compared. The most commonly implemented gFOBT, 
Hemoccult-II® (Beckman Coulter, Fullerton, CA, USA) was used. For the iFOBT an 
automated semi quantitative immunochemical faecal occult blood test: OC-Sensor® 
(Eiken Chemical Co. Ltd., Tokyo, Japan) was chosen in order to allow quality control. 
No diet instructions were given and people were instructed to prevent contact of 
feces with toilet bowl water and urine and not to perform the test if visible blood 
was present. Illustrations as well as written instructions and examples aided in faecal 
sampling. To assure consistent testing quality, two especially trained laboratory 
workers analysed all FOBTs in one gastroenterlogy research laboratory in Nijmegen. 
A complete Hemoccult-II® test consists of three separate cards. With that six applicator 
sticks, a collecting envelope and written instructions were sent. Each card should be 
used on a consecutive day with defecation and on each card two samples of different 
parts of the defecation should be applied with a separate applicator stick. People 
were instructed to put all three test cards in a supplied collecting envelope and to 
return it as freepost. The cards were not rehydrated.24 If the test was performed 
incorrect or less then 3 cards were returned, new test cards were sent with an 
explaining letter how to avoid the incorrectness. Incomplete tests were rare and 
almost always due to applying the stool on the wrong side of the card. Positivity was 
defined as blue discoloration of any of the 6 stool samples within 30 to 60 seconds 
after applying the developing solution. Ninety-nine percent of the tests were developed 
within 6 days. Tests were stored according to manufacturer instructions.
The OC-Sensor® test consisted of a single sampling tube and written instructions. 
The sampling tube, filled with stabilizing buffer, had an integrated faecal probe. 
Participants were instructed to scrape different parts of the surface of their 
defecation with the probe. The amount of feces which can be inserted into the 
sample bottle is regulated to approximately 10 mg.14 Participants were instructed to 
return the test as soon as possible, since lasting exposition to room temperature 
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might result in degradation of haemoglobin in the sampling solution.13 If the 
test could not be returned immediately, storage in a refrigerator was advised. In the 
laboratory, tests were immediately developed or stored at 4º C. Of the tests, 75% 
were developed within 2 days and 99.6% within 6 days. Samples were processed by the 
OC Micro instrument (Eiken Chemical Co. Ltd., Tokyo, Japan).14 All patients with an iFOBT 
≥50 ng haemoglobin per ml sample solution (ng/ml) were invited for colonoscopy. 
Since the manufacturer recommends a cut off of 100 ng/ml (corresponding to ±20μg 
haemoglobin/gram feces14), and since this cut-off value has been applied in several 
studies,25-30 we decided beforehand to use the 100 ng/ml cut-off level in the analysis 
of this study. 
Colonoscopy and lesions
Colonoscopy was offered to all FOBT positive patients. All colonoscopies were per-
formed by experienced gastroenterologists using conscious sedation with midazolam. 
If the cecum could not be reached at the initial colonoscopy the procedure was 
repeated using propofol anesthesia, and occasionally a CT-colonoscopy was performed 
followed by a second colonscopy if necessary. If possible, all observed neoplasias 
were removed, and other lesions were biopsied if necessary. Lesions were classified 
as pedunculated or sessile polyps, carcinoma or other lesions and recorded in 
number, size (≤5, 6 to 9 or ≥10mm) and location [proximal (cecum to splenic flexure) 
or distal (descending colon to rectum)]. Histology was evaluated by an experienced 
pathologist and graded as carcinoma, tubular adenoma, tubulo-villous adenoma, 
villous adenoma, serrated adenoma, hyperplastic polyp or miscellaneous. Polyp size 
was measured by the endoscopist. Advanced adenomas were defined as adenomas 
≥10mm, with high grade dysplasia or with a villous component ≥20%.31 All early and 
late complications of colonoscopy were recorded. All colonoscopies were completed 
in May 2007.
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Data Analysis
The participation rate was calculated as the number of persons returning a FOBT 
relative to the number of invitations sent. The positivity rate was calculated as the 
number of persons with a positive FOBT (positives) relative to the number of persons 
returning a FOBT. In screening studies usually only the detection rate of true positives 
relative to the number of persons actually participating by returning a FOBT are 
presented, i.e. detection rate according to per-protocol analysis. We will also present 
the detection rate according to intention-to-screen analysis, i.e. the number of true 
positives relative to the number of invited persons. By determining the intention-to-
screen detection rate, the difference in participation and performance are combined 
in one overall rate. The number needed-to-screen to find one true positive was 
calculated as the number of invited persons relative to the number of true positives. 
The positive predictive value (PPV) was calculated as the number of true positives 
relative to the total number of positives followed-up by colonoscopy. The number 
needed-to-scope to find one true positive was calculated as the number of endoscopies 
relative to the number of true positives. 
The specificity was calculated under the rare disease assumption, as 1 minus the 
number of false positives relative to the total number of participants reduced by the 
number of true positives, disregarding false FOBT negative patients (negatives).32 In 
relatively rare diseases overestimation of the specificity, due to disregarding false 
negatives, will be limited to the confidence interval of the true specificity. A small 
decrease in specificity in mass screening can be clinically relevant as this would result 
in many more colonoscopies. Therefore we only present the specificity for advanced 
adenomas and cancer and discuss the precision of the estimation in the discussion.
Rates and rate differences of participation, positivity, detection, PPV and specificity 
were calculated and all percentages were reported with 95% confidence intervals 
(95%CI). Rate differences are statistically significant if the confidence interval does 
not include zero. Statistically significant differences are supplemented with p-values. 
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In the tables statistically significant differences were put in bold. If more than one 
lesion was present, a patient was classified by the most advanced lesion. As such, 
were classified from more to less severe: from carcinoma, to at least one adenoma 
≥10 mm, to ≥3 small adenomas. With adjusted logistic regression analysis the 
influence of gender and age on the performance of the tests was evaluated. Statistical 
analysis and randomization were performed with SAS system for windows, software 
version 8.02 (SAS Institute Inc., Cary, NC, USA).
Power was based on the lowest expected difference of all subgroups, i.e. difference in 
detection rate, for CRC between FOBTs. Based on literature data a minimal difference of 
0.3% in CRC detection was expected. With a 6083 sample size in each group, a two group 
chi-square test with a 0.05 two-sided significance level would have 80% power to detect 
a 0.3% difference between FOBTs, assuming detection rates of 0.2% for gFOBT and 0.5% 
for iFOBT. A sample size of 10,000 in each group was considered to be sufficient. 
Ethical approval and consent
The study was ethically reviewed and approved by the Dutch Health Council 
(2005/03WBO, The Hague, The Netherlands). All participants gave written informed 
consent for the FOBT and if positive for colonoscopy. 
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Results
Population
Overall 20,623 individuals were invited of which 10,301 received a gFOBT and 10,322 
an iFOBT (figure 1). The mean age of the invited individuals was 60.7 ± 7.1 years 
(mean±SD) and was not different between the FOBT groups. More women than men 
were randomly selected with a difference of 3.4% (95% CI: 2.5 to 4.4, p<0.01). After 
test allocation, gender differences remains equal for both tests (table 1). 
Exclusion:
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gFOBT
10,301
invitation
4,836
46.9% (46.0-47.9)
participation
117
2.4% (2.0-2.9)
positive test
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no follow-up
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Figure 1. Flow chart from invitation to detection with numbers
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Tests were returned by 10,993 individuals, 4,836 (46.9%) in the gFOBT group and 6,157 
(59.6%) in the iFOBT group. The difference of 12.7% (95% CI: 11.3 to 14.1, p<0.01) was 
statistically significant. Time for adherence, after correction for three day testing for 
gFOBT and one day testing for iFOBT, was on average longer for gFOBT (21 days) than for 
iFOBT (19 days) (p<0.01). For 75% of the participants time for adherence was within 28 
and 23 days, respectively (p<0.01) and for <1% of both FOBTs >100 days  (p=0.2). 
Of the gFOBT participants 117 (2.4%) tested positive and 339 (5.5%) of the iFOBT 
participants, with a difference of 3.1% (95%CI: 2.3 to 3.8, p<0.01) (figure 1 and 
table 3). Of the female participants 190 (3.1%), and of the male participants 266 (5.4%) 
were positive, with a difference of 2.3% (95%CI: 1.6 to 3.1, p<0.01). Of the participants 
≤60 years, 172 (3.2%) and of the participants ≥60 years 283 (5.1%), were positive, 
with a difference of 1.9% (95% CI: 1.2 to 2.7, p<0.01). The age of one iFOBT participant 
was unknown. Age and gender were equally distributed over both FOBTs (table 1). 
Colonoscopy results 
To evaluate the outcome in the 456 FOBT positives, a colonoscopy was performed 
in 383 (84%). The cecum was reached in 358 patients (94%). In patients in whom the 
cecum was not reached during the initial colonoscopy a successful second colonoscopy 
was performed under propofolol anesthesia. In the 383 patients endoscoped, a total 
of 35 cancers and 899 polyps were found (table 2). 
Table 1. Characteristics of invited persons and participants according to test with 95% confidence 
interval. 
 Invited (n=20,623) Participants (n= 10,993) 
 gFOBT 
(n=10,301) 
iFOBT 
(n=10,322) 
gFOBT 
(n=4,836) 
iFOBT 
(n=6,157) 
 % (95%CI) % (95%CI) % (95%CI) % (95%CI) 
Gender     
Male 47.8 (46.8 to 48.8) 48.8 (47.8 to 49.7) 43.2 (41.8 to 44.6) 45.8 (44.6 to 47.0) 
Female 52.2 (51.2 to 53.2) 51.2 (50.3 to 52.2) 56.8 (55.4 to 58.2) 54.2 (53.0 to 55.4) 
Age     
<60 50.4 (49.4 to 51.4) 51.7 (50.7 to 52.7) 47.5 (46 to 48.9) 51.0 (49.7 to 52.2) 
t60 49.6 (48.6 to 50.6) 48.3 (47.3 to 49.3) 52.5 (51.1 to 54.0) 49.0 (47.8 to 50.3) 
 
Chapter 2
~62~
Table 2. The number of colonoscopies and the number of polyps and cancer per test, with 
subdivisions for kind of polyp, kind of adenoma and size of polyps. 
 G-FOBT I-FOBT 
Number of colonoscopies 103 280 
Number of polyps and cancer1 231 703 
Cancer 11 24 
Polyps 220 679 
Subdivision of polyps2 220 679 
Adenomas 154 470 
Hyperplastic polyps 62 163 
Serrated polyps 2 31 
Other polyps 2 15 
Subdivision of all adenomas3 154 470 
Tubular 93 295 
Tubulovillous 42 138 
Villous 12 15 
Unclassified 7 22 
Size of all polyps4 220 679 
t10mm 60 155 
6-9 mm 43 125 
5 mm 117 399 
1the number of lesions was higher than the number of colonoscopies, because more than  
one lesion per colonoscopy is possible.  
2polyps were subdivided in adenomatous, hyperplastic, serrated or other polyps 
3adenomas were subdivided in tubular, villous, tubulo-villous or unclassified adenomas 
4all polyps were subdivided by size in t10 mm, 6 to 9 mm and 5 mm. 
Cancer was found in 11 of the gFOBTs and in 24 of the iFOBTs. Advanced adenomas 
were found in 46 of the gFOBTs and in 121 of the iFOBTs. The intention-to-screen 
detection rates of the iFOBT were significantly higher than the intention-to- 
screen detection rates of the gFOBT (table 3). The difference in intention-to-screen 
detection rates for patients with all polyps and cancer was 1.3% (95% CI: 1.0 to 1.7, 
p<0.01). The difference in intention-to-screen detection rates for all patients with 
advanced adenomas and cancer was 0.9% (95% CI: 0.6 to 1.1, p<0.01) and for all 
patients with cancer 0.1% (95% CI: 0.0 to 0.2, p<0.05). The number needed-to-screen 
according to intention-to-screen to find an advanced adenoma or carcinoma was 181 for 
gFOBT and 71 for iFOBT, and to find one cancer was 936 for gFOBT and 430 for iFOBT.
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Table 3. Test performance of gFOBT versus iFOBT(t100 ng/ml). 
 gFOBT iFOBT Difference1 
Test performance N % (95%CI) N % (95%CI) % (95%CI) 
Participation rate2 4.836 47 (46-48) 6.157 60 (59-61) 12.7 (11-14) 
FOBT positive patients 117 2.4 (2.0-2.9) 339 5.5 (4.9-6.1) 3.1 (2.3-3.8) 
Complete follow-up of FOBT positive 
patients 3 
103 88 (82-94) 280 82.6 (79-87) -5.4 (-13.1;2.3)
Detection rate intention-to-screen4    
All polyps and cancer 80 0.8 (0.6-0.9) 218 2.1 (1.8-2.4) 1.3 (1.0-1.7)
All adenomas and cancer  72 0.7 (0.5-0.9) 201 1.9 (1.7-2.2) 1.2 (0.9-1.6)
All advanced adenomas and cancer5 57 0.6 (0.4-0.7) 145 1.4 (1.2-1.6) 0.9 (0.6-1.1)
Cancer 11 0.1 (0.0-0.2) 24 0.2 (0.1-0.3) 0.1 (0.0-0.2)
t1 adenoma t10mm 41 0.4 (0.3-0.5) 106 1.0 (0.8-1.2) 0.6 (0.4-0.9) 
t1 adenoma with high grade dypslasia 3 0.0 (0.0-0.1) 4 0.0 (0.0-0.1) 0.0 (0.0-0.1) 
t1 adenoma with a villous component t20% 2 0.0 (0.0-0.0) 11 0.1 (0.0-0.2) 0.1 (0.0-0.2) 
Detection rate per-protocol6    
All polyps and cancer 80 1.7 (1.3-2.0) 218 3.5 (3.1-4.0) 1.9 (1.3-2.5)
All adenomas and cancer  72 1.5 (1.1-1.8) 201 3.3 (2.8-3.7) 1.8 (1.2-2.4)
All advanced adenomas and cancer5 57 1.2 (0.9-1.5) 145 2.4 (2.0-2.7) 1.2 (0.7-1.7)
Cancer 11 0.2 (0.1-0.4) 24 0.4 (0.2-0.5) 0.2 (0.0-0.4)
t1 adenoma t10mm 41 0.8 (0.6-1.1) 106 1.7 (1.4-2) 0.9 (0.4-1.3) 
t1 adenoma with high grade dypslasia 3 0.1 (0.0-0.1) 4 0.1 (0.0-0.1) 0.0 (-0.1;0.1) 
t1 adenoma with a villous component t20% 2 0.0 (0.0-0.1) 11 0.2 (0.1-0.3) 0.1 (0.0-0.3) 
Positive Predictive Value7    
All polyps and cancer 80 77.7 (70-86) 218 77.9 (73-83) 0.2 (-9.2;9.6) 
All adenomas and cancer 72 69.9 (61-79) 201 71.8 (67-77) 1.9 (-8.3;2.1) 
All advanced adenomas and cancer5 57 55.3 (46-65) 145 51.8 (46-58) -3.6 (-14.8;7.7)
Cancer 11 10.7 (5-17) 24 8.6 (5-12) -2.1 (-8.6;4.4) 
t1 adenoma t10mm 41 39.8 (30-49) 106 37.9 (32-44) -1.9 (-12.9;9.0)
t1 adenoma with high grade dypslasia 3 2.9 (0.0-6.2) 4 1.4 (0.0-2.8) -1.5 (-4.5;1.5) 
t1 adenoma with a villous component t20% 2 1.9 (0.0-4.6) 11 3.9 (1.7-6.2) 2.0 (-2.1;6.1) 
Specificity 8    
All advanced adenomas and cancer5 46 99.0 (99-99) 135 97.8 (97-98) -1.3 (-1.8;-0.8)
Cancer 92 98.1 (98-99) 256 95.8 (95-96) -2.3 (-2.9;-1.6)
t1 adenoma t10mm 62 98.7 (98-99) 174 97.1 (97-98) -1.6 (-2.1;–1.0) 
t1 adenoma with high grade dypslasia 100 97.9 (98-98) 276 95.5 (95-96) -2.4 (-3.1;-1.7) 
t1 adenoma with a villous component t20% 101 97.9 (98-98) 269 95.6 (95-96) -2.3 (-3.0;-1.6) 
1 Differences with a 95%CI completely lower or higher than 0 are statistically significant (bold) which 
means that the p-value does not exceed 0.05.  
2 Participation rate is the number of persons returning a FOBT relative to the number of invitations sent. 
3 Complete follow-up with colonoscopy of FOBT positive patients (positives). Rates are the number of 
colonoscoped patients relative to the number of positives. 
4 Detection rate intention-to-screen is the percentage of persons with lesions relative to the number of 
persons invited to be screened 
5 The subgroups of advanced adenomas and cancer are ordered relative to the most advanced lesion per 
patient into cancer. at least one adenoma t10 mm (and no cancer) or high grade dysplasia (and no 
cancer or any adenomas t10 mm) or t 20% villous component (and no cancer or any adenomas t10 mm 
or high grade dysplasia). 
6 Detection rate per-protocol is the percentage of persons with lesions relative to the number of participants 
7 Positive predictive value is the percentage of persons with lesions relative to the number of positives with 
follow-up with a colonoscopy. 
8 Specificity is the number of true negatives relative to the number of persons without lesions under the 
rare disease assumption. Numbers presented are the number of false positives per group. Specificity is 
only presented for the subgroup “advanced adenoma and cancer”. because the estimation might not be 
robust enough for the other subgroups. 
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None of the differences in PPVs (table 3) between gFOBT and iFOBT were statistically 
significant: the difference in PPV for advanced adenomas and cancer was estimated to 
be 3.6% (95% CI: -14.8 to 7.7, p=0.5) and for cancer was estimated to be -2.1% (95% CI: 
-8.6 to 4.4, p=0.4) lower for iFOBT. The number needed-to-scope to find one person with 
an advanced adenoma or cancer was <2 for both FOBTs. The estimated specificity of 
the iFOBT was statistically significantly lower, but only -1.3% (95% CI: -1.8 to -0.8, p< 0.01) 
for advanced adenomas and cancer and -2.3% (95% CI: -2.9 to -1.6, p<0.01) for cancer.
Age and gender were randomised equally over the FOBTs, but as known risk factors for 
advanced adenomas and cancer we studied the differences between FOBTs for age 
and gender (table 4). The detection rates for women and younger participants were 
lower, but the differences between FOBTs were consistent. The unadjusted, and for 
gender and age adjusted Odds Ratios for the intention-to-screen detection rates of 
advanced adenomas and cancer for FOBTs were both 0.4 (95%CI: 0.3 - 0.5, p<0.01).
 
Discussion
In this population study we randomly compared the performance of a gFOBT with 
an iFOBT in a previously screening naïve population.33 Another study comparing 
gFOBT (Hemoccult-II®) with iFOBT was not randomised, included far less persons and 
used a different iFOBT. This iFOBT (!nform®) was not quantitative, making quality con-
trol less adequate.10 Despite these drawbacks the results of this study were in line 
with ours. Other studies evaluating iFOBTs included far less subjects and did not focus 
on a screening population, but investigated high-risk groups, like symptomatic patients, 
patients with a positive gFOBT or even patients with colorectal cancer.15-19 Other 
studies were indeed designed for a screening population, but less subjects were 
included and asked to perform both the gFOBT and the iFOBT at the same time, 
which might induce selection bias in favor of highly motivated participants.20-23
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Our study revealed several interesting results. Firstly, direct comparison of the tests 
demonstrated a significantly higher participation rate for the iFOBT. The reasons for 
this difference are not apparent, and presently under investigation. Secondly, the 
specificity of the iFOBT for advanced adenomas and cancer was significantly lower 
Table 4. Positive tests and detection rates according to intention-to-screen of gFOBT and iFOBT by gender 
and age <60 and t60. 
 Men Women Age < 60 Age t60 
 N % (95%CI) N % (95%CI) N1 % (95%CI) N1 % (95%CI) 
FOBT positives2       
gFOBT 69 3.3 (2.5-4.1) 48 1.7 (1.3-2.2) 48 2.1 (1.5-2.7) 69 2.7 (2.1-3.4) 
iFOBT 197 7.0 (6.0-7.9) 142 4.3 (3.6-4.9) 124 4.0 (3.3-4.6) 214 7.1 (6.2-8.0) 
Complete follow-up3     
gFOBT 6 0 87.0 (79-95) 43 89.6 (81-98) 41 85.4 (75-95) 62 89.9 (83-97) 
iFOBT 163 82.7 (78-88) 117 82.4 (76-89) 107 86.3 (80-92) 172 80.4 (75-86) 
Detection rate intention-to-screen4 
All polyps and cancer       
gFOBT 52 1.1 (0.8-1.3) 28 0.5 (0.3-0.7) 29 0.6 (0.4-0.8) 51 1.0 (0.7-1.3) 
iFOBT 131 2.6 (2.2-3.0) 87 1.6 (1.3-2.0) 80 1.5 (1.2-1.8) 138 2.8 (2.3-3.2) 
All adenomas and cancer 
gFOBT 46 0.9 (0.7-1.2) 26 0.5 (0.3-0.7) 24 0.5 (0.3-0.7) 48 0.9 (0.7-1.2) 
iFOBT 123 2.4 (2.0-2.9) 78 1.5 (1.2-1.8) 72 1.4 (1.0-1.7) 129 2.6 (2.2-3.0) 
All advanced adenomas and cancer5 
gFOBT 39 0.8 (0.5-1.0) 18 0.3 (0.2-0.5) 23 0.4 (0.3-0.6) 34 0.7 (0.4-0.9) 
iFOBT 93 1.8 (1.5-2.2) 52 1.0 (0.7-1.2) 51 1.0 (0.7-1.2) 94 1.9 (1.5-2.3) 
Cancer 
gFOBT 5 0.1 (0.0-0.2) 6 0.1 (0.0-0.2) 3 0.1 (0.0-0.1) 8 0.2 (0.0-0.3) 
iFOBT 16 0.3 (0.2-0.5) 8 0.2 (0.0-0.3) 6 0.1 (0.0-0.2) 18 0.4 (0.2-0.5) 
t1 adenoma t10mm 
gFOBT 30 0.6 (0.4-0.8) 11 0.2 (0.1-0.3) 19 0.4 (0.2-0.5) 22 0.4 (0.3-0.6) 
iFOBT 71 1.4 (1.1-1.7) 35 0.7 (0.4-0.9) 42 0.8 (0.6-1.0) 64 1.3 (1.0-1.6) 
t1 adenoma with high grade dysplasia 
gFOBT 2 0.0 (0.0-0.1) 1 0.0 (0.0-0.1) 0  3 0.1 (-0.0;0.1)
iFOBT 2 0.0 (0.0-0.1) 2 0.0 (0.0-0.1) 0  4 0.1 (0.0-0.2) 
t1 adenoma with a villous component t20% 
gFOBT 2 0.1 (0.0-0.2) 0  1 0.0 (0.0-0.1) 1 0.0 (-0.0;0.1)
iFOBT 4 0.1 (0.0-0.3) 7 0.2 (0.1-0.4) 3 0.1 (-0.0-0.2) 8 0.3 (0.1-0.4) 
        
1 The age of one female iFOBT participant was unknown 
2 Positivity rates are the number of positives relative to the number of participants. 
3 Complete follow-up with colonoscopy of FOBT positive patients (positives). Rates are the number of 
colonoscoped patients relative to the number of positives. 
4 Detection rate intention-to-screen is the percentage of persons with lesions relative to the number of 
persons invited to be screened.  
5 The subgroups of advanced adenomas and cancer are ordered relative to the most advanced lesion per 
patient into cancer. at least one adenoma t10 mm (and no cancer) or high grade dysplasia (and no cancer 
or any adenomas t10 mm) or t 20% villous component (and no cancer or any adenomas t10 mm or high 
grade dysplasia). 
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compared with the gFOBT, but the detection rate for advanced adenomas and cancer 
of the iFOBT was significantly higher. Consequently, three times more subjects tested 
with the iFOBT will be referred for a negative colonoscopy. On the other hand, three 
times more patients with advanced adenomas, and over two times more patients 
with cancer will be left undetected in the gFOBT group compared with the iFOBT 
group, ultimately resulting in comparable PPVs for both tests.
There is ongoing debate on how to screen the population for relevant colorectal 
lesions. The available FOBTs have suboptimal specificity and sensitivity. The generally 
accepted gold standard, colonoscopy, is cumbersome, expensive, has capacity problems 
and complications. In addition sigmoidoscopy will miss advanced adenomas and cancer 
in the right side of the colon. In previous colonoscopy based screening studies detection 
rates for advanced adenomas are between 1.8% and 10.6%, and for cancer between 
0.3% and 1.0%.26,34-37 In our study, including all participants, the detection rate of 
advanced adenomas and cancer was on average 1.9%, and for cancer 0.3%. However, 
in 56% of the participants with a positive FOBT advanced adenomas and cancer were 
found and cancer alone in 8.6%. 
What is the meaning of our findings for a general screening population? In 2004 a total 
of 410,000 endoscopies including gastroduodenoscopies, ERCPs and colonoscopies were 
performed in Dutch endoscopy centres.38 In our country 4.5 million people between 
50 and 75 years of age are potential candidates for screening. This implicates that 
in a gFOBT based screening programme 42,500 additional colonoscopies have to be 
performed to detect almost 4,500 cancers and 20,000 advanced adenomas. In an 
iFOBT based screening programme almost 125,000 additional colonoscopies have to 
be performed to detect about 11,000 cancers and 55,000 advanced adenomas. If the 
population at risk will primarily be screened by colonoscopy, about 1.2 million extra 
colonoscopies have to be performed to detect about 9,700 cancers and 75,000 
advanced adenomas presuming that, according to Segnan et al,35 26.5% of the popu-
lation will participate in such a screening program, that 0.8% of these subjects will 
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have cancer and 6.3% advanced adenomas. Thus the number-to-scope to find one 
cancer or one advanced adenoma are comparable between gFOBT and iFOBT 
based screening programmes. Compared with FOBT based screening programmes, 
the number-to-scope to find one cancer in a colonoscopy based screening programme 
is 13 times higher and the number to find one advanced adenoma is 7 times higher.
Another major advantage of the iFOBT we used, is that the test is semi quantitative. 
This allows shifting the cut off value of the test. When resources are limited and the 
prevalence of colorectal cancer in the population is expected to be low, one could 
consider to increase the cut off value of the test and vice versa. In addition, the iFOBT 
does not need dietary restrictions, since it is specific for human blood. In contrast, 
quite extensive dietary restrictions are advised for the gFOBT in order to avoid false 
positive test results, although others question this.39,40 In our study we did not 
advise dietary measures for subjects receiving the gFOBT, because this would make 
comparison unfairly biased in favor of the iFOBT. 
Despite written and verbal information about colonoscopy before and after performing 
a FOBT, still 16% of the subjects with a positive test did not have this follow-up 
examination. This was comparable to other FOBT based screening studies.19,20,27,30 
The majority of the subjects who actually refused colonoscopy did so because of 
anxiety. Increased adherence positively would influence detection rates and the 
precision of the confidence intervals for both tests, but the conclusions of our study 
would not change, because adherence was not dependent on the kind of FOBT. 
Advanced adenomas and cancer were found more often in men than in women, 
despite more women than men participated in the study. In addition, advanced 
adenomas and cancer were also more often detected in older persons. This is in line 
with other studies.36,41,42 Thus, the diagnostic yield increases with age. These 
findings may help to narrow the age range for screening in different populations, 
depending on resources and prevalence of advanced adenomas and cancer. Male 
preponderance for advanced adenomas and cancer may be attributed to sex 
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hormones, since it has been claimed that estrogens may have protective effects 
on the development of CRC, or to gender differences in exposure to environmental 
factors, like smoking, dietary fiber or exercise.43 There was no difference between 
FOBTs concerning the preponderance of males and older individuals having advanced 
adenomas or cancer.
Several previous studies dealt with the diagnostic performance of FOBTs. Most 
of these studies reported comparable results to our data.4,5,10,25-28,44 Although 
some studies reported lower diagnostic performance for gFOBTs, others showed 
somewhat better results for iFOBTs.4,5,25,26 Up to now a randomised comparison 
between gFOBT and iFOBT in a screening population was lacking. There can be 
several reasons for the observed differences between these studies. One of the most 
important variables is the definition of advanced adenomas, which varies between 
studies. It remains unclear which lesions ultimately will develop into cancer and 
in what timeframe.45,46 Therefore we were quite conservative in defining advanced 
adenomas and we also provided subgroup analysis to make comparison between 
studies more feasible.
There is a small difference in specificity between gFOBT and iFOBT. But, even 
small differences in specificity will result in high absolute numbers of false positives, 
increasing costs and work load for endoscopy units. The method we used for estimating 
specificity, will slightly overestimate the true specificity especially for more prevalent 
lesions and more sensitive tests.32 In turn, the difference in specificity will be slightly 
underestimated up to at most 0.2% for advanced adenomas and cancer increasing 
the difference in favour of the gFOBT. Overall, the conclusions about statistical 
significance and clinical relevance will therefore not change by the systematic error of 
the specificity estimation.
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Conclusion
Direct comparison between a gFOBT and an iFOBT revealed that the number- 
to-scope to find one CRC is not different between gFOBT and iFOBT. However, 
participation and detection rates for advanced adenomas and cancer were 
significantly higher in the group tested with iFOBT. By result, 2.5 times more advanced 
adenomas and cancer and 2.2 times more cancers were detected with iFOBT 
compared with gFOBT. Therefore gFOBT significantly underestimates the prevalence 
of advanced adenomas and cancer compared with iFOBT in a screening population.
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Question 6.
Is colorectal cancer mortality expected to decrease by FOBT 
screening compared with no screening?
Question 7.
Is colorectal cancer mortality expected to decrease more by iFOBT 
screening than by gFOBT screening compared with no screening?
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Abstract
Introduction The aim of colorectal cancer screening is to improve prognosis by the 
detection of early cancer and precursor stages. We compared the stage distribution of 
asymptomatic colorectal cancer patients detected by a positive immunochemical or gua-
iac based faecal occult blood test (FOBT) with symptomatic colorectal cancer patients. 
Methods In a longitudinal cohort study tumour stages were assessed in 144 
symptomatic (mean age 69.3 years, 56% male) and 41 asymptomatic colorectal 
cancer patients (mean age 64.9 years, 56% male) of which 11 were detected with guaiac 
FOBTs (gFOBT, Hemoccult-II®) and 30 with immunochemical FOBTs (iFOBT, OC-Sensor®). 
Stage distributions were used to calculate average stage specific predicted 5-year 
survival rates and to analyze group differences with Wilcoxon log-rank test.
Results Colorectal cancer was detected in significantly earlier stages in asymptomatic 
compared with symptomatic patients (p<0.0001). Average stage specific predicted 5-year 
survival was 59.1% in symptomatic and 76.6% in asymptomatic patients. Compared with 
the symptomatic patients the stage distribution for colorectal cancer patients detected 
with gFOBT was not significantly different (p=0.29), whereas colorectal cancer was 
detected in significantly earlier stages with the iFOBT (p<0.0001). Treatment could be 
confined to colonoscopy in 27% of the asymptomatic patients compared with 3% of the 
symptomatic patients (p<0.0001). Cancer distribution over the colon was comparable 
between symptomatic and asymptomatic patients (p=0.3).
Conclusions Compared with symptomatic patients, patients detected by FOBT and 
especially immunochemical FOBT, presented significantly more often with earlier 
stages suggesting increased survival. Additionally treatment could more often be 
confined to colonoscopy.
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Introduction
Colorectal cancer is, after breast cancer, the second most frequent cancer in women, 
and after lung and prostate cancer, the third most frequent cancer in men in the 
Netherlands. The life time risk of developing colorectal cancer is approximately 6% 
(www.IKCnet.nl). In 2003 colorectal cancer was responsible for more than 56,000 life 
years lost and for 70,000 disability adjusted life years in the Netherlands. Total costs 
for management of colorectal cancer patients amounted to 230 million euros.1 
The aging population will have an enormous impact on the incidence of colorectal 
cancer and costs in the near future. Until 2025 the incidence of colorectal cancer will 
gradually increase by 40% in the Netherlands and medical costs for colorectal cancer 
patients will considerably increase due to growing application of biologicals.2 When 
colorectal cancer is detected as a result of symptoms, the prognosis is still rather poor 
with an average 5-year survival between 50% to 60% (www.IKCnet.nl).3 In order to 
improve the prognosis of colorectal cancer, colorectal cancer should be detected in 
earlier stages or even precursor stages. Colorectal cancer is a heterogeneous disease 
arising from a complex series of molecular events. The successive evolution of normal 
colonic mucosa to a benign adenoma, then to an adenomatous polyp containing 
cancer, and then to a potentially life-threatening invasive cancer is associated with a 
series of genetic events occurring over a period of approximately 10 years.4 So before 
colorectal cancer becomes clinically manifest many years pass and therefore there is 
opportunity to improve prognosis by early detection of colorectal cancer with screening.
In 2006, colorectal cancer screening studies were started in the Netherlands randomly 
employing two different types of faecal occult blood tests (FOBTs); guaiac based 
FOBTs and immunochemical FOBTs. In order to verify if prognosis of colorectal cancer 
is improved by FOBT screening and if improvement depends on the type of FOBT, we 
compared the stage distribution of colorectal cancer patients detected as a result of 
FOBT screening with colorectal cancer patients detected because of symptoms.
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Materials and methods
Between July 2006 and March 2007, asymptomatic subjects with a positive FOBT 
were invited for colonoscopy. These subjects were recruited from two colorectal cancer 
screening studies in the Netherlands with comparable designs, registered at Current 
Controlled Trials (ISRCTN57917442). All invited participants were asymptomatic, between 
50 and 75 years of age and without apparent family history of colorectal cancer. Data 
from the largest of the two studies comparing the performance of two types of FOBTs, 
supported by the Netherlands Organization for Health Research and Development 
(ZonMW: number 50-50115-98-060, project 63000004), were published previously.5 
From the patients with colorectal cancer detected in these studies, the following data 
were collected: Age, gender, location of the tumour, surgical or endoscopic treatment 
and TNM classification. These data were also collected from 144 consecutive sympto-
matic colorectal cancer patients without a family history of colorectal cancer, in the same 
region in the Netherlands and in the same period, from July 2006 to March 2007. Tumour 
staging was performed according to the American Joint Committee on Cancer (AJCC) 
system, also called the TNM system, which describes stages using Roman numerals I 
through IV. Three experienced pathologists staged all the detected colorectal cancers 
of both the symptomatic and the asymptomatic patients. According to data from the 
Surveillance, Epidemiology, and End Results (SEER) program, each stage has an average 
stage specific 5-year survival (table 1).6 The follow-up after our study was to short to 
measure actual 5-year survival and furthermore actual 5-year survival would have to 
be corrected for overdiagnosis and lead-time bias of which the extent is largely unknown. 
Therefore the stage specific average 5-year survival rates were used to predict the 5-year 
survival of the patients in our study group. For each colorectal cancer stage we assumed 
that the 5-year survival would eventually prove to be identical for symptomatic or asymp-
tomatic patients and identical to the SEER data. Of course this approximation method 
has certain drawbacks, but also advantages which we will discuss in the discussion.
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In the asymptomatic patients participating in the colorectal cancer screening study, 
the type of FOBT was also registered.5 Two types of FOBT were used, a guaiac based 
FOBT (Hemoccult-II®) or an immunochemical based FOBT (OC-Sensor®). A specific 
advantage of the iFOBT is, that the test is quantitative allowing changing the 
cut-off value for positivity. As threshold for positivity, the manufacturer recommends 
a cut-off value of 100ng/ml, applied in several studies.7-12 The literature as well as 
data provided by the manufacturer show that the test results of the OC-Sensor® are 
reliable in the range from 50ng/ml to 2000ng/ml.13 In the previous publication in 
Gastroenterology we compared the gFOBT with the iFOBT. In that publication, for gene-
ralizability with previous studies, we presented data for the iFOBT with a cut-off value 
of 100ng/ml. However we invited all patients for colonoscopy with an iFOBT result of 
≥50ng/ml, corresponding to about 10 microgram haemoglobin per gram faeces.14 In 
the current study we use the data of all invited patients with a cut-off value of 50ng/ml. 
With iFOBTs as little as 0.3 ml of daily blood loss in the stool can be detected.15 
In contrast, gFOBTs are qualitative tests of which the minimal amount of blood that 
can be detected in faeces is probably about 10 times higher compared with immuno-
chemical FOBTs.15,16 Therefore, we speculated that the iFOBT detects colorectal cancer 
at earlier stages. 
Table 1. Stage specific average five-year survival rates for colorectal cancer. 
T N M Dukes Stage 5-year survival* 
Tis N0 M0 - 0 98% 
T1 N0 M0 A I 93% 
T2 N0 M0 A I 93% 
T3 N0 M0 B1 IIA 85% 
T4 N0 M0 B2 IIB 72% 
T1,2 N1 M0 C1 IIIA 83% 
T3,4 N1 M0 - IIIB 64% 
Each T N2 M0 C2 IIIC 44% 
Each T Each N M1 D IV 8% 
* according to data from the Surveillance, Epidemiology, and End Results (SEER) program
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We calculated descriptive statistics of the symptomatic and asymptomatic study 
populations. We used nonparametric analysis with the Wilcoxon log rank test to 
compare the stage distribution between the two groups. Statistical significance was 
accepted if the level of probability of a type I error was lower than or equal to 5% 
(p<0.05). Statistical analyses were performed with SAS system for windows, software 
version 8.02 (SAS Institute Inc., Cary, NC, USA). 
Results
Colonoscopies in the asymptomatic group with a positive FOBT revealed in total 
41 patients with colorectal cancer (23 Male, 18 Female; mean age 64.9 years, range 
53-75 years). Nine of the tumours were located in the rectum, 19 in the sigmoid, 3 in 
the descending colon, 1 in the splenic flexure, 2 in the transverse colon, 1 in the 
hepatic flexure, 4 in the ascending colon, and 2 in the cecum (table 2). Twenty of the 
tumours were classified as stage I; 6 as stage IIa; 3 as stage IIIa; 5 as stage IIIb; 4 as 
stage IIIc; and 3 as stage IV (table 3). The average predicted 5-year survival deduced 
from the TNM staging system and SEER programme (table 1) in this group of 41 
patients was 76.6% (SD 25%). In 11(27%) of these 41 patients tumour treatment could 
be confined to endoscopy. Tumours were found in 11 patients with a positive gFOBT and 
in 30 patients with a positive iFOBT. The predicted 5-year survival for the patients 
with a positive gFOBT test was 60.5% (SD 37%), and for the patients with a positive 
iFOBT 82.4% (SD 16%). 
Colonoscopies performed in subjects referred with symptoms, like visible blood loss 
and changed bowel habits, revealed 144 patients with colorectal cancer (81 Male, 
63 Female; mean age 69.3 years, range 32 to 93 years). Sixty-one of the tumours were 
located in the rectum, 33 in the sigmoid, 3 in the descending colon, 3 in the splenic 
flexure, 5 in the transverse colon, 5 in the hepatic flexure, 17 in the ascending colon, 
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15 in the cecum and of 4 tumours the specific location was uncertain (table 2). Two 
patients had a double tumour and these patients were staged according to the most 
advanced carcinoma. Six of the patients were classified as stage I, 23 as stage IIA, 43 
as stage IIB, 15 as stage IIIA, 12 as stage IIIB, 13 as stage IIIC, and 32 as stage IV (table 
3). The predicted 5-year survival for this group of 144 patients was 59.1 % (SD 29%). 
In 4(3%) of these 144 patients tumour removal could be confined to endoscopy. 
Colorectal cancer was detected significantly earlier in asymptomatic patients 
compared with symptomatic patients (p<0.0001). Average stage specific predicted 
5-year survival was 59.1% in symptomatic and 76.6% in asymptomatic patients. 
Additionally treatment for colorectal cancer could be confined to colonoscopy in 27% 
of the asymptomatic patients compared with 3% of the symptomatic patients 
(p<0.0001). Ten (24%) of the colorectal cancer tumours in asymptomatic patients 
and 45 (31%) of the colorectal cancer tumours in symptomatic patients were located 
proximal of the descending colon (p=0.3). 
Compared with the symptomatic patients the stage distribution for colorectal 
cancer patients detected with gFOBT was not significantly different (p=0.29), whereas 
Table 2. Location of colorectal cancer in 
symptomatic and asymptomatic patients. 
 Symptomatic 
patients 
Asymptomatic 
patients 
 N=144* (%) N=41 (%) 
    
Rectum 61 (42%) 9 (22%) 
Sigmoid colon 33 (23%) 19 (46%) 
Descending colon 3 (2%) 3 (7%) 
Splenic Flexure 3 (2%) 1 (2%) 
Transverse colon 5 (3%) 2 (5%) 
Hepatic Flexure 5 (3%) 1 (2%) 
Ascending colon 17 (12%) 4 (10%) 
Cecum 15 (10%) 2 (5%)
Unknown 4 ( 3%) 0 (0%)  
   
*2 patients had 2 concurrent colorectal tumors 
 
Table 3. Staging of colorectal cancer in 
symptomatic and asymptomatic patients. 
Colorectal 
cancer 
stage 
Symptomatic 
patients  
Asymptomatic 
patients  
N=144 (%) N=41 (%) 
 
I 6 (4%) 20 (49%) 
    
IIA 23 (16%) 6 (15%) 
IIB 43 (30%) 0  (0%)  
    
IIIA 15 (10%) 3 (7%) 
IIIB 12 (8%)  5 (12%) 
IIIC 13 (9%) 4 (10%)
    
IV 32 (22%) 3 (7%) 
 
Mortality
~81~
colorectal cancer was detected significantly earlier in patients detected with iFOBT 
compared with the symptomatic patients (p<0.0001). The average predicted 5-year 
survival was 82.4% for the asymptomatic patients detected with the iFOBT and 60.5% 
for the patients detected with the gFOBT. 
Discussion
In this study we demonstrated that colorectal cancer in asymptomatic persons aged 
between 50 and 75 years with a positive FOBT is on average detected at a significantly 
earlier stage compared with symptomatic subjects with colorectal cancer diagnosed 
in the same time period and in the same geographical region. In addition, treatment 
of colorectal cancer could significantly more often be confined to colonoscopy in the 
asymptomatic screening group than in the symptomatic group. The most important 
finding in this study was that, compared with symptomatic patients, colorectal cancer 
was detected in significantly earlier stages for the patients detected with the iFOBT, 
but not for patients detected with the gFOBT.
From a German study by Hüppe et al we calculated the gain in predicted 5-years 
colorectal cancer survival according to stage distribution in 5066 asymptomatic patients 
(participating in colonoscopy screening) compared with 4099 symptomatic patients.17 
The 18% gain in survival from their data, compares well to the 22% gain in average 
predicted survival we observed with FOBT screening. In addition Hüppe et al had 
followed-up their population up to 5 years (on average 33 months). Up to the time of 
their publication no subjects in the screening group had died of colorectal cancer 
compared with 20% of the symptomatic colorectal cancer patients, confirming the 
predicted gain in 5-years survival according to stage distribution.17 We propose this 
indicates that the stage distribution of colorectal cancer detected with primary 
colonoscopy screening is comparable with the stage distribution of colorectal cancer 
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detected with faecal occult blood testing. Additionally the follow-up data by Hüppe et 
al indicate that colorectal cancer survival predicted by stage distribution on average 
might correlate well with actual survival. We think this is interesting for policy makers, 
who are considering to implement colorectal cancer screening with either primary 
colonoscopy or FOBT.
Another important finding of our study was the difference that we observed in the 
stage distribution between subjects with colorectal cancer detected after a positive 
gFOBT test, compared with a positive iFOBT test. Both the gFOBT test and the iFOBT 
test are developed to detect haemoglobin in faeces. In contrast to the gFOBT test, the 
iFOBT test is specific for human haemoglobin and iFOBT (OC-Sensor®) is quantitative, 
allowing shifting the cut-off values for positivity. The gFOBT test is probably at least 
10 times less sensitive to haemoglobin compared with the iFOBT test.15,16 The stage 
distribution of colorectal cancer patients detected with the iFOBT in this study was 
significantly better than the stage distribution in the symptomatic patients. In contrast, 
the stage distribution of colorectal cancer patients detected with the gFOBT was not 
significantly different from the symptomatic patients. Therefore we propose, that 
colorectal cancer patients detected by a positive iFOBT can probably on average expect 
to have an increased 5-year survival compared with those with a positive gFOBT.
Although slightly more proximal colorectal cancers were detected in the symptomatic 
patients compared with the asymptomatic patients, this difference was not statistically 
significant. Therefore, tumours in the proximal colon are also detected by FOBT. For 
the iFOBT this is confirmed in a recent study, where it was shown that the amount of 
blood in the stool detected in patients with proximal colorectal cancer is lower than 
in distal colorectal cancer, but never below the cut-off value of 50ng/ml that we used 
in our study population.14 In another study with a different iFOBT (Magstream 1000®), 
a lower sensitivity for proximal compared with distal colorectal cancer was reported, 
but this difference was not statistically significant.18 Wexner et al. demonstrated there 
was no difference in colorectal cancer location for gFOBT negative and gFOBT positive 
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colorectal cancer patients.19 Fujita et al also failed to detect any differences in colorectal 
cancer distribution over the colon in asymptomatic patients screened with guaiac 
slides compared with symptomatic patients.20 
Conclusion
In conclusion, we demonstrated that colorectal cancer is detected at significantly 
earlier stages in asymptomatic patients detected by a positive FOBT compared with 
symptomatic patients. In addition, in significantly more asymptomatic patients with 
a positive FOBT treatment of colorectal cancer could be confined to colonoscopy 
compared with the symptomatic group. Furthermore there was no difference in dis-
tribution of colorectal cancer over the colon between the asymptomatic and 
symptomatic colorectal cancer patients, indicating that tumours in the proximal colon 
are also detected by FOBT. Colorectal cancer was not detected in significantly earlier 
stages in patients detected with the gFOBT (Hemoccult-II®) compared with symptomatic 
patients. However colorectal cancer was detected in significantly earlier stages in 
patients detected with the iFOBT (OC-Sensor®) compared with symptomatic patients. 
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Question 8.
Is screening with FOBT cost-effective compared with no screening?
Question 9.
Is screening with iFOBT cost-effective compared with gFOBT 
screening?
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Abstract
Introduction Comparability of cost-effectiveness of colorectal cancer screening 
strategies is limited if heterogeneous study data on tests, populations, and designs 
are combined. We compared cost-effectiveness of screening with either one round 
immunochemical faecal occult blood test (iFOBT, OC-Sensor®) or guaiac based FOBT 
(gFOBT, Hemoccult-II®) and no screening.
Methods Empirical data from a randomised controlled trial with either one round 
of iFOBT or gFOBT screening in Dutch individuals aged 50-75 years with average risk 
for colorectal cancer, were completed with cancer registry and literature data and 
implemented in a Markov model and analysed with first and second order Monte 
Carlo simulation over ten years of one year cycles. Analysis was performed from a 
third-party payer perspective and costs were measured in Euros(€) using a 4% 
discount rate and effects in life years gained using a 1.5% discount rate.
Results iFOBT resulted in more life years gained and costs saved compared with 
gFOBT and no screening (i.e. iFOBT dominated). A hypothetical person invited for 
iFOBT screening would on average save 0.003 life-years and €5 compared with gFOBT 
and compared with no screening 0.006 life-years and €45. In the Dutch population 
(n=4,460,265) aged 50-75 years, 10 years after one round iFOBT screening, 25,200 
life-years and €220 million would have been saved compared with no screening. 
iFOBT remained dominant in sensitivity analyses, varying colorectal cancer incidence 
and major cost drivers.
Conclusion Colorectal cancer screening with iFOBT dominated gFOBT and no 
screening. Accounting for uncertainty surrounding important parameters did not alter 
this conclusion.
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Introduction
Usually colorectal cancer (CRC) screening is carried out exploring a single type of test 
or strategy. A literature search showed that if data from studies with more than one 
type of test were available, they suffered from no random allocation of tests and limited 
comparability due to differences in inclusion criteria, follow-up periods and geographical 
regions.1-6 Consequently cost-effectiveness studies on CRC screening suffer from hetero-
geneous data based on partially ambiguous evidence.2 Most studies are accompanied 
by extensive sensitivity analyses covering a broad range of outcomes, but authors 
seldom report on decreased precision and possible lack of generalizability.1,3-7 
Besides these potential biases several of these cost-effectiveness studies suffered 
from unrealistic assumptions. For example participation in screening can vary between 
populations and screening tests. Primary endoscopy screening hardly ever exceeds 
30% and is consistently lower than participation in guaiac faecal occult blood test 
(gFOBT) screening which hardly ever exceeds 50% participation.8-12 However in cost-
effectiveness analysis participation is often assumed to be 100%, regardless of the 
population, test or strategy. If imperfect participation is taken into account, it is often 
assumed to be only dependent on the population and not on the test or strategy.4,6,7 
In reality participation levels related to different types of tests can vary considerably 
within a population, because of test specific aspects such as the design of the test or 
the number of days a test has to be performed.9 Also adherence to colonoscopy to 
verify a positive indirect screening test like a faecal occult blood test (FOBT) can vary 
considerably, ranging from 70% to almost 100%.9,13,14 However in cost-effectiveness 
studies colonoscopy adherence is frequently assumed to be 100%.1,7 Similar incorrect 
assumptions will be made for test performance aspects, like sensitivity, specificity, 
detection rates or positive predictive value. Therefore, to date, it cannot be ascertained 
if conclusions of cost-effectiveness studies comparing different types of screening 
tests or strategies for CRC screening are robust.
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In the Netherlands no CRC screening programmes or studies were implemented, and 
therefore we had a unique position to counter these problems with a randomised 
controlled trial comparing two different types of FOBT in the general population.9 The 
evidence based data were used as input for this cost- effectiveness study aiming at 
comparing immunochemical FOBTs (iFOBTs), traditional gFOBTs and no screening on 
costs and effects.
Methods 
Model overview
We designed a Markov model to evaluate the cost-effectiveness of CRC screening and 
no screening in asymptomatic average risk individuals between 50 and 75 years of 
age, using a third-party payer perspective (figure 1). The model is based on the natural 
history of CRC in the general population without screening and the time frame of the 
Average
risk population;
age 50-75
Cancer
Dead
CRC Screening
Advanced Adenoma
Participation
Positive FOBT
Colonoscopy
No
Yes
No
No
Yes
Yes
 
Figure 1. Markov states in the cost-effectiveness model. Average risk Dutch persons between 50 and 75 
years of age make 10 cycles of 1 year. Markov States and cycle flows are given in curved boxes and 
lines. The implementation of a once only FOBT screening (with participation, positivity and colonoscopy 
steps) is illustrated with straight boxes and lines.  
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analysis considered a single round of FOBT screening and with one year cycles the esti-
mated cost and effects over 10 years. The model incorporated all aspects of one round of 
screening from invitation, to participation, to FOBT result, to adherence to colonoscopy 
in FOBT positives, to colonoscopy results and in case of CRC to surgery or additional 
treatment if necessary. In descending order of prognostic seriousness, FOBT positives 
having a colonoscopy might have CRC, advanced adenomas, or no or insignificant 
neoplastic lesions. Differences in prognosis are included in the model as differences 
in CRC incidence and survival. Also differences in treatment, due to differences in 
stage distributions are taken into account (for example differences in surgery rates).
Clinical Data
We used data from a single trial in the Netherlands, in which 20,623 persons between 
50 and 75 years of age were invited for CRC screening. Invited individuals were random-
ly allocated to receive either a gFOBT (Hemoccult-II®), or an iFOBT (OC-Sensor®). Details 
of the study design and the performance of the tests have previously been described 
in more detail.9 The inputs for the model were completed with relevant data from the 
Dutch National Cancer Registry database (www.ikcnet.nl) and literature (table 1a).
Only a single semi-quantitative iFOBT was performed and was considered positive 
when the test result was ≥ 100ng/ml. The gFOBT was considered positive if any blue 
discoloration occurred in one or more of 6 samples of 3 consecutive stools.
Dutch cancer registry data were used to calculate average 10-years survival, according 
to CRC stage distributions, as derived from TNM classifications per strategy: iFOBT 
screening, gFOBT screening and no screening.15 Advanced adenomas were defined as 
adenomas ≥ 10mm in size, with high grade dysplasia or with ≥ 20% villous component.
Costs
We considered direct health care costs only (table 1b). The costs of the FOBTs 
consist of costs that are independent and dependent on the type of test. Costs that 
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Table 1a. Base-Case effects 
Variable Base-case Range‡ Reference 
Effects    
CRC* Incidence† 0.00138 0-0.0015 DCR§ 
CRC Incidence post polpypectomy† 0.00028 ±50% 26 
CRC prevalence† 0.00815 0.00138-0.01 11, 24, 27 
Mortality rate Overall per year† 0.00943  SN|| 
Mortality rate CRC per year† 0.00049  DCR§ 
Mortality rate per colonoscopy 0.00001 ±100% 24 
Complication colonoscopy¶    
with polypectomy 0.005 ±30% 24 
without polypectomy 0.00008 ±250% 24 
Response Rate % 95%CI 9 
gFOBT 0.469 46.0-47.9  
iFOBT 0.596 58.7-60.6  
Positivity Rate % 95%CI 9 
gFOBT 0.024 2.0-2.9  
iFOBT 0.055 4.9-6.1  
Adherence to Colonoscopy 0.84 80.6-87.4  
Positive Predictive Value % 95%CI  
advanced adenoma    
gFOBT 0.447 0.35-0.54  
iFOBT 0.432 0.37-0.49  
colorectal cancer    
gFOBT 0.107 0.05-0.17  
iFOBT 0.086 0.05-0.12  
5 year CRC survival % 95%CI DCR§ 
no screening 0.55 0.55-0.55  
gFOBT 0.61 0.55-0.88  
iFOBT 0.82 0.70-0.96  
Endoscopic treatment of CRC % 95%CI 15 
no screening 0.03 0.0-0.055  
gFOBT 0.18 0.0-0.41  
iFOBT 0.30 0.14-0.46  
Chemotherapy (Stage III and IV) % 95%CI 15 
no screening 0.51 0.43-0.59  
gFOBT 0.45 0.35-0.59  
iFOBT 0.33 0.17-0.50  
Radiotherapy (Stage IIIC and IV) % 95%CI 15 
no screening 0.32 0.24-0.40  
gFOBT** 0.32 0.24-0.40  
iFOBT 0.1 0.0-0.20  
Metastasis (Stage IV) % 95%CI 15 
no screening 0.22 0.15-0.29  
gFOBT** 0.22 0.15-0.29  
iFOBT†† 0.01 0.0-0.05  
*CRC=Colorectal Cancer 
†calculated for the 50-75 years of age population 
‡Range: range used in sensitivity analysis where appropriate 
§ DCR = Dutch Cancer Registry (http://www.ikcnet.nl) 
|| SN = Statistics Netherlands (http://statline.cbs.nl/statweb) 
¶Complication of colonoscopy (mainly perforation and bleeding) are in terms of percentage calculated into 
the cost of complications due to colonoscopy 
**gFOBT worse than no screening, therefore set equal to no screening 
††no persons with metastasis in the iFOBT group 
Chapter 4
~92~
are independent of the type of test were costs related to the invitation for screening 
as letters and information brochures, basic administration of tests, feedback of test 
results to the patient and postal charges. Costs dependent on the type of test were 
costs of the FOBT itself and costs for laboratory analyses. For FOBT we used retail prices. 
For the analysis of FOBTs, costs were calculated for administration, laboratory work 
and correspondence of test results only for returned tests. Consequently participation 
rates influenced the total cost of FOBT screening (figure 2). For the gFOBT a complete 
test-kit of Hemoccult-II® includes a number of tests as well as the test developer 
solution. For the iFOBT, OC-Sensor®, testing materials are made available separately 
and therefore calculated for returned tests only. The costs of the automated analyser 
OC-micro, used for the analysis of the OC-Sensor®, were also included into the costs 
of a returned iFOBT given the assumption of 100,000 tests per year and depreciated 
Table 1b. Base-Case costs 
Variable Base-case Reference 
Screening Costs   
Costs independent of test € 5.44 retail prices 
Test specific invitation costs   
gFOBT € 2.80 retail prices 
iFOBT € 1.35 retail prices 
Test specific costs of returned tests  
gFOBT € 1.39 retail prices 
iFOBT € 2.01 retail prices 
Direct Health Care Costs  
Colonoscopy  
including polypectomy and pathology report* € 921 Dutch Health Care Authority † 
Complication (bleeding or perforation) € 6,532 Dutch Health Care Authority † 
Colorectal Cancer   
Surgery € 12,366  Dutch Health Care Authority † 
Chemotherapy € 12,731  Dutch Health Care Authority † 
Surgery and Chemotherapy Metastasis € 23,097  Dutch Health Care Authority † 
Radiotherapy € 5,710  Dutch Health Care Authority † 
   
*In the costs of colonoscopies a fixed proportion for polypectomies and pathology reports is calculated 
†Dutch Health Care Authority database (http://ctg.bit-ic.nl/Nzatarieven/top.do) 
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over 3 years. All other clinical costs for the follow-up of positive FOBT results were 
directly derived from the Dutch Health Care Authority database (Nza: http://ctg.bit-ic.nl/
Nzatarieven/top.do). The Nza is the supervisory body for all the healthcare markets in 
the Netherlands and supervises both healthcare providers and insurers, in the curative 
markets as well as the long-term care markets.
Analysis
Analyses were performed in accordance with intention to screen. Costs and effects 
were calculated in respectively Euros (€) and life years gained. All costs were discounted 
at 4% and effects at 1.5%.16 The baseline results from our model were translated to a 
Figure 2. The overall costs per FOBT relative to participation 
*Overall costs are all the cost of sending the test including general information and test manual, returning 
the test, administration and analysis.†The symbols on the lines represent the actual measured 
participation and corresponding costs for iFOBT and gFOBT, referenced in the figure with drop-down lines 
axes. 
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population level of individuals between 50 and 75 years of age (n=4,460,265, Statistics 
Netherlands, http://www.cbs.nl/en-GB). The model was validated by comparing 
results obtained from the no screening arm of the model to available data on the 
management of CRC in the Netherlands. Sensitivity analyses were performed on the 
incidence of CRC, the costs of colonoscopy and chemotherapy, the stages in which 
chemotherapy could be prescribed and the discount rates of both costs and effects 
(reasoning in the discussion). We performed multidimensional first and second order 
simulation with the Monte Carlo method using 20,000 samples and 100 trials. The 
software we used for building the model and analyzing the data was TreeAge Pro 
Suite 2008 Release 1.6, TreeAge Software Inc.
Results
The variable costs of the gFOBT and the iFOBT are dependent on participation rates 
and therefore the overall costs of the FOBT are dependent on participation (figure 2). 
The participation independent costs are: € 5.20 for gFOBT and € 3.75 for iFOBT. 
Compared with the manually operated and evaluated gFOBT, the automated analyser 
(OC-Sensor micro) reduced operation and evaluation time for the iFOBT with more 
than 90%. When assuming 100% participation one gFOBT overall costs € 9.05 and one 
iFOBT costs € 8.24. The actual participation was 47% for gFOBT and 60% for iFOBT.9 
Therefore the overall cost for one gFOBT was € 7.06 and for one iFOBT € 6.22. 
Figures 3a en 3b represent scatter plots of the joint distribution of the mean incremental 
costs and mean incremental effects for the patient cohorts using Monte Carlo simulation 
for iFOBT versus no screening (3a) and iFOBT versus gFOBT (3b).17 A slight tendency 
towards the first dominant quadrant (upper left) of the cost-effectiveness plane can be 
observed for iFOBT compared with no screening and for iFOBT compared with gFOBT. 
Over a period of 10 years, an average person between 50-75 years of age, will consume 
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Figure 3. Scatter plots of the joint distribution of the mean incremental costs and mean incremental effects 
for iFOBT versus no screening (3a) and iFOBT versus gFOBT (3b). 
The four quadrants I to IV enclosed by above and below zero incremental costs (vertical) and effects 
(horizontal) respectively represent: 
I Upper Left = gain in effect and gain in costs 
II Lower Left = gain in effect and loss in costs 
III Lower Right = loss in effect and loss in costs 
IV Upper Right = loss in effects and gain in costs 
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CRC related costs in the amount of € 360.80 without screening, € 316.20 with gFOBT 
and € 311.50 with iFOBT screening. Considering a period of 10 years, an average invited 
person, will live 9.6889 years without screening, 9.6912 years with gFOBT and 9.6946 
years with iFOBT screening (table 2 and figure 4). Therefore an average invited per-
son for iFOBT screening can expect to gain 0.003 life years or 1.1 days compared with 
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Figure 4. Average cost-effectiveness for the screening strategies, “no screening”, gFOBT and iFOBT, 
using probabilistic Monte Carlo simulation. 
Table 2. Cost-effectiveness according to intention to screen of once only iFOBT screening compared with 
gFOBT screening or no screening. 
Strategy Cost per 
person 
Incremental 
Cost* 
Effect per 
person† 
Incremental 
Effect‡ 
Cost per  
effect 
Incremental 
Cost per Effect
iFOBT € 311.50  9.6946  € 32.13  
gFOBT € 316.20 € 4.70 9.6912 -0.003 € 32.63 Dominated§ 
No Screening € 360.80 € 49.30 9.6889 -0.006 € 37.24 Dominated§ 
*Differences in costs compared with iFOBT 
†Average life-years per person invited to participate in once only screening with FOBT 
‡Life-years gained compared with iFOBT (1 day is 1/365.25=0.0027 years) 
§Dominated means both costs and effects are favourable for iFOBT
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Figure 5. Sensitivity analysis of varying CRC incidence per 10,000 persons plotted against average cost-
effectiveness (€ per life year gained). 
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gFOBT and 0.006 life years or 2.2 days compared with no screening. Additionally an 
average invited person for iFOBT screening would save € 5 compared with gFOBT and 
€ 45 compared with no screening (table 2). Therefore iFOBT dominated both gFOBT 
and no screening. Considering the entire screening population in the Netherlands 
between 50 and 75 years of age (n=4,460,265, Statistics Netherlands, http://www.
cbs.nl/en-GB), a single round of iFOBT screening compared with no screening would 
result in 25,200 life-years gained and € 220 million saved over a period of 10 years. 
In the Netherlands the incidence of CRC is 13.8 per 10,000 persons between 50 and 
75 years of age per year and is still increasing according to the Comprehensive Cancer 
Centres in the Netherlands (http://www.ikcnet.nl/). An effective screening strategy 
will eventually lower the incidence of colorectal cancer.18 Therefore, we performed a 
sensitivity analysis on the incidence of CRC in which we decreased the incidence in the 
50 to 75 years age-group from 15 per 10,000 persons to 0 per 10,000 persons (figure 5). 
Compared with no screening the iFOBT (100 ng/ml) remained the optimal strategy, 
until the incidence would drop below approximately 7 per 10,000 persons. 
In the Netherlands CRC treatment with surgery and chemotherapy on average costs 
€ 37,000 without screening, and would be € 22,000 with iFOBT screening. Although it 
is more realistic to assume costs for colorectal cancer to increase than to decrease, 
we also performed sensitivity analysis on the major cost drivers in which we decreased 
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the cost of CRC treatment from € 150,000 to € 0. iFOBT remained cost-effective over 
no screening because higher assumed costs resulted in higher incremental costs in 
favour of iFOBT screening (figure 6). Similarly iFOBT remained the optimal strategy 
compared with no screening if a sensitivity analysis was performed on the cost of a 
colonoscopy. Even when a highly progressive range of €300 to €1500 was considered. 
iFOBT would lose dominance over gFOBT only when colonoscopy costs would 
increase above €1200. Furthermore the average 5-year survival of persons with CRC 
detected by a positive iFOBT was also very robust for sensitivity analysis. 
Discussion
iFOBT screening resulted in life-years gained and cost savings compared with gFOBT 
and compared with no screening. The dominance of iFOBT over gFOBT and no screening 
proved to be very robust in sensitivity analysis. 
Overall our finding that FOBT screening is more cost-effective than no screening, is in 
accordance with the findings of other authors, although the size of the incremental 
effect differs.4-7 Differences in size of effect might to some extent be explained by the 
fact, that we considered only one round of FOBT screening. Another explanation 
Figure 6. Sensitivity analysis of varying CRC treatment costs considering only main cost drivers (surgery 
and chemotherapy) plotted against average cost-effectiveness (€ per life year gained). 
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probably is the intention-to-screen basis of our analysis. The major advantage of 
our study compared with other studies is that for both FOBTs effect parameters like 
participation rates, FOBT positivity rates, adherence to follow-up with colonoscopy 
and positive predictive values were prospectively measured.9 Therefore we did not 
have to make assumptions concerning the differences of the effect parameters between 
FOBTs and we showed that these rates have a considerable impact on the overall effect 
of a screening test or strategy. Studies in which FOBT participation and colonoscopy 
adherence rates are assumed 100%, overestimate the effect of screening.1,19 
Since data in this cost-effectiveness study are based on one FOBT screening round, we 
cannot determine cost-effectiveness of consecutive rounds of FOBT screening, which 
would probably increase the overall detection of CRC and advanced adenomas. In 
other studies findings of first or sometimes second round screening results were extra-
polated to consecutive screening rounds.1,4,19 However participation and detection 
rates usually are not stable during consecutive screening rounds.20,21 Therefore in 
screening studies where several screening rounds are introduced into the model 
under various indefinite assumptions, the corresponding errors in these assumptions 
will be magnified over consecutive screening rounds. The aim of our study was to 
avoid systematic errors as much as possible. Therefore we did not introduce consecutive 
rounds of FOBT screening and focused on one screening round. From invitation to the 
letter with the FOBT result, both types of FOBT cost less than 10 euro per test. As only 
returned tests have to be administrated and analysed, costs of FOBTs are affected by 
participation rates. Although participation rates of iFOBT (OC-Sensor®) screening are 
substantially higher compared with gFOBT (Hemoccult-II®) screening, the overall 
costs according to intention-to-screen of iFOBT were lower than the overall gFOBT 
costs. In contrast to gFOBT, where the test kit is all-inclusive, iFOBT analysing materials 
are sold separately, relatively reducing overall costs. However the most substantial 
cost reduction for iFOBT compared with gFOBT, is caused by differences in operation 
and evaluation of the iFOBT. The automated analyser (OC-Sensor micro) minimised 
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operation and evaluation time for the iFOBT compared with the manually operated 
and evaluated gFOBT. Additionally, compared with the gFOBT, possibilities for quality 
control of the iFOBT are quite extensive. Thus, the iFOBT test can be handled much more 
efficiently and investment costs in the equipment have a more than adequate return. 
Although costs of the FOBTs have to be calculated for all invited subjects with an 
additional sum for participants, in total these costs were negligible compared with 
colonoscopy costs to verify positive FOBTs and costs of treatment of (metastasised) 
CRC. The short term implementation of FOBT screening will result in a considerable 
increase in the number of colonoscopies performed each year, requiring extensive 
investments in personnel and facilities. However in the long term the number of 
colonoscopies might actually decrease, because in a successful FOBT screening 
programme the incidence of (pre)malignant colorectal lesions will decrease.18 
Even if a sensitivity analysis with a more broad range of colonoscopy costs of €300 to 
€1500 was applied, iFOBT screening remained dominant over no screening. IFOBT 
only lost dominance over gFOBT above €1200 per colonoscopy. Currently colonoscopy 
costs in the Netherlands are approximately €900, which are more likely to decrease 
than increase.
Overall CRC cancer treatment costs will decrease as CRC is detected at earlier stages 
by screening, saving costs for metastasised CRC. On the other hand, because of the 
results of recent studies, adjuvant chemotherapy might be recommended in selected 
stage II CRC patients.22,23 It is still quite uncertain if this recommendation will become 
common practice. However in sensitivity analyses iFOBT screening remained dominant, 
even if costly adjuvant chemotherapy would become indicated in all CRC stages.
We did not directly use prevalence data of CRC in our model, but the positive predictive 
value of FOBT is dependent on prevalence and therefore prevalence was used indirectly. 
In the Netherlands the prevalence of CRC is largely unknown as only data exist from 
autopsy databases. CRC prevalence can only reliably be obtained from high numbers of 
participants in primary colonoscopy screening, which are unfortunately not available in 
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our country. The incidence of CRC is approximately the same in most European coun-
tries without nationally implemented screening programmes, which we also applied in 
our model.24 We used data from studies in other European countries, where prevalence 
of CRC was approximately 0.8% in the age cohort of interest for screening.11,25,26 
Additionally we performed extensive sensitivity analysis on the incidence of colorectal 
cancer, since the incidence of CRC will gradually decrease with a successful screening 
program.18 FOBT screening was very robust in sensitivity analysis compared with no 
screening for both prevalence and incidence of CRC. iFOBT remained dominant over 
no screening, even when the prevalence of CRC dropped to the incidence level of 
CRC. Cost-effectiveness of iFOBT screening compared with no screening would gradually 
become minimal, when the incidence of CRC would decrease with 50%. At present 
such a dramatic decrease seems rather unrealistic, however the sensitivity analysis of 
incidence is also informative in generalizing the results to the rest of the European 
Union. In countries with much lower CRC incidence than the Netherlands the cost- 
effectiveness of the iFOBT might become compromised much quicker. Especially 
Greece and to a lesser extent Finland may have a substantially lower incidence of CRC 
compared with the Netherlands.24 We do not present data of other cut-off values in 
this study, but raising the cut-off value might very well increase cost-effectiveness in 
countries with lower incidence rates.
Conclusion
Based on the findings of this study we concluded that iFOBT is cost-effective in CRC 
screening and dominated no screening as well as gFOBT screening, i.e. both costs are 
saved and life years are gained with iFOBT screening compared with the alternatives. 
Cost-effectiveness of iFOBT screening is robust for prevalence and incidence changes 
and major cost drivers. If CRC screening is to be implemented, iFOBT screening should 
be preferred over gFOBT screening. We propose the results of this study can be 
generalised to most European countries, even if the costs for cancer treatment 
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would be much lower or the cost of colonoscopy would be much higher than in the 
Netherlands. However cost-effectiveness should be monitored over time and per 
country, as incidence rates vary per country and should be expected to decrease over 
time when screening is implemented.
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Abstract
Introduction Immunochemical faecal-occult-blood-tests(iFOBTs) are semi-quantita-
tive: changing cut-off influences detection and colonoscopy referrals. We studied the 
performance of the iFOBT, OC-Sensor®, in colorectal cancer(CRC) screening at different 
cut-offs.
Methods Dutch subjects with average risk for CRC, 50 to 75 years of age, with an iFOBT 
result ≥50ng/ml were invited for colonoscopy. The detection rate was percentage par-
ticipants with CRC or advanced adenomas (≥10mm, ≥20% villous, high-grade dysplasia). 
The number-needed-to-scope (NNTScope), was the number of colonoscopies needed 
to find one person with CRC or advanced adenoma(s). 
Results Of 6,157 participants, 526(8.5%) had a result ≥50ng/ml of which 430(82%) 
underwent colonoscopy: 28 had CRC and 161 advanced adenomas. The CRC and 
advanced adenomas detection rate was 3.1% (95%CI 2.6%-3.5%) and the NNTScope 
2.3. With a cut-off of 75ng/ml the detection rate was 2.7%, NNTScope 2.0 and the 
cancer miss-rate <5%(N=1). With the standard 100ng/ml cut-off the detection rate 
was 2.4% and NNTScope <2. Up to 200ng/ml the cancer miss-rate compared with 
50ng/ml, remained 14% (n=4). 
Conclusions Cut-offs below the standard 100ng/ml of the iFOBT, OC-Sensor®, 
resulted in higher detection rates of colorectal cancer and advanced adenomas, 
however relatively more colonoscopies were needed. With cut-offs up to 200ng/ml 
less colonoscopies were needed and the cancer miss-rate remained stable compared 
with 100ng/ml, but was substantial compared with 50ng/ml.
Chapter 5
~108~
Introduction
One of the main advantages of immunochemical faecal occult blood tests (iFOBTs) 
compared with the guaiac-based FOBT (gFOBT) is that some allow haemoglobin 
quantification.1-3 The semi-quantitative nature of these tests permits adjustment 
of the cut-off value for detection of colorectal cancer (CRC) in order to optimise 
screening programmes for specific populations and health care practices. Changing the 
cut-off value can have considerable implications on the performance of the test in a 
screening population. Lowering the cut-off value will usually increase sensitivity, but 
consequently decrease specificity and vice versa. An increase in sensitivity means an 
increase in detection of patients with colorectal cancer or advanced adenomas, but 
the consequential decrease in specificity results in more persons without relevant 
lesions undergoing a colonoscopy (false positives). Some studies in screening popula-
tions have been published on changing the cut-off value of iFOBTs. However, in these 
studies only a few selected cut-off values are presented and therefore the complete 
range of possible cut-off values is not addressed.1,2 Usually colonoscopy data, verifying 
the presence or absence of pathology, are presented for test results equal to or above 
the threshold recommended by the manufacturer. The two most frequently presented 
quantitative iFOBTs, the OC-Sensor® (Eiken Chemical) and the Magstream 1000® 
(Fujierebio Diagnostics), were developed in Japan, where incidence rates for CRC are 
lower than in Europe.4 Therefore, the cut-off value with optimal overall performance 
may be different in Europe compared with Japan. In a recent study, including 1000 
symptomatic and other high-risk patients in Israel, cut-off values below the 
recommended threshold of 100ng/ml were evaluated.5 The authors concluded 
that the optimal cut-off value might be as low as 75ng/ml, but they also noted that 
the test performance in screening average-risk patients is unknown. Our aim was to 
evaluate the performance and efficiency of a semi-quantitative iFOBT in an average-risk 
screening population.
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Materials and methods
Design and population
Study design and most materials and methods relevant for the present study are 
published elsewhere.6 The study was primarily designed as a randomised controlled 
trial in an average-risk screening population between 50 and 75 years of age comparing 
a gFOBT with an iFOBT. Here we only describe data of the semi-quantitative iFOBT, 
OC-Sensor®, in order to evaluate the performance of the iFOBT at different cut-off values 
in population-based CRC screening. 
In population-based colorectal cancer screening only the test positive participants 
will be followed-up with a colonoscopy. Primary outcome measures like sensitivity 
and specificity are therefore not available. We used detection rate and number needed 
to scope to evaluate the performance of the iFOBT at different cut-off levels. Participants 
were defined as subjects who responded to the invitation by returning a used iFOBT. 
The detection rate, defined as the percentage of participants with colorectal cancer 
or ≥1 advanced adenomas, was used to describe the yield of the test. Cancer miss 
rate was defined as the percentage of cancer patients missed relative to the number 
of cancer patients at the minimal cut-off value of 50ng/ml of the iFOBT. The expense 
of the test was captured with the number needed to scope, representing the delicate 
ratio between true positives (all endoscoped FOBT positives with CRC or ≥1 advanced 
adenomas) and false positives (no or non-advanced adenomas). The number needed 
to scope (NNTScope) as reciprocal of the positive predictive value (NNTScope= 1/PPV) 
is defined as the number of persons undergoing a colonoscopy to detect one person 
with CRC or ≥1 advanced adenomas. 
Immunochemical Faecal Occult Blood Test
In this study the automated semi quantitative OC-Sensor® (Eiken Chemical Co. Ltd., 
Tokyo, Japan) was used. The faecal samples, preserved in a plastic container in a liquid 
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buffer, were processed with the OC Micro instrument (Eiken Chemical Co. Ltd., Tokyo, 
Japan).5 As threshold for positivity of the test, the manufacturer recommends a cut-off 
value of 100ng/ml, which has been applied in several studies.2,6-11 The literature as 
well as data provided by the manufacturer show that the test results of the OC-Sensor® 
are reliable in the range from 50ng/ml to 2000ng/ml.12 In a previous publication we 
compared the gFOBT Hemoccult® with the iFOBT OC-Sensor®.6 In that publication, for 
generalizability with the previous studies, we presented data for the iFOBT with a cut-off 
value of ≥100ng/ml. However we invited all patients with an iFOBT result of ≥50ng/ml 
for colonoscopy, which data we use in the current analysis. Below 50ng/ml, test results 
may become gradually more unreliable and, to our knowledge, no data on test reliability 
are available for cut-off levels below 50ng/ml, corresponding with ±10µg/g faeces.5 
Colonoscopy
At colonoscopy all polyps and colorectal cancer were removed if possible, and other 
lesions were biopsied if necessary. Advanced adenomas were defined as adenomas 
with a size ≥10mm, adenomas with a villous component ≥20%, or adenomas with 
high grade dysplasia. CRCs were staged according to the American Joint Committee 
on Cancer system (AJCC), also called the TNM system, which describes stages using 
Roman numerals I through IV.13
Data Analysis
Detection rates and NNTScope were calculated and reported with 95% confidence 
intervals (95%CI). In figures detection rates and NNTScope are presented relative to 
the amount of haemoglobin (ng/ml) on a continuous scale. Normal distribution of 
the iFOBT result was achieved by logarithmic transformation. The logarithmic mean 
difference in amount of haemoglobin found in patients without cancer or advanced 
adenomas compared with patients with CRC or ≥1 advanced adenoma, was analysed 
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with logistic regression analysis and reported with p-values. The influence of gender 
and age on logarithmic mean difference was evaluated with multivariable logistic 
regression analysis. Statistical analysis was performed with SAS system for windows, 
software version 8.02 (SAS Institute Inc., Cary, NC, USA).
Ethical approval and consent
The study was ethically reviewed and approved by the Dutch Health Council 
(2005/03WBO, The Hague, The Netherlands). All participants gave written informed 
consent for the FOBT and if positive for colonoscopy. 
Results
Overall 6,157(60%) of the 10,322 subjects invited to perform the iFOBT returned a 
used test. Women (63%) participated more often than men (56%) and persons < 60 
years of age a little less than persons ≥60 years of age (table 1). A positive iFOBT, i.e. 
a test result ≥50ng/ml, was found in 526 subjects, corresponding with a positivity rate 
of 8.5% (95% CI: 7.8-9.2) of the participants. The positivity rate was 6.6% for women 
and 10.9% for men and respectively 6.4% and 10.8% for participants <60 and ≥60 
years of age. The age of one female participant was unknown.
In 428(81%) of the 526 iFOBT positive patients a colonoscopy was performed. The 
cecum was reached in 402 patients (94%). In patients in whom the cecum could not be 
reached a successful second colonoscopy was performed. CRC was detected in 28(7%) 
of the 428 patients, and ≥1 advanced adenoma was found in an additional 161(38%) 
patients (table 2). Thus, 189 patients were found to have either CRC or ≥1 advanced 
adenoma, which amounts to 44% (95% CI 40%-49%) of the patients that underwent 
colonoscopy.
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iFOBT performance
The mean amount of haemoglobin detected in iFOBT positive subjects without CRC or 
advanced adenomas was 314ng/ml (95% CI 239-388) (table 2). The mean amount of 
haemoglobin in patients with CRC was 785ng/ml (95% CI 563-1008) and in patients 
with ≥1 advanced adenoma 523ng/ml (95% CI 420-627), was significantly higher. The 
amount of haemoglobin in the faecal sample does not follow a normal distribution. 
Therefore the difference in amount of haemoglobin in the sample of patients with CRC 
or ≥1 advanced adenoma compared with patients without significant lesions is less 
 
Table 1. Basic numbers and descriptive statistics of the study population invited to perform an iFOBT in 
population based colorectal cancer screneing 
    Study Phase Number   Statistic % total (95%CI) Gender (%) Age (%) 
         male female <60 t 60
    
Invited 10322 
        
            
Male + Female 5035+5287         
Age <60 + Age t60 5298+4952         
    
Participants 6157 
  Participation1 60% (59%-60%) 56% 63% 59% 61%
            
Male + Female 2820+3337         
Age <60 + Age t60 3128+3009         
    
iFOBT 50ng/ml 526 
  Positivity2 9% (8%-9%) 11% 7% 6% 11%
            
Male + Female 306+220   
Age <60 + Age t60 199+326         
    
Colonoscopy 428 
  Adherence3 81% (78%-82%) 84% 78% 88% 77%
            
Male + Female 257+171         
Age <60 + Age t60 175+252         
A  B  Colorectal Cancer or  
t1 Advanced Adenoma 189 
  PPV4 44% (39%-45%) 47% 40% 40% 47%
     NNTScope5 2.3 (2-2.5)     
Male + Female 121+68        
Age <60 + Age t60 70+119  Detection Rate6     
   per protocolA 3.1% (2.6%-3.5%) 4.3% 2.0% 2.2% 4.0%
   Intention-to- 1.8% (2.7%-3.4%) 2.4% 1.3% 1.3% 2.4%
   screenB      
         
1Participation Rate is the number of participants relative to the number of invited persons 
2Positivity Rate is the number of persons with a positive test (iFOBT t50ng/ml) relative to the number of 
participants 
3Adherence Rate is the number of persons undergoing a colonoscopy relative to the number of persons with 
a positive test 
4PPV is the positive predictive value the number of persons with colorectal cancer or 1 advanced adenoma 
relative to the number of persons undergoing a colonoscopy  
5NNTScope is the Number Needed To Scope, which is the reciprocal of the PPV (1/PPV), i.e. the number of 
persons undergoing a colonoscopy relative to the number of persons with colorectal cancer or 1 advanced 
adenoma 
6Detection rates are calculated Aper protocol, i.e. the number of persons with colorectal cancer or 1 
advanced adenoma relative to the number of participants and Bintention to screen, i.e. the number of 
persons with colorectal cancer or 1 advanced adenoma relative to the number of invited persons. 
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pronounced than the averages in table 2 indicate. By logarithmic transformation of 
the test value a normal distribution for the (log) amount of haemoglobin was reached. 
Univariable logistic regression analysis showed quantity-response relations for the log 
transformed test value and likelihood of finding CRC (p<0.0001), stage I or II CRC 
(p<0.01), stage III or IV CRC (p<0.001) or advanced adenomas (p<0.001). Correction 
with logistic regression analysis for the possible confounders age and gender did not 
change any of the relations found and statistical significance was robust for all groups.
In figure 1 the detection rates for CRC and advanced adenomas are presented for the 
functional range (50-2000ng/ml) of the iFOBT. Besides the overall detection rates for 
CRC and advanced adenomas, also the separate detection rates for CRC and advanced 
adenomas are presented. At a cut-off value of 50ng/ml the overall detection rate for 
CRC and advanced adenomas was 3.1% (95% CI 2.6-3.5) and the NNTScope was 
2.3(95% CI 2.2-2.3) (figure 2, table 3). At the cut-off value >75ng/ml the detection rate 
was 2.7% and the NNTScope 2, i.e. every second colonoscopy a patient with CRC or ≥1 
 
Table 2. Characteristics of lesions found at colonoscopy and iFOBT result (ng/ml). 
      Range Percentile 
iFOBT positives (50ng/ml) N(%) MEAN [95% CI] MIN MAX 25th MEDIAN 75th
Without colonoscopy 98(19) 455 [326-583] 52 2916 76 144 497 
With colonoscopy 428(81) 434 [377-492] 50 4168 80 175 482 
Neither cancer nor adenomas1 134(31) 314 [239-388] 50 2818 76 125 347 
Non-advanced Adenomas2 105(25) 356 [232-481] 50 4168 69 109 326 
Advanced Adenomas3 161(38) 523 [420-627] 52 3322 100 251 582 
Cancer4 28(7) 785 [563-1008] 59 1871 283 662 1226
  Stage I or II cancer 19(68) 652 [400-904] 59 1871 280 384 1099
  Stage III or IV cancer 9(32) 1066 [662-1470] 202 1845 622 1182 1635
1Neither cancer nor adenomas: colonoscopies without any lesions or only hyperplastic polyps, 
serrated adenomas or unclassified polyps. 
2Non advanced adenomas: colonoscopy with adenomas but without advanced adenomas and cancer. 
3Advanced adenomas: colonoscopies without cancer but with adenomas 10mm in size, high grade 
dysplasia or a villous component 20%. 
4Staging according to TNM classification: there were only 4 stage II (0 stage IIb), 0 stage IV patients. 
Therefore stage I and II, and III and IV were combined.   
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Figure 1. The detection rate (%) for colorectal cancer and advanced adenomas for the operative range of the iFOBT (50-2000ng/ml).  
Overall detection rate of colorectal cancer and advanced adenomas (O), subgroup detection rates of colorectal cancer (C) and advanced adenomas (A) 
(adenomas 10mm, adenomas with high-grade dysplasia or adenomas with a villous component 20%). 
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Figure 2. The overall detection rate and number needed to scope for cancer and 1 advanced adenomas focused on the range between 50 and 200ng/ml. 
Left axis: detection rate for colorectal cancer and advanced adenomas (-Ɣ-) 
Right axis: number needed to scope for colorectal cancer and advanced adenomas (-Ƒ-) (by definition >=1.0). 
 
ng hemoglobin per ml sample solution
50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 4500
De
tec
tio
n R
ate
 (%
)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
Nu
mb
er 
Ne
ed
ed
 To
 S
co
pe
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
Cut-off value for iFOBT positivity
~115~
 
Figure 1. The detection rate (%) for colorectal cancer and advanced adenomas for the operative range of the iFOBT (50-2000ng/ml).  
Overall detection rate of colorectal cancer and advanced adenomas (O), subgroup detection rates of colorectal cancer (C) and advanced adenomas (A) 
(adenomas 10mm, adenomas with high-grade dysplasia or adenomas with a villous component 20%). 
ng hemoglobin per ml sample solution
100 200 300 400 500 600 700 800 900 10001100120013001400150016001700180019002000 4500
D
et
ec
tio
n 
R
at
e 
(%
)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
OOOOOOOOOOOOO
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO O O OOOOOOOOOOOOO O OOO O OO OOOOO
CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC C CCCCCCCCCCCCCCC CCCC C C C C C CC CCCC
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA A A AAAA AAA A AA A AA A AA A AA
 
Figure 2. The overall detection rate and number needed to scope for cancer and 1 advanced adenomas focused on the range between 50 and 200ng/ml. 
Left axis: detection rate for colorectal cancer and advanced adenomas (-Ɣ-) 
Right axis: number needed to scope for colorectal cancer and advanced adenomas (-Ƒ-) (by definition >=1.0). 
 
ng hemoglobin per ml sample solution
50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 4500
De
tec
tio
n R
ate
 (%
)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
Nu
mb
er 
Ne
ed
ed
 To
 S
co
pe
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
advanced adenoma was detected. At this level only one patient (<5%) with cancer 
was missed compared with the cut-off value ≥50ng/ml: a 64 year old male patient 
with a stage I sigmoid carcinoma and an iFOBT result of 59ng/ml. At a cut-off value of 
100ng/ml, the overall detection rate for CRC and advanced adenomas was 2.4% (95% 
CI 2.0-2.7) and the NNTScope 1.9 (95% CI 1.9-2.0). At a cut-off value of 200ng/ml, 
the detection rate for CRC and advanced adenomas was 1.8% (95% CI 1.5-2.2) and the 
NNTScope 1.8 (95% CI 1.7-1.8). In the range from 100-200ng/ml the cancer miss rate 
compared with the cut-off value ≥50ng/ml was stable at 14% (N=4). 
For subjects < 60 years of age and women it might be reasonable to consider a higher 
cut-off value (figure 3a, 3b, 3c and 3d). We consider our data at the moment insuffi-
cient to substantiate possible recommendations for specific cut-off values for younger 
subjects or women.
Table 3. The performance characteristics of the iFOBT, OC-Sensor®, at different cut-off levels. 
  Cut-off values (ng/ml)     
  50 75 100 125 150 175 200 225 
iFOBT positives 1  (N) 428 336 280 248 234 215 198 187 
Positivity rate2 (%) 7.0% 5.5% 4.5% 4.0% 3.8% 3.5% 3.2% 3.0% 
Number of lesions (n) 
Colorectal Cancer 28 27 24 24 24 24 24 23
CRC + Adv. adenomas 189 163 145 136 131 121 113 109 
Detection rate 3 (%) 
Colorectal Cancer 0.45% 0.44% 0.39% 0.39% 0.39% 0.39% 0.39% 0.37%
95% CI 0.3-0.6 0.3-0.6 0.2-0.6 0.2-0.6 0.2-0.6 0.2-0.6 0.2-0.6 0.2-0.5 
CRC + Adv. adenomas 3.1% 2.6% 2.4% 2.2% 2.1% 2.0% 1.8% 1.8%
95% CI 2.6-3.5 2.3-3.1 2-2.7 1.8-2.6 1.8-2.5 1.6-2.3 1.5-2.2 1.4-2.1 
Number Needed To Scope 4 (N/n) 
Colorectal Cancer 15.3 12.4 11.7 10.3 9.8 9.0 8.3 8.1 
95% CI 11.3-23.8 9.1-19.5 8.4-18.9 7.5-16.7 7.1-15.7 6.5-14.4 6-13.2 5.9-13.2
CRC + Adv. adenomas 2.3 2.1 1.9 1.8 1.8 1.8 1.8 1.7 
95% CI 2.6-2.5 1.9-2.3 1.7-2.2 1.6-2.1 1.6-2 1.6-2 1.6-2 1.5-2 
CRC Miss Rate5 (%) n.a. 3.6% 14.3% 14.3% 14.3% 14.3% 14.3% 17.9% 
95% CI n.a. -3.3-,10.4 1.3-27.2 1.3-27.2 1.3-27.2 1.3-27.2 1.3-27.2 3.7-32 
95% CI = 95% Confidence Interval  
1iFOBT positives = patients with a positive iFOBT who had a colonoscopy; 
2Positivity rate = percentage of participants with a positive iFOBT who had a colonoscopy; 
3Detection rate = percentage of participants with lesions of reference; 
4Number Needed To Scope = the number of patients to find one extra patient with lesions of reference; 
5CRC miss rate = the percentage of the colorectal cancer patients at that cut-off relative to the colorectal 
cancer patients at the minimal 50ng/ml cut-off 
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Figure 3. The detection rate (%) and number needed to scope for colorectal cancer and >=1 advanced adenomas 
focused on the range between 50 and 200ng/ml for males(A), for females (B), patients <60 years of age (C) and 
patients >=60 years of age (D)
Left axis: detection rate for colorectal cancer and advanced adenomas
Right axis: number needed to scope (NNTScope) for colorectal cancer and advanced adenomas (by definition >=1.0).
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Discussion
In the present study, we have evaluated the performance and efficiency of a semi-
quantitative iFOBT, the OC-Sensor®, in an average-risk screening population. We have 
presented detection rates and numbers needed to scope over the effective range of 
the test and we have shown that below the threshold of 100ng/ml recommended by 
the manufacturer of the test, good performance could be achieved even at the lowest 
functional value of 50ng/ml tested. A decrease of the cut-off value from 100ng/ml 
to 50ng/ml results in a higher detection rate of colorectal cancer and advanced 
adenomas. However the NNTScope gradually rises, disturbing a positive balance 
between true positives (CRC or advanced adenomas) and false positives. An increase 
of the cut-off value above 100ng/ml decreases the detection rate, but the NNTScope 
also decreases below 2, i.e. less than 2 colonoscopies have to be performed to detect 
one CRC or advanced adenoma. However with a cut-off value of 50ng/ml relevantly 
more CRC is detected compared with a cut-off value of 100ng/ml or higher. 
The cut-off value with the most optimal performance of the iFOBT may differ in various 
populations and may change over time, because the performance is dependent on 
prevalence of CRC and advanced adenomas. In addition, local resources and capacity for 
colonoscopy have to be taken into account. Therefore, the data from this study should 
not be extrapolated to other populations, without considering these variables. However 
we do think extrapolation of the results will be quite appropriate for most European 
countries since the prevalence of CRC and the capacity of adequate health care are 
comparable.14,15 Based on our findings and the current capacity for colonoscopy, 
a cut-off value between 50 and 200ng/ml should be feasible and acceptable, for the 
West-European population. 
In a previous publication we showed that the performance of the gFOBT, Hemoccult-II®, 
is lower than the performance of the iFOBT, OC-Sensor®, at the standard cut-off value 
of 100ng/ml.6 The PPV for CRC and advanced adenomas of the gFOBT was 55.3%, 
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which was reached with the iFOBT at a cut-off value of 130ng/ml. However at this 
cut-off level the detection rate for CRC and advanced adenomas of the iFOBT 
was 2.2%, which was almost twice as high as the 1.2% detection rate for CRC and 
advanced adenomas of the gFOBT.
Previous studies published about semi-quantitative iFOBTs in screening populations, 
did not address the true continuous nature of these tests.1,2 Furthermore, these studies 
did not present colonoscopy results below the threshold recommended by the manu-
facturer. In a recent study in 1000 symptomatic and other high risk patients in Israel with 
the same OC-Sensor® test from Eiken Chemical, cut-off values below the recommended 
threshold were evaluated.5 The results of this study are comparable to our results 
and these authors suggest that a cut-off level of 75ng/ml would probably achieve 
optimal results, but acknowledge that screening data are needed for confirmation. 
A limitation of our study was that we only have data for one sample of iFOBT. In the 
previously mentioned study 1000 symptomatic and other high risk patients in Israel 
were asked to perform 3 separate samples.5 The authors observed an increased 
sensitivity for more than one sample, although the difference between two and three 
samples was not quite relevant. It is conceivable that a strategy with a combination 
of two samples results in a different cut-off value with optimal results, compared with 
one sample. On the other hand it also conceivable, that an increase in sensitivity and 
therefore detection rate is matched by a decrease in participation, which would result 
in a decrease in detection rate according to intention-to-screen.
Advanced adenomas and CRC were found more often in men than in women and 
advanced adenomas and CRC were also more often detected in older persons. This is 
in line with other studies.16-18 Thus, the diagnostic yield increases with age and male 
gender. We showed that for gender and different age groups other optimal cut-off 
values might be valid, but with the present data we were unable to verify the validity 
of any specific recommendations. It might be interesting to investigate the possibility, 
but also the acceptability of age and gender specific cut-off values.
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According to the manufacturer of the iFOBT, the test result gradually becomes less 
reliable at values lower than 50ng/ml. There are no studies in population-based 
screening with data below 50ng/ml to verify the level of unreliability. If the test 
gradually becomes more unreliable below 50ng/ml the NNTScope would increase 
relatively quicker than the detection rate. Levi at al concluded in their study that 
the optimal cut-off value might be as low as 75ng/ml in symptomatic and high risk 
patients.5 The optimal cut-off value in average risk screening individuals could be even 
lower. We decided to use a minimal cut-off value of 50ng/ml, because of the possible 
unreliability of the iFOBT below this level.
The results of our study and therefore also our conclusions are based on a screening 
population between 50 and 75 years of age. The risk of colorectal cancer gradually rises 
above the age of 50, and does not cease to rise at age 75. The choice to limit the 
screening population to people above 50 and below 75 matches European guidelines. 
In determining the choice for a cut-off value, the age range for screening should be 
taken into account. In a population with a lower prevalence (e.g. younger age-groups) 
a higher cut-off value might be considered.
Conclusion
In this study evidence is presented that below the threshold of 100ng/ml recommended 
by the manufacturer of the iFOBT, OC-Sensor®, good performance could be achieved 
even at the lowest functional value of 50ng/ml. We propose that a cut-off value below 
100ng/ml is feasible and acceptable in screening programmes in most western Euro-
pean countries, assuming resources and colonoscopy capacity are sufficient. However 
when resources and colonoscopy capacity are not sufficient also cut-off values above 
100ng/ml, up to 200ng/ml, will result in a relatively limited miss rate for colorectal 
cancer and a still very acceptable performance of the iFOBT, compared with a relatively 
high decrease in the number needed to scope. Policy makers will determine the optimal 
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cut-off value based on a largely arbitrary balance between the acceptability of 
missing (early stage) cancer and the possibility and acceptability of assigning essential 
resources.
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Question 11.
Is stability of haemoglobin in the faecal sample of the iFOBT 
sufficient?
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Abstract
Introduction Delayed return of immunochemical faecal occult blood test (iFOBT) 
samples to a laboratory, might cause false negatives due to haemoglobin degradation. 
Quantitative iFOBTs become increasingly more accepted in colorectal cancer screening. 
Therefore we studied the effects of delay between sampling and laboratory delivery 
on iFOBT performance. 
Methods IFOBT positivity (≥50ng/ml) in colorectal cancer screening participants 
without delay between sampling and laboratory delivery (<5 days), was compared 
with positivity in participants with ≥5 and ≥7 days delay. Additionally positive tests 
were stored at room temperature and retested 5 times within 10-14 days. 
Results The sampling date was reported by 61%(n=3767) of the participants: in 19% 
delay was ≥5 days and in 5% ≥7 days. Compared with no-delay, the adenoma detection 
rate was already significantly decreased after ≥5 days delay (OR 0.6; 95%CI 0.4-0.9). 
We retested iFOBT samples of 170 positives of which 139(82%) had a colonoscopy: 
45(32%) had advanced adenomas (not colorectal cancer) and 8(6%) had colorectal 
cancer. Mean haemoglobin decrease was 29ng/ml (SD 38 and median 11ng/ml) per 
day. In patients with advanced adenomas, haemoglobin in the sample was <50ng/ml 
in 5(11%) 2-3 days after the initial test and in 16(36%) after 10-14 days. Seven days 
after the initial test, 2(25%) colorectal cancer patients became false negative. Both had 
stage I colorectal cancer and initial values below 100ng/ml, where the average for 
stage I was 532ng/ml. 
Conclusion Delay in sample return increased false negative immunochemical FOBTs. 
Mainly precursor lesions, but also colorectal cancer, will be missed due to delayed 
sample return.
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Introduction 
Immunochemical faecal occult blood tests (iFOBT) performed at home by screening 
participants are promising in population-based screening for colorectal cancer.1 Some 
iFOBTs are quantitative and the faecal sample is stored in a sample bottle 
containing a haemoglobin stabilizing buffer.2,3 However the stability of faecal 
haemoglobin in the stabilizing buffer has not been studied comprehensively. Several 
factors may influence haemoglobin stability like storage conditions and lag time 
before the faecal sample is analysed.
In the stabilizing buffer of the iFOBT (OC-Sensor®, Eiken Chemical Co. Ltd., Tokyo, 
Japan), faecal haemoglobin proved to be quite stable at temperatures at or below 4 
degrees Celsius in a laboratory simulation study.2,4,5 However at higher tempera-
tures degradation of faecal haemoglobin could be more rapid, even under controlled 
laboratory circumstances.5,6 Vilkin et al performed a simulation study with a limited 
number of samples on the validity of the OC-Sensor.2 Indeed they found a decrease 
over time of faecal haemoglobin concentrations especially at room temperature and 
above. However this study was performed completely under laboratory conditions 
with only 19 samples used for retests at room temperatures or above. Also more than 
half of these samples contained a higher than average initial amount of haemoglobin. 
In a colorectal cancer screening population we aimed to study, whether delay 
between faecal sampling and delivery at the laboratory influences the performance 
of the iFOBT, OC-Sensor®.
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Material and methods
Patients
From June 2006 to February 2007, we performed a large prospective population-
based screening study in over 20,000 persons, randomly selected from the general 
population in the Netherlands. The methods and results of this study were published 
previously.1 Half of the study population was randomly allocated to receive an iFOBT. 
The study was ethically approved by the Health Council in the Netherlands 
(2005/03WBO, The Hague, The Netherlands) and the minister of Health and all 
participants gave written informed consent. 
 
Immunochemical faecal occult blood test
The semi-quantitative iFOBT, OC-Sensor® (Eiken Chemical Co. Ltd., Tokyo, Japan), 
was processed with the OC-Micro instrument (Eiken Chemical Co. Ltd., Tokyo, Japan). 
The iFOBT kit contained written instructions and a single sampling tube, with 2ml 
haemoglobin stabilizing buffer. The design of the tube regulates the amount of faeces 
inserted into the sample bottle to approximately 10 mg.2 Participants performed 
the sampling for the test at home and were instructed to return the test as soon as 
possible by mail. They were asked to report the date of faecal sampling on the sample 
tube. If the test could not be returned immediately, storage in a refrigerator was 
advised. As threshold for positivity, the manufacturer recommends a cut-off value of 
100ng/ml, applied in several studies.7-12 The literature as well as data provided by the 
manufacturer show that the test results of the OC-Sensor® are reliable in the range 
from 50ng/ml to 2000ng/ml.2 In a previous publication we compared the guaiac 
FOBT (gFOBT, Hemoccult-II®) with the iFOBT (OC-Sensor®).1 In that publication, for 
generalizability with the previous studies, we presented data for the iFOBT with a 
cut-off value of ≥100ng/ml. However we invited all patients with an iFOBT result of 
≥50ng/ml for colonoscopy, which data we use in the current analysis. Below 50ng/ml, 
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test results may become gradually more unreliable and, to our knowledge, no data on 
test reliability are available for cut-off levels below 50ng/ml, corresponding with 
±10µg/g faeces.13 For generalizability we also present data concerning a cut-off value 
of 100ng/ml in the results and the tables, which was applied in several studies.7-12
Colonoscopy and lesions
All colonoscopies were performed by experienced gastroenterologists using 
conscious sedation with midazolam. If the cecum could not be reached during the 
initial colonoscopy, the procedure was repeated usually under propofol anaesthesia. 
If possible, all observed neoplasias were removed, and other lesions were biopsied if 
necessary. Histology was evaluated by an experienced pathologist and advanced 
adenomas were defined as adenomas ≥10 mm, with high-grade dysplasia or with 
a villous component ≥20%. Adenomas that were by definition not advanced 
adenomas, were defined as minor adenomas.
Study design and data analysis
The study was designed into two separate parts: a pragmatic trial in the screening 
population and a confirmatory simulation study under laboratory conditions. In the 
first part, the pragmatic trial, the proportions of (true) positive patients with and 
without delay between self-reported home faecal sampling and laboratory delivery 
were compared. During this interval the sample, possibly containing haemoglobin in 
the faeces, was exposed to room temperature at least most of the time. Therefore 
only subjects who reported the date of sampling could be included in the analysis of 
the first part of the study. We analysed if the rates of (true) positives decreased with 
more days of delay with logistic regression analysis. To analyse the differences in 
(true) positives we divided the study population into a group without significant delay 
(<5 days), and two groups with different cut-off values for delay: a group with ≥5 days 
delay and a group having ≥7 days delay, because the maximum decay due to exposure 
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to higher temperatures was expected approximately at the end of the first week.4 
Odds ratio’s (OR) and 95% confidence intervals (95% CI) are presented 
for the differences between participants with delay compared with participants 
without delay. Odds ratios were corrected for age, gender and place of residence with 
multivariate logistic regression analysis. Although the number of screened persons 
was high, the number of persons who returned there sample with delay was relatively 
small, limiting power of the study and a type II error had to be taken into account. 
In the second part of the study, the laboratory simulation study, we retested the tests 
of positive patients 5 times within 10-14 days. We started the laboratory simulation 
in November 2006, four months before inclusion was closed, because only at that 
time did we realize there might be a problem with delay from the data of the first part 
of the study. We did not include samples of participants who had tested positive 
and were frozen before this period, because there are hardly any scientific data of 
the effects on haemoglobin in the sample due to freezing.5 The 2 ml buffer with the 
faecal sample in the sample tube was sufficient for at least 5 retests. We simulated 
home conditions in this experiment: after each series of testing, tests were resealed 
and stored at room temperature (±20ºC) without actively keeping conditions like 
temperature and humidity constant. We measured mean and median decrease of 
faecal haemoglobin in the sample solution over time and estimated the risk of false 
negatives due to degradation of faecal haemoglobin (<50ng/ml). Odds ratio’s (OR) 
and 95% confidence intervals (95% CI) were presented for the differences between 
retests. Statistical analysis was performed with SAS system for windows, software 
version 8.02 (SAS Institute Inc., Cary, NC).
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Results 
Pragmatic study.
The iFOBTs were returned by 6157 (60%) of the invited subjects. In the laboratory, 
most tests were analysed the same day and if not stored at 4°C: 75% of the tests 
were analysed within 2 days and 99.6% within 6 days after delivery of the test at the 
laboratory. 
A total of 3767(61%) participants self-reported the date of faecal sampling: in 705(19%) 
delay was ≥5 days and in 195(5%) ≥7 days (Figure 1). OC-Sensor tests were positive 
(≥50ng/ml) in 265(8.7%) of the tests delivered without delay, in 42(6.0%) with a 
delay ≥5 days and in 8(4.1%) with a delay ≥7 days. Logistic regression analysis, 
corrected for gender, age, and place of residence, showed that the positivity rate 
significantly decreased with each extra day of delay with an odds ratio of 0.9 (95%CI 
0.8-1.0) with a cut-off value ≥50ng/ml. Using a cut-off value ≥100ng/ml the results 
were consistent but not statistically significant (OR 0.9 95%CI 0.8-1.0). Compared with 
OC-Sensor tests returned without delay, the positivity rate was significantly decreased 
after a delay ≥5 days (OR 0.7; 95%CI 0.5-0.9), and after a delay ≥7 days (OR 0.5; 95%CI 
0.2-0.9). In 264 of the 314(84%) positives, who reported the date of faecal sampling, 
a colonoscopy was performed. The adherence to colonoscopy was similar to the overall 
colonoscopy adherence rate (81%). Although adherence rates were not significantly 
different for the groups with delay compared with the groups without delay, delayed 
return consistently coincided with a slightly decreased adherence to colonoscopy 
(Table 1).
Compared with participants without delay, participants with delay were more often 
male, more often <60 years of age and more often from the city of Amsterdam (as 
opposed to the city of Nijmegen and the rural parts around Nijmegen and Amsterdam). 
Compared with participants without delay, the rate of male participants was signifi-
cantly higher in the ≥5 days delay group (OR 1.2; 95%CI 1.1-1.5), but not in the ≥7 days 
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Figure 1. Flow diagram of the two parts of the study, which are described in detail in the methods. 
 
delay group (OR 1.1; 95%CI 0.9-1.5). The rate of participants <60 years of age was 
significantly higher in both the ≥5 days (OR 1.5; 95%CI 1.2-1.7) and ≥7 days (OR 1.6; 
95%CI 1.2-2.2) delay groups. The rate of participants from the city of Amsterdam was 
significantly higher in both the ≥5 days (OR 2.5; 95%CI 1.9-3.2) and ≥7 days (OR 5.3; 
95%CI 3.7-7.5) delay groups. All following odd ratios were corrected for gender, age 
and place of residence.
Delay was especially detrimental for the detection of the precursor stages minor and 
advanced adenoma, but less for colorectal cancer. With each extra day of delay both 
with a cut-off value ≥50ng/ml and ≥100ng/ml the detection of all adenomas including 
advanced adenomas significantly decreased with an odds ratio of 0.9 (95%CI 0.8-1.0) 
and the detection of advanced adenomas significantly decreased with an odds ratio 
of 0.8 (95%CI 0.7-1.0). 
With a cut-off value of 50ng/ml compared with the group without delay the detection 
rate of all adenomas, including advanced adenomas, but not colorectal cancer was 
significantly lower for the ≥5 days delay group (OR 0.5; 95%CI 0.3-0.9). Compared 
with the group without delay, the detection rate for adenomas for the ≥7 days delay 
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group was even lower than for the ≥5 days delay group, but this difference did not 
reach statistical significance (OR 0.4; 95%CI 0.1-1.1). The detection rate of participants 
with advanced adenomas was consistently decreased in the groups with ≥5 days 
(1.0%, OR 0.5; 95%CI 0.3-1.0) and ≥7 days delay (1.7%, OR 0.3; 95%CI 0.1-1.5), again 
not significantly for the ≥7 days group.
Table 1. Characteristics of all the participants in the primary study with and without delayed return* of the 
iFOBT and detection of colorectal cancer and adenomas with a cut-off value of 50ng/ml and 100ng/ml. 
 Not delayed Delay >=5 days Delay >=7 days 
 N = 3062 N = 705 N = 195 
 N % (95% CI)6 N % (95% CI) 6 N % (95% CI) 6 
Male gender 1347 44% (42-46) 348 49% (46-53) 92 47% (40-54) 
Age < 60 years 1512 49% (47-52) 415 59% (55-62) 118 61% (54-67) 
Amsterdam 193 6% (5-7) 101 14% (12-17) 51 26% (20-32) 
Cut-off 50ng/ml       
Positive patients 265 8.7% (7.7-9.7) 42 6.0% (4.2-7.7) 8 4.1% (1.3-6.9) 
Colonoscopy adherence 224 7.3% (6.4-8.2) 34 4.8% (3.2-6.4) 6 3.1% (0.7-5.5) 
Detection of       
Adenomas1 143 4.7% (3.9-5.4) 20 2.8% (1.6-4.1) 4 2.1% (0.1-4) 
Minor Adenomas only 2 59 1.9% (1.4-2.4) 8 1.1% (0.4-1.9) 2 1.0% (-0.4-2.4) 
Advanced Adenomas3 84 2.7% (2.2-3.3) 12 1.7% (0.7-2.7) 2 1.0% (-0.4-2.4) 
Colorectal cancer4 14 0.5% (0.2-0.7) 5 0.7% (0.1-1.3) 1 0.5% (-0.5-1.5) 
Proximal neoplasia only5 9 0.3% (0.1-0.5) 6 0.4% (-0.1;0.9) 1 0.5% (-0.5-1.5) 
Cut-off 100ng/ml       
Positive patients 163 5.3% (4.5-6.1) 29 4.1% (2.6-5.6) 5 2.6% (0.3-4.8) 
Colonoscopy adherence 143 4.7% (3.9-5.4) 22 3.1% (1.8-4.4) 2 1.0% (-0.4;2.4) 
Detection of       
Adenomas1 95 3.1% (2.5-3.7) 10 1.4% (0.5-2.3) 1 0.5% (-0.5;1.5) 
Minor Adenomas only 2 31 1.0% (0.7-1.4) 2 0.3% (-0.1;0.7) 0 0% 6 
Advanced Adenomas3 64 2.1% (1.6-2.6) 8 1.1% (0.4-1.9) 1 0.5% (-0.5;1.5) 
Colorectal cancer4 12 0.4% (0.2-0.6) 5 0.7% (0.1-1.3) 1 0.5% (-0.5;1.5) 
Proximal neoplasia only5 6 0.2% (0.0-0.4) 5 0.7% (0.1-1.3) 1 0.5% (-0.5;1.5) 
*delayed return; delay between self-reported sampling and laboratory delivery 
1Adenomas = patients with adenomas, without carcinoma 
2Minor adenomas only = patients with exclusively minor adenomas, no carcinoma or advanced adenomas 
3Advanced adenomas = patients with advanced adenomas (adenomas >=10 mm, with high-grade 
dysplasia or with a villous component >=20%) without carcinoma 
4Colorectal cancer = patients with colorectal cancer 
5Proximal neoplasia only = patients without distal advanced adenomas or carcinoma 
6Detection rates are number relative to participants. For numbers of 5 or lower the approximation of the 
95% confidence interval around the corresponding proportion is gradually less reliable. For N=zero no 
confidence interval can be calculated. 
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Applying the more commonly used cut-off value for positivity of 100ng/ml did not 
relevantly alter the odds ratios for the influence of delay on detection. Similar to the 
cut-off value of 50ng/ml statistical significance was reached for the ≥5 days delay 
group both for all adenomas (OR 0.4; 95%CI 0.2-0.8) but not for advanced adenomas 
(OR 0.1; 95%CI 0.0-1.1) and not for the ≥7 days delay group both for adenomas (OR 
0.4; 95%CI 0.2-1.0) as well as advanced adenomas (OR 0.2; 95%CI 0.0-1.5). 
Laboratory simulation study
We retested positive OC-Sensor tests (≥50ng/ml) of 170 participants five times, usually 2 
and occasionally 3 days apart, within 10 to 14 days. Quantifiable haemoglobin in the 
faecal sample solution decreased by a mean of 29ng/ml per day (SD 38) and a median 
of 11ng/ml (Figure 2). Of the 170 participants with retested positive tests, eventually 
139(82%) had a colonoscopy (Figure 1). Colonoscopy adherence rates and detection 
rates were not statistically significantly different from the total population.
Consistent with the pragmatic part of our study protocol, delay was most detrimental 
for minor adenomas and less for advanced adenomas and colorectal cancer (Table 2). 
Over 5 retests with logistic regression analysis, corrected for gender, age, and place of 
residence, a significant decrease in the proportion of positive samples of participants 
with minor adenomas only (OR 0.7, 95%CI 0.6-0.8) and advanced adenomas (OR 0.9, 
95%CI 0.8-1.0) was observed. For colorectal cancer patients (OR 0.9, 95%CI 0.8-1.1) 
the decrease was not significant. After 2 retests, 65% (95%CI 49-81) of the samples of 
participants with only minor adenomas were still positive, whereas 78% (95%CI 66-
90) of the samples of participants with at least one advanced adenomas and 100% of 
the samples of participants with colorectal cancer remained positive. After 3 retests 
53% (95%CI 36-70) of the samples of participants with only minor adenomas were still 
positive and 71% (95%CI 58-84) of the samples of participants with advanced adenoma. 
Only after 7 days 2 (25%, 95%CI 0-55) of the samples of participants with colorectal 
cancer became negative. Both had stage I cancer and initial faecal haemoglobin 
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Table 2. Number and percentage positive participants, participants with adenomas, advanced adenomas 
and cancer per retest. 
 Initial Retest5  1 Retest5 2 Retest5 3 Retest5 4 Retest5 5 
 N N %6 
(95% CI) 
N %6 
(95% CI)
N %6 
(95% CI)
N %6  
(95% CI) 
N %6 
(95% CI)
Adherent to 
colonoscopy1 
139 122 88% 
(82-93) 
106 76% 
(69-83)
86 62% 
(54-70)
76 55% 
(46-63) 
76 55% 
(46-63) 
Minor adenoma2 34 28 82% 
(70-95) 
22 65% 
(49-81)
18 53% 
(36-70)
13 38% 
(22-55) 
13 38% 
(22-55) 
Advanced 
adenoma3 
45 40 89% 
(80-98)
35 78% 
(66-90)
32 71% 
(58-84)
30 67% 
(53-80) 
29 64% 
(50-78) 
>=10mm 42 37 88% 
(78-98) 
33 79% 
(66-91)
30 71% 
(58-85)
28 67% 
(52-81) 
27 64% 
(50-79) 
high-grade 
dysplasia 
29 25 86% 
(74-99) 
23 79% 
(65-94)
21 72% 
(56-89)
19 66% 
(48-83) 
19 66% 
(48-83) 
villous 
component 
28 24 86% 
(73-99)
23 82% 
(68-96)
21 75% 
(59-91)
19 68% 
(51-85) 
19 68% 
(51-85)
Colorectal 
cancer4 
8 8 100%  8 100%  6 75% 
(45-100)
6 75% 
(45-100) 
6 75% 
(45-100) 
1Adherent to colonoscopy= positive participants who were adherent to colonoscopy 
2Minor adenomas = patients with only minor adenomas (without advanced adenomas or carcinoma)  
3Advanced adenomas = patients with advanced adenomas (10 mm, high-grade dysplasia or villous 
component 20%), without carcinoma 
4Colorectal cancer = patients with colorectal cancer 
5Eacht retest was performed 2 to 3 days after the previous test. In total 5 retests ranging 10 to 14 days.  
6All percentages were calculated relative to the initial number from the initial test result. For 100% and 
0%, 95% confidence interval (95%CI) can not be calculated. Upper limits >100%, were rounded down. 
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Figure 2. Average decrease of haemoglobin in the sample solution over time depending on the 
detection of minor adenomas, advanced adenomas and cancer. 
* Each retest was performed 2 to 3 days after the previous test. In total for each positive sample 5 
intervals entailed 10-14 days.
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levels in the sample solution below 100ng/ml, which is relatively low for stage I 
cancer patients, who on average had 532ng/ml of faecal haemoglobin in the sample 
solution.
Discussion
In the present study we described the influence of delay between faecal sampling and 
delivery at the laboratory, on the performance of the iFOBT, OC-Sensor®. We found that 
delay between faecal sampling and laboratory delivery, due to continued exposure to 
room temperature, decreases the test performance of the iFOBT. Degradation of haemo-
globin over time at room temperature and consequently higher false negative rates, was 
confirmed in a laboratory. Degradation of haemoglobin did lead to higher false negative 
rates in all patient categories, but most of all in patients with minor adenomas, some-
what less in patients with advanced adenomas and fewest in patients with colorectal 
cancer. The decreased performance of the iFOBT due to delayed return of the sample 
was observed to be independent of the cut-off value for positivity of the iFOBT. 
Previous studies have also demonstrated that patients with adenomas on average 
have lower faecal haemoglobin levels than colorectal cancer patients.13 We found 
that, already after limited delay in iFOBT delivery, a gradual decrease of haemoglobin 
levels could result in failure to detect colorectal cancer patients. This confirms the 
laboratory data reported by Vilkin et al, who observed that degradation of haemoglobin 
over time at room temperature or above occurred in a quite limited and selected 
number of highly haemoglobin positive samples. 2,4
Due to the successful implementation of our colorectal cancer screening study, we 
only had a relatively small proportion of participants with delayed return after faecal 
sampling. Also the number of delayed tests could only be confirmed in 61% of the 
participants who reported the sampling date. The relatively low number of persons 
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with delayed return after faecal sampling, in turn resulted in relatively even lower 
numbers of persons with adenomas and especially colorectal cancer in the group 
with delayed return. Therefore a type II error, i.e. ruling out an actual difference 
between the groups with and without delay, could not be excluded. Although we 
consider the risk of selection bias quite limited in our study because the population 
was completely naïve about colorectal cancer screening, we ca not rule out completely 
that participants who responded relatively quick could be more at risk for colorectal 
cancer than late responders. We dealt with these problems by designing the study in 
two separate parts and confirmed the results of the pragmatic trial in the laboratory 
simulation study. In the study by Rozen et al., in a limited number of selected high 
positive samples the maximum decay was observed approximately at the end of the 
first week.4 In the pragmatic trial we analysed two groups with increased delay: 
a group with ≥5 days delay and a group ≥7 days delay. The cut-off values of ≥5 or ≥7 
days is not completely arbitrary as it comprises a workweek respectively a total week. 
In the laboratory simulation study we performed 5 retests after an initial positive test 
and observed a gradual and sometimes quite rapid increase in the false negative rates 
over the in total 5 retests. Because we realized only late in the inclusion period that 
delay could be a problem we started including samples for the laboratory simulation 
quite late in the inclusion period, limiting the number of consecutively collected positive 
samples. Data on the effects of freezing at -40ºC are promising but only limited to a a 
few weeks.5 Therefore we decided not to include all the samples which tested positive 
before the start of the simulation study, because many of these had already been frozen 
at -20ºC for many months. Despite these limitations we were able to conclude, that 
false negatives can occur due to delay between faecal sampling and laboratory delivery. 
We can not rule out that delay can also be detrimental for detection of colorectal cancer. 
In fact data from the laboratory simulation study suggested, that also colorectal cancer 
patients will eventually become false negative approximately 7 days after the initial 
test. However a delay of ≥7 days was very rare in our study population. Nevertheless 
Quality control
~137~
in other countries with different cultures or where the postal service is not so quick 
as in the relatively small Netherlands, a longer delay might occur more frequently. 
Furthermore in countries where temperatures are relevantly higher than the average 
room temperature of ±20 degrees Celsius in the Netherlands, less delay might prove 
too long. We would also like to caution against freezing the samples over prolonged 
periods (more than a few weeks) before analysing positivity. The data about the effects 
of freezing at -40ºC are promising, but limited to a few weeks.5 
In the written test instructions we asked participants to keep the faecal sample in the 
sample tube in a provided sample bag as cool as possible and preferably refrigerated 
until returning the test. We were unable to verify if subjects kept a sample refrigerated 
until posting, but we think it is quite unlikely that many of them did. However correction 
for refrigeration of the sample, would have only strengthened our conclusions, because 
keeping the test refrigerated would postpone haemoglobin degradation, resulting in 
an underestimated effect of delay on false negative rates.
The evidence in this study shows how important it is to control all aspects and logistics 
of screening protocols. Subjects invited for screening should be adequately informed 
of the necessity of prompt return of the sample and reporting the date of taking the 
sample. However more complicated information and effort, as well as the pressure of 
prompt return, might also result in decreased participation. Another, even less elegant, 
option would be to ask subjects with delay and a negative test, to perform a retest. 
We also considered the possibility of a dynamic cut-off value, i.e. a cut-off value relative 
to the number of days delay. Although this could very well prove an elegant solution, 
we lacked the data to consider analysing this option. We suggest that the best approach 
to counter the problem is, to produce a less sensitive haemoglobin stabilizing buffer: 
the maximum delay and climates in different countries should be taken into account 
according to a worst case scenario. Previously reported data suggest that the currently 
used buffer is more stable than the buffer in previous generations of the test.5 Therefore 
it should very well be possible to improve the stability.
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Conclusion
The performance of the immunochemical faecal occult blood test, OC-Sensor®, 
is decreased by delay between faecal sampling and laboratory delivery. Later stage 
colorectal cancer patients will probably not be missed due to this delay, but at least a 
relevant proportion of patients with advanced adenomas and possibly stage I colorectal 
cancer might be missed even with a delay of a few days. Until a less sensitive haemo-
globin stabilizing buffer is produced, monitoring delay between faecal sampling and 
laboratory research should be part of quality control for screening with immuno-
chemical FOBT. Inviting participants to perform a second test when delay is 5 days or 
more could be considered.
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tart Production!
In this thesis a wide-range of questions about colorectal cancer screening were 
addressed. The scope of the thesis ranged from general questions like “are the Dutch 
willing-to-be-screened?” to more basic research into the stability of an immunochemical 
faecal occult blood test. The aim was to study advantages and disadvantages of imple-
mentation of colorectal cancer screening in the Netherlands. The major requirements 
to accept implementation of population-based screening according to the Wilson & 
Jungner guidelines and issues raised by several stakeholders in public health, were 
used as foundation to formulate the questions answered in this thesis.1-4 In total 11 
questions were studied and answered comprised in 6 chapters. 
Chapter 1. Willingness-to-be-screened
Question 1. Are the Dutch aware of colorectal cancer and screening? 
A questionnaire, containing several items about awareness of colorectal cancer and 
screening, was sent to 500 subjects in the targeted age-range for colorectal cancer 
screening (50-75 years of age). None of the responders answered all 21 questions 
correctly and less than a quarter could be considered relatively aware of colorectal 
cancer and screening. The results confirm the results of a European study about 
awareness of colorectal cancer in which the Dutch scored least of all participating 
countries.5
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After informing subjects about colorectal cancer and screening, a different questionnaire 
with awareness items was sent to all subjects invited to be screened.6 Almost all 
considered the written information to be clear and readable. Still only 20% of the 
responders was able to answer all questions concerning awareness correctly. It can 
be concluded that awareness about colorectal cancer and screening is low in the 
Netherlands and raising awareness might prove difficult.
Question 2. Are the Dutch willing-to-be-screened for colorectal cancer? 
In the same questionnaire subjects were asked about their willingness-to-be-screened 
for colorectal cancer (with a ‘simple faecal test’) and 74% of the responders were willing-
to-be-screened. Probably willingness-to-be-screened would be relevantly lower in non-
responders. This was confirmed in the other study we performed after informing and 
inviting subjects for screening.6 Only 6% of the subjects who did not participate in 
screening, did fill-out the questionnaire. It was concluded that willingness-to-be-
screened in the Netherlands is high.
Question 3. Do willing subjects participate and what about the 
unwilling?
One year after the survey, all subjects still eligible for screening were invited for 
screening with an immunochemical faecal occult blood test. Evidence was provided 
that participation was very high (90%) in subjects who previously reported willing-to-
be-screened. Although participation was lower in subjects who previously reported 
not or less willing-to-be-screened, still many did participate (76%). Participation was 
much lower in subjects who previously did not fill-out the questionnaire (41%). There 
is much to gain in this generally unresponsive group, as some do participate, but 
information about these subjects is limited. It will be quite a challenge to increase 
participation in those subjects.
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Overall Dutch in general are willing-to-be-screened and willing subjects will usually 
participate in colorectal cancer screening with FOBT. However to increase participation 
in unwilling and especially unresponsive subjects will probably prove difficult. Informing 
about colorectal cancer and screening will hardly improve awareness and increased 
awareness has no association with higher participation. 
Chapter 2. Which tests and why
Question 4. Which tests are available for population-based colorectal 
cancer screening and what is the performance of these tests?
In contrast to most other types of cancer, for colorectal cancer many possible alternative 
screening tests exist: guaiac based faecal occult blood tests, immunochemical faecal 
occult blood tests, DNA tests, barium enema, sigmoidoscopy, colonoscopy, virtual 
colonoscopy (or CT-colonoscopy). Many of these alternatives have been investigated 
and in chapter 2 a basic overview is given, illustrating in a table the advantages and 
disadvantages of the five most promising alternatives for population-based colorectal 
cancer screening. The conclusion was that faecal occult blood tests (FOBT) still are 
the best screening alternatives for colorectal cancer screening. Additionally, it was 
concluded, that it was impossible to choose between the two main types of FOBT, the 
classic guaiac based (gFOBT) and the newer immunochemical FOBT (iFOBT), without 
a randomised controlled trial in population-based screening. The data of that trial 
were presented in more detail in the next part of chapter 2, but already discounted in 
the conclusion in the first part.
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Question 5. What is the performance of the Hemoccult-II®, guaiac based 
faecal occult blood test, compared with the OC-Sensor®, immuno-
chemical faecal occult blood test, in a screening population?
Over 20,000 subjects between 50 and 75 years of age were invited for colorectal 
cancer screening in two regions in the Netherlands and per household each subject 
was randomly assigned either a gFOBT or an iFOBT.7 Both screening participation and 
detection of colorectal cancer and adenomas were substantially higher for the iFOBT 
group compared with the gFOBT group. The positive predictive values of cancer and 
adenomas were not different between gFOBT and iFOBT and the much higher detection 
rates of the iFOBT went together with a lower but good specificity compared with the 
gFOBT. In conclusion the iFOBT performed much better than the gFOBT in population-
based colorectal cancer screening, both according to intention-to-screen and per-
protocol analysis: the iFOBT combined a much higher participation and detection rate 
with a very good specificity. In general these results confirm the results of previous 
studies in different populations with gFOBTs and iFOBTs.8-12
Chapter 3. Mortality
Only for the gFOBT direct evidence exists, that colorectal cancer mortality can be 
decreased by screening.13 As iFOBT and gFOBT basically both test for the same 
biomarker, i.e. blood or more specifically haemoglobin, and because the iFOBT has 
an increased detection rate for cancer and for advanced adenomas compared with 
the gFOBT,7 the decrease in mortality for the iFOBT should at least be similar 
to gFOBT.14,15 However because the detection rate of the iFOBT is much higher 
compared with the gFOBT, also a more decreased mortality rate might be expected. 
Colorectal cancer mortality can only be decreased, if detection of colorectal cancer 
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by screening with FOBT (screened) is more often diagnosed in early stages 
compared with detection of colorectal cancer on indication of symptoms or 
complaints (not-screened). Therefore in the next study the stage distributions from 
not-screened colorectal cancer patients from the same region and diagnosed in the 
same period as screened colorectal cancer patients were compared with answer the 
following two questions.16
Question 6. Is colorectal cancer mortality expected to decrease by FOBT 
screening compared with no screening?
Colorectal cancer was significantly more often detected in early stages in screened 
compared with not-screened patients. Based on average stage specific survival it can 
be estimated that the average 5-year survival of screened patients can be improved 
with 18% compared with not-screened patients.
Question 7. Is colorectal cancer mortality expected to decrease more by 
iFOBT screening than by gFOBT screening compared with no screening?
The stage distribution for colorectal cancer detected with gFOBT was not different 
compared with not-screened patients. Colorectal cancer was detected more 
often in early stages with the iFOBT compared with not-screened patients. Additionally 
treatment of colorectal cancer could frequently be confined to colonoscopy in the 
screened patients compared with hardly ever in the not-screened patients.
The data from this study were almost completely confirmed by a German study, with 
patients screened with primary colonoscopy compared with not-screened patients.17 
In line with editorials by Allison14 and Imperiale15 there is a secondary conclusion 
that can be derived from comparing the study in this thesis with the German study: 
the decrease in colorectal cancer mortality by iFOBT and primary colonoscopy screening 
might be similar.
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Chapter 4. Cost-effectiveness
Cost-effectiveness of colorectal cancer screening has been studied before. However the 
comparability of cost-effectiveness of colorectal cancer screening strategies is limited 
by differences in inclusion criteria, follow-up periods and geographical regions.18-23 
Also these studies are frequently limited by erroneous assumptions. For example 
participation in colorectal cancer screening is usually assumed 100% in cost- 
effectiveness studies and indifferent of the applied test for colorectal cancer 
screening. These limitations might bias the results and even with (extensive) 
sensitivity analysis the impact on the conclusions could be significant. 
The data of the randomised controlled trial described in chapter 2 were completed 
with data concerning cancer incidence and stage distribution without screening using 
data from the Dutch Cancer Registry (www.IKCnet.nl), to compare the cost-effectiveness 
of one round of gFOBT and iFOBT to no screening, in a Markov model with first and 
second order Monte Carlo simulation over 10 years. 
Question 8. Is screening with FOBT cost-effective compared with no 
screening?
Evidence was provided that FOBT screening was cost-effective compared with no 
screening as it dominated no screening, i.e. with FOBT screening both costs were 
saved and life years were gained.
Question 9. Is screening with iFOBT cost-effective compared with gFOBT 
screening?
Additionally, iFOBT screening was dominant over gFOBT, saving costs and gaining life 
years. The dominance of iFOBT screening was robust in sensitivity analyses varying 
colorectal cancer incidence and major cost drivers. 
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Colorectal cancer is one of the most frequent forms of cancer, fortunately however it 
still is a quite rare disease. The incidence of cancer in most European countries and 
also the Netherlands is quite similar24 as is the prevalence of colorectal cancer.17,25-27 
Therefore the prevalence of colorectal cancer in Dutch individuals between 50 and 75 
years of age, will be in the range of 0.7-0.9%. Consequently the incremental gains in 
costs and life years per subject invited to perform an iFOBT is limited. However on a 
population level the gains are considerable: with about 4.5 million Dutch individuals 
between 50 and 75 years of age, after a single round of screening the gain is over 
25,000 life years and €220 million euros. Overall these data confirm the results of the 
previously referenced cost-effectiveness studies.18-23 However the gains calculated in 
the study presented in this thesis were relatively limited compared with the previously 
published studies. It was proposed that these differences in the estimation of the size 
of the effect are attributable to the combination of heterogeneous study data and 
erroneous assumptions. Therefore the Netherlands will gain from screening with 
iFOBT, but less than was observed in previous cost-effectiveness studies.
Chapter 5. Cut-off value  
for iFOBT positivity
The iFOBT, OC-Sensor®, is a quantitative test. Therefore the cut-off value above which 
a subject is considered to have a positive test, can be chosen in accordance with 
acceptability and feasibility: test performance parameters, capacity for colonoscopy 
and treatment of cancer, and the availability of resources.
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Question 10. How does the performance of the iFOBT relate to the 
cut-off value?
According to the manufacturer, the iFOBT, OC-Sensor®, is reliable above a cut-off value 
of 50ng haemoglobin per millilitre sample solution (50ng/ml), which corresponds 
with 10 µg haemoglobin per gram faeces.28 In the randomised controlled trial all 
participants in the iFOBT screening arm with a value of ≥50ng/ml were invited for 
colonoscopy. The performance of the iFOBT was studied according to different cut-off 
values. Evidence was presented that below the threshold of 100ng/ml recommended 
by the manufacturer of the OC-Sensor®, the detection rate increased and the specificity 
decreased but remained very acceptable. The data of the presented study in this thesis 
are almost in complete agreement with a study in which mainly symptomatic patients 
and patients with a family history of colorectal cancer had a colonoscopy and 
additionally performed in total 3 samples on 3 consecutive stools with the same 
iFOBT used in our study.29 In complete agreement with our study, although not 
performed in a screening population, the authors concluded that a cut-off value of 
75ng/ml would be most efficient. 
Therefore we proposed that a cut-off value below 100ng/ml should be feasible and 
acceptable in screening programmes in most western European countries, assuming 
resources and colonoscopy capacity are sufficient. If resources and capacity are 
insufficient also cut-off values above 100ng/ml, up to 200ng/ml, will result in quite 
good performance. Up to 200ng/ml colorectal cancer will rarely be missed compared 
with 100ng/ml. Higher cut-off values result in a decreased detection rate, but also in 
a decreased number needed to scope; i.e. less patients have to undergo a colonoscopy 
to detect one patient with colorectal cancer. 
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Chapter 6. Quality control
Quality control is an important issue in screening and in the presented study the 
focus was on the iFOBT as the most promising test to be implemented for nationwide 
screening. During the inclusion of subjects in the randomised controlled FOBT trial7 
it was observed, that subjects who were late returning their iFOBT after sampling had 
a lower test positivity rate compared with subjects who returned their test more 
promptly. Which might be attributable to prolonged exposure to higher temperatures 
than refrigerator level, during which time haemoglobin in the sample solution 
degraded.30 This prompted the study in this chapter, which has been provisionally 
accepted with minor revisions by the International Journal of Cancer.31
Question 11. Is stability of haemoglobin in the faecal sample of the 
iFOBT sufficient?
The number of late responders was relatively low and the difference could also be 
accountable to selection bias. Therefore, in addition to a pragmatic study, positive 
samples were retested over a period of 10-14 days, during which time 
the samples were stored at room temperature. Evidence was provided, that delay 
between faecal sampling and receipt at the laboratory resulted in lower detection 
rates. This evidence was consistent both in the pragmatic study with delayed tests 
and the laboratory simulation with retests. Especially minor and advanced adenomas, 
but also colorectal cancer can be missed with relatively limited delay. Quite possibly 
the problem can be solved by using a buffer in the sample tube which makes faecal 
haemoglobin less sensitive to higher temperatures. It was proposed that improvement 
of the buffer should be feasible.30
Discussion
To screen or not to screen?
‘To screen or not to screen?’ is fundamentally the question which covers all questions 
in this thesis. In short the answer is: Yes, screening can begin in the Netherlands. With 
the research in this thesis all important problems, threatening the implementation 
of colorectal cancer screening in the Netherlands, are practically eliminated. It was 
concluded that the Dutch in general are willing-to-be-screened and will participate in 
colorectal cancer screening with FOBT. Evidence is provided that the best test for 
colorectal cancer screening is the immunochemical FOBT. The immunochemical FOBT 
performs better than the classic guaiac FOBT, is more cost-effective, will probably 
result in significantly more effect on colorectal cancer mortality, results in less 
colorectal cancer patients needing surgery and the cut-off value can be changed to 
fit feasibility and acceptability. False negatives can occur due to delay in the return 
of faecal samples. However the proportion of tests returned late is limited and until 
an improved haemoglobin stabilizer is available, this problem can be controlled by 
sending a new test if the test is returned late and is negative. 
The only remaining threat to the implementation of colorectal cancer screening 
with immunochemical FOBT is the capacity for colonoscopy. In addition to the extra 
screening colonoscopies, according to the guidelines for surveillance after polypectomy 
all patients with adenomas should receive regular follow-up colonoscopies. On the 
other hand it can be calculated that the extra screening colonoscopies should be 
temporary, because these can mostly be counterbalanced by a decrease in clinical 
colonoscopies. Furthermore many of the surveillance colonoscopies, especially in 
patients with only 1 or 2 minor adenomas, will probably be unwarranted because 
of the limited yield of surveillance. Surveillance of patients with adenomas with the 
immunochemical FOBT might be considered as an alternative for colonoscopic 
surveillance. The efficiency of this hypothesis can quite easily be researched, if colorectal 
cancer screening and surveillance are implemented in a joined protocol and registered 
and monitored up to research standards.
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Colorectal cancer screening with immunochemical FOBT is, like many other forms of 
population-based screening, not a one time test. It is a strategy of usually annually or 
biannually repeated tests, until a positive test occurs, the subject dies or reaches the 
predefined maximum age limit or is generally lost to follow-up. New research on 
colorectal cancer screening should focus on the optimisation of the screening strategy 
and surveillance protocols: e.g. more consecutive samples, different cut-off values for 
(to be defined) risk groups and timing between samples. 
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ummary
In this thesis the aim was to study advantages and disadvantages of implementation 
of colorectal cancer screening in the Netherlands. The 11 questions were based on 
screening guidelines by Wilson & Jungner and issues raised by stakeholders in public 
health. 
In a European study about awareness of colorectal cancer the Dutch scored least of 
all participating countries. In chapter 1 study 1 of this thesis data from a questionnaire 
sent to subjects in the age-range for colorectal cancer screening (50-75 years), 
containing items about awareness of colorectal cancer and screening, confirmed 
that awareness of colorectal cancer and screening is low. In study 2 after informing 
subjects about colorectal cancer and screening, a second different questionnaire with 
awareness items was sent to all subjects invited to be screened. Almost all considered 
the written information clear and readable, but awareness remained relatively low. 
In study 1 in the first questionnaire subjects were also asked about willing-to- 
be-screened for colorectal cancer and 74% were. Willingness-to-be-screened can be 
expected to be relevantly lower in non- responders, which was confirmed in study 2 
performed after informing and inviting subjects for screening: only 6% of the subjects 
not participating in screening, did fill-out the questionnaire. 
One year after the first questionnaire was sent in study 1, all subjects still eligible 
were invited for screening with an immunochemical faecal occult blood test (iFOBT). 
Participation was 90% in subjects who previously reported willing-to-be-screened. 
Participation was lower in subjects who previously reported not or less willing-to-be-
screened, but with 76% still quite high and higher than average in the screening 
naïve population in the same region. Participation was only much lower than average 
in non-responders to the questionnaire, but with 41% far from zero. Overall the Dutch 
in general are willing-to-be-screened and willing subjects will usually participate in 
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colorectal cancer screening with FOBT. However to increase participation in 
unresponsive subjects will probably prove difficult. Informing about colorectal 
cancer and screening will hardly improve awareness and increased awareness is not 
associated with higher participation. 
In contrast to most other types of cancer, for colorectal cancer many possible 
alternative screening tests exist. In chapter 2, study 3, after an overview of the most 
promising alternatives for population-based colorectal cancer screening, we concluded 
that FOBTs still are the best screening alternatives for colorectal cancer screening. 
Also in this chapter in study 4, data from a randomised controlled trial were presented 
comparing the classic guaiac based FOBT (gFOBT) and the newer immunochemical 
FOBT (iFOBT) in population-based screening. A representative Dutch population of 
over 20,000 subjects 50 to 75 years of age were invited for colorectal cancer 
screening and randomly assigned either a gFOBT or an iFOBT. Both screening 
participation and detection of colorectal cancer and adenomas were substantially 
±2.5 times higher in the iFOBT group compared with the gFOBT group while relatively 
the same number of patients had to undergo colonoscopy. Finally, with the aid of 
a new outcome measure presented in this thesis, the population-sensitivity-impact 
(i.e. participation*colonoscopy adherence*sensitivity), it was concluded that iFOBT 
should be preferred over all other alternatives in population-based screening. 
Only for the gFOBT direct evidence exists, that colorectal cancer mortality can be 
decreased by screening. Because iFOBT and gFOBT both test for the same biomarker 
(i.e. blood), the decrease in mortality for the iFOBT can expected to be at least similar to 
gFOBT. Consensus is that colorectal cancer mortality can be decreased, if screening 
(screened) more often results in earlier staged colorectal cancer compared with 
colorectal cancer detected due to symptoms or complaints (not-screened). In chapter 
3, study 5, colorectal cancer was more often detected in early stages in screened 
colorectal cancer patients from the same region and diagnosed in the same period 
compared with not-screened colorectal cancer patients. This was not observed for the 
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gFOBT, only for the iFOBT. Furthermore treatment of colorectal cancer in screened 
patients could frequently be confined to colonoscopy (27%), compared with hardly 
ever in not-screened patients(3%). 
Cost-effectiveness studies of colorectal cancer screening have been performed, 
but these were limited by differences in inclusion criteria, follow-up periods, 
geographical regions and erroneous assumptions. Even with sensitivity analyses the 
limitations could influence the conclusions significantly. In chapter 4, study 6, data of 
the randomised controlled trial from chapter 2 were completed with Dutch cancer 
registry data to compare the cost-effectiveness of one round gFOBT and iFOBT 
screening to no screening. In a Markov model with first and second order Monte Carlo 
simulation iFOBT screening was cost-effective compared with both gFOBT screening 
and no screening and it dominated both, i.e. costs were saved and life years were 
gained. For the individual the risk of colorectal cancer is rare and therefore incremental 
gains in costs and life years are limited per subject invited to perform an iFOBT, but 
quite considerable on a population level. Generally these data confirmed previous 
studies, that although the gains were relatively limited, the Netherlands will gain from 
iFOBT screening. 
The iFOBT, OC-Sensor®, is quantitative, enabling the choice of a cut-off in agreement 
with acceptability and feasibility. In the randomised study all participants with an 
iFOBT value ≥50ng/ml were invited for colonoscopy. In chapter 5, study 7, data were 
presented, that below the standard 100ng/ml cut-off, the detection rate increased and 
specificity decreased but remained very acceptable. It was concluded that a cut-off 
<100ng/ml should be feasible and probably optimal at 75ng/ml. However if resources 
and capacity are insufficient also a cut-off up to 200ng/ml has quite good performance: 
colorectal cancer will rarely be missed compared with 75ng/ml and much less patients 
will have to undergo a colonoscopy to detect one patient with colorectal cancer. 
In the last chapter of this thesis the stability of haemoglobin in the iFOBT sample 
was investigated. This study was initiated on the observation, that iFOBTs returned 
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relatively late after sampling had a lower positivity rate compared with more prompt-
ly returned samples. Delayed return of the faecal sample resulted in lower detection 
rates of especially minor and advanced adenomas. Late responders were relatively 
rare and selection bias could not be completely ruled out. Therefore positive samples 
were also retested over a period of 10-14 days and stored at room temperature. 
The retests confirmed the pragmatic study and showed that colorectal cancer 
can be missed as well with relatively limited delay. Possibly a different haemoglobin 
stabilizing buffer in the sample tube, less sensitive to higher temperatures, might 
solve the problem. 
To screen or not to screen? The title of this thesis is answered positive. In this thesis 
threats to implementation of colorectal cancer screening in the Netherlands 
are eliminated, except the colonoscopy capacity for screening and surveillance 
after polypectomy. New research on colorectal cancer screening should focus on 
the optimisation of the screening strategy and surveillance protocols: e.g. more 
consecutive samples, different cut-off values for (to be defined) risk groups and the 
timing of intervals between samples.
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amenvatting
Dit proefschrift heeft als doel voordelen en nadelen van darmkankerscreening in 
Nederland te bestuderen. Op basis van de criteria van Wilson & Jungner en vragen 
van verschillende belanghebbenden in de volksgezondheid werden 11 vragen 
geformuleerd.
In een Europese studie naar kennis over darmkanker scoorden Nederlanders het 
laagst van alle deelnemende landen. In hoofdstuk 1, studie 1, in dit proefschrift wordt, 
met een vragenlijst voor personen in de leeftijdsrange voor darmkankerscreening 
(50-75 jaar), bevestigd, dat kennis over darmkanker en screening laag is. In studie 
2, na voorlichting over darmkanker en screening, werd een tweede vragenlijst 
met kennisvragen gestuurd naar alle personen, die waren uitgenodigd voor darm-
kankerscreening. Bijna iedereen vond de informatie leesbaar en duidelijk, maar het 
voorlichtingseffect was vrij laag. 
In studie 1 in de eerste vragenlijst werd ook gevraagd naar deelnamebereidheid: 74% 
van de respondenten gaf aan te willen deelnemen aan darmkankerscreening met 
een ontlastingtest. Het is aannemelijk, dat deelnamebereidheid lager is onder niet- 
respondenten. Inderdaad wordt dat bevestigd in studie 2: van de genodigden voor 
screening, die niet deelnamen, stuurde slechts 6% de vragenlijst terug. 
In studie 1 werden, één jaar na versturen van de eerste vragenlijst, alle nog voor 
screening in aanmerking komende personen (ook oorspronkelijk niet-respondenten) 
uitgenodigd voor screening met een immunochemische fecaal occult bloedtest 
(iFOBT). Van de mensen die hadden aangegeven deelnamebereid te zijn, nam 90% 
inderdaad deel. Van de mensen, die hadden gerapporteerd niet of minder deelname-
bereid te zijn, was de deelname lager, maar met 76% hoger dan gemiddeld in de 
compleet screeningnaïeve populatie in hetzelfde gebied (68%). De deelname was 
alleen veel lager dan gemiddeld in de niet-respondenten, maar zeker niet nihil (41%). 
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De algemene conclusie was dat Nederlanders veelal deelnamebereid zijn en dat 
deelnamebereide personen over het algemeen ook deelnemen aan screening met 
FOBT. Echter, het verhogen van de deelname van personen, die screening vooralsnog 
onverschillig lijkt te laten, zal moeilijk blijken. Het effect van voorlichting over 
darmkankerscreening lijkt laag en kennis van darmkanker en screening was niet 
geassocieerd met hogere deelname. 
In vergelijk met de meeste andere soorten kanker, zijn er veel alternatieve screenings-
testen voor darmkanker beschikbaar. In hoofdstuk 2, studie 3, werd een overzicht 
gegeven van de beste alternatieven en hun waarde in populatie screening. In hoofd-
stuk 2, studie 4, werd een gerandomiseerde gecontroleerde studie gepresenteerd, 
waarin de klassieke guaiac FOBT (gFOBT) werd vergeleken met de nieuwere immuno-
chemische FOBT (iFOBT) in een screeningspopulatie. Een representatieve random 
steekproef van ruim 20.000 Nederlanders tussen 50 en 75 jaar werd random uitgenodigd 
voor een gFOBT of een iFOBT. Zowel deelname als opsporing van darmkanker en 
adenomen was significant ±2,5 keer hoger in de iFOBT-groep dan in de gFOBT-groep 
waarvoor relatief evenveel mensen een coloscopie ondergingen. Met een nieuw ontwik-
kelde uitkomstmaat, de populatie-sensitiviteits-impact (participatie * coloscopie-
adherentie * sensitiviteit), kon worden geconcludeerd, dat de iFOBT de voorkeur heeft 
in screening in vergelijk met de andere besproken alternatieven. 
Alleen voor gFOBT is daling van darmkankermortaliteit door screening aangetoond. 
Omdat met iFOBT en gFOBT beide voor dezelfde ‘biomarker’ (bloed) wordt getest, wordt 
minimaal dezelfde mortaliteitdaling voor iFOBT als voor gFOBT aannemelijk geacht. 
Volgens de heersende consensus kan darmkankermortaliteit alleen verminderen, als 
screening (‘gescreend’) vaker leidt tot ontdekking van darmkanker in een vroeger 
stadium in vergelijk met darmkanker ontdekt op basis van symptomen of klachten 
(‘ongescreend’). In hoofdstuk 3, studie 5, werd in ongescreende patiënten, uit hetzelfde 
gebied en gediagnosticeerd tijdens dezelfde periode, darmkanker minder vaak ontdekt 
~161~
Samenvatting
in vroegere stadia, vergeleken met gescreende darmkankerpatiënten. Dit werd niet 
waargenomen voor gFOBT, maar slechts voor iFOBT. Daarnaast kon behandeling van 
darmkanker vaak tot coloscopie worden beperkt in gescreende patiënten (27%) en 
nauwelijks in ongescreende patiënten (3%).
Kosteneffectiviteitstudies over darmkankerscreening zijn eerder uitgevoerd, maar 
werden gekenmerkt door verschillen in inclusiecriteria, follow-upduur, geografische 
gebieden en onjuiste veronderstellingen. Zelfs met de gebruikelijke gevoeligheids-
analyses kunnen deze beperkingen de conclusies hebben beïnvloed. In hoofdstuk 4, 
studie 6, werden data van de gerandomiseerde gecontroleerde studie uit hoofdstuk 2 
gecompleteerd met data van de kankerregistratie, om de kosteneffectiviteit van één ronde 
gFOBT of iFOBT screening te vergelijken met géén screening. In een Markov model 
met eerste en tweede orde Monte Carlo simulatie domineerde iFOBT screening zowel 
gFOBT als géén screening; d.w.z. kosten werden bespaard en levensjaren gewonnen. 
Individueel is de kans op darmkanker laag en daarom is de winst per uitgenodigde 
persoon voor iFOBT screening beperkt, maar aanzienlijk op bevolkingsniveau. De 
algemene conclusie was, dat screening met iFOBT lonend kan zijn in Nederland.
De iFOBT, OC-Sensor®, is kwantitatief, waardoor in overeenstemming met aanvaard-
baarheid en haalbaarheid een afkappunt kan worden gekozen. In de gerandomiseerde 
gecontroleerde studie werden alle deelnemers met een iFOBT ≥50ng/ml uitgenodigd 
voor coloscopie. In hoofdstuk 5, studie 7, werden beneden 100ng/ml meer patiënten 
met darmkanker en gevorderde adenomen ontdekt. De specificiteit was lager, 
maar nog zeer aanvaardbaar. De conclusie was, dat een afkappunt onder de 100ng/
ml haalbaar is en waarschijnlijk optimaal bij 75 ng/ml. Indien echter de financiën of 
capaciteit ontoereikend zijn voor de extra coloscopieën, is een afkappunt tot 200ng/
ml ook nog acceptabel: vergeleken met 75ng/ml zal darmkanker zelden gemist 
worden en minder patiënten hoeven een coloscopie te ondergaan om één patiënt 
met darmkanker te ontdekken. 
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In het laatste hoofdstuk van dit proefschrift werd de stabiliteit van haemoglobine in 
het ontlastingsmonster van de iFOBT onderzocht. De aanleiding was dat een lager 
percentage testen positief waren, wanneer ontlastingsmonsters relatief laat werden 
teruggestuurd. Dit leidde ook tot een lagere detectie van adenomen. Het aantal laat 
teruggestuurde monsters was beperkt en selectiebias kon niet worden uitgesloten. 
Daarom werden positieve iFOBTs over een periode van 10-14 dagen een aantal keer 
getest en bij kamertemperatuur bewaard. Hiermee werd het pragmatische studie-
deel bevestigd en concludeerden we dat zelfs darmkanker kan worden gemist door 
laat teruggestuurde iFOBT monsters. Verbetering van de buffer zou een oplossing 
voor dit probleem kunnen zijn.
Screenen of niet screenen? De titel van dit proefschrift wordt met ja beantwoord. 
Behalve de coloscopiecapaciteit voor screening en surveillance na poliepectomie, 
zijn in dit proefschrift de belangrijkste belemmeringen voor de implementatie van 
screening op darmkanker in Nederland ontkracht. Nieuw onderzoek zou gericht 
moeten zijn op de optimalisatie van strategieën voor screening en surveillance: b.v. 
aantal monsters, afkappunten op maat voor risicogroepen en timing van intervallen 
tussen screeningsrondes.
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Ik ben er niet zo goed in om te laten weten hoe dankbaar ik iedereen ben, in het 
algemeen en in het bijzonder voor de totstandkoming van dit proefschrift. Hoewel dat 
misschien niet altijd zo lijkt als je me hoort praten, ben ik meer een man van daden 
dan van woorden. Ik hoop en denk, dat iedereen die me na staat dat wel van mij 
weet. Ik wil ook niemand te kort doen met dit dankwoord, maar ik zal allicht achteraf 
tot mijn schande moeten bekennen dat ik iemand vergeten ben.
Professor Jansen, beste Jan, moeilijk om een loftrompet te blazen voor een man als 
jij. Als je eenmaal begint, waar moet je dan stoppen? Ik zal het daarom maar heel kort 
houden. Ik hou van de extreme nuchterheid waarmee je in het leven staat. Ik heb 
respect voor wat jij allemaal weet en het gemak waarmee je van die kennis gebruik 
maakt. Ik hoop dat ik daar nog lang van mag genieten, hoewel je pensioengerechtigde 
leeftijd dat mogelijk enigszins in de weg zal staan.
Professor Verbeek, beste André, wij gaan al ver terug samen. Vanaf het moment dat 
ik mijn (vervangende) dienstplicht kwam vervullen bij de afdeling epidemiologie, heb 
jij al aan mij getrokken om mijn gestaakte studie te hervatten. Niet vergelijkbaar met 
de beruchte senator Cato, maar uiteindelijk is het je wel gelukt en ben ik nu zelfs je 
promovendus. Ik kan moeilijk uitdrukken wat je vertrouwen in mij voor me betekent, 
en ik hoop dat we in de toekomst nog veel goed werk samen kunnen doen.
Doctor Adang, beste Eddy, ik ben blij dat jij toch nog mijn copromotor bent. Al in de 
tijd dat ik nog min of meer voor de afdeling HTA werkte als datamanager, konden we 
het goed vinden. Toen ik mijn studie weer oppakte en startte met mijn promotietraject 
hebben we onze samenwerking geïntensiveerd en dat heeft tot een mooi eindproduct 
geleid. Ik hoop dat ik nog veel mag genieten van je joviale ‘zuidelijke’ karakter en je 
gedegen wetenschappelijke visie.
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Doctor Laheij, beste Robert, al weer jaren geleden mocht ik jouw paranimf zijn. 
Ik weet nog wel dat ik me zo trots voelde als een broer. Nu ben jij mijn copromotor en 
dat hadden we allebei toentertijd nog niet gedacht. Ik in ieder geval niet en ik ben 
eigenlijk nog steeds verbaasd, dat je me zo ver gekregen hebt om mijn studie op te 
pakken. Maar zo zijn er meer mensen die door jouw overredingskracht ineens een 
heel andere richting zijn ingeslagen. Er zijn niet veel werkgevers die een werknemer 
zoveel ruimte geven zichzelf te ontwikkelen. 
Martijn, naaste collega en goede vriend, ik kan me nog precies herinneren hoe jij bij 
ons kwam. Je wilde een gladde jongen worden met een mooie leaseauto. Ook jij was 
uiteindelijk slachtoffer van de TGV Laheij, die je meesleurde in een heel andere richting 
die volgens mij ook veel beter bij je past. Sinds die TGV alweer een tijdje geleden uitge-
rangeerd is, heb jij je pas echt ontplooid. Ik ben trots dat ook ik je heb mogen helpen om 
zo ver te komen en ondertussen is de leerling de meester al voorbij gegroeid. Jij bent nu 
een bron van inspiratie voor mij en een belangrijke steun en toeverlaat, zowel persoon-
lijk als wetenschappelijk. Je humor ontwikkelt zich nog steeds en ik kan er geen genoeg 
van krijgen: hoe flauwer, hoe beter! Dank je wel dat je mijn paranimf wil zijn en dat ik dat 
ook voor jou mag zijn. Overigens jammer dat we er niet meer toe zijn gekomen om de hit 
‘Calibration’ en al die andere poephits die we hadden verzonnen op cd te zetten. 
Lieke, ex-naaste collega en vriendin. Jij bent een van de weinigen die zich uiteindelijk 
niet liet stuiten door de TGV Laheij. De uitdrukking met vallen en opstaan heb jij zo 
ongeveer uitgevonden, zowel letterlijk als figuurlijk. Vooral vind ik het mooi om 
te zien, dat je daardoor alleen maar gemotiveerd wordt om weer iets nieuws te 
gaan aanpakken. Jouw durf en vertrouwen in jezelf, ervaar ik ook voor mezelf als 
zeer motiverend. Je nuchterheid heeft er meer dan eens toe geleid, dat ik mijn 
eigen gedrag en meningen heb moeten relativeren. Je humor is op een prettige 
manier bijtend. Alleen je ochtendhumeur kon ik missen, hoewel Martijn en ik er 
ook wel smakelijk om hebben kunnen lachen toen wij naar Rotterdam vertrokken. 
Dank je wel dat ik je paranimf mocht zijn en dat jij dat ook voor mij wilt zijn.
Dankwoord
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Ik wil natuurlijk ook de afdeling MDL, inclusief het lab, niet vergeten. Ik ben zelf niet 
zo graag in het lab bezig, maar ben wel blij met de prettige samenwerking en sfeer 
waarin ik alle meer dan 10.000 poeptesten heb mogen uitvoeren samen met Martijn. 
Ook op de afdeling MDL is de sfeer over het algemeen goed en motiverend. Ik werk 
graag met jullie allen samen en hoop dat ook in de toekomst nog intensief te mogen 
doen. Graag wil ik de endoscopisten specifiek bedanken, die al de extra screenings-
coloscopieën mochten doen, die onze poeptesten hen bezorgden. Maria van Vugt 
verdient ook speciale vermelding voor alle patiënten die zij heeft ontvangen en heeft 
voorgelicht over wat er stond te gebeuren nu ze een positieve poeptest hadden.
Alle deelnemers aan het bevolkingsonderzoek wil ik ook bedanken. Niet alleen omdat 
zij er voor gezorgd hebben, dat ik mijn eerste artikel in een gerenommeerd tijdschrift 
op mijn CV mocht bijschrijven. Echter vooral ook omdat een aantal van hen er ons 
toch steeds weer op wist te wijzen dat onze informatie voor meer dan een uitleg 
vatbaar was, wat regelmatig leidde tot soms bijna aandoenlijke maar vooral erg 
komische methoden om de screening en vooral de poeptesten mis te laten gaan.
De samenwerking met onze onderzoekspartners in Amsterdam (AMC en IKA) en 
Nijmegen (IKO) verliep niet altijd soepel, maar ook daar heb ik veel van geleerd. Anne 
jou wil ik bedanken voor de klus die we samen toch maar mooi hebben geklaard. Ik 
vond het heel mooi om te zien hoe jij je promotie hebt ervaren: je stond zo te stralen. 
Ik kan alleen hopen, dat ik er ook zo van kan genieten.
Ook mijn stagiaires, waarvan ik Anoek, Marjan en Mieke met name wil noemen, hebben 
mij geholpen kritisch naar mezelf te kijken. Ze hebben mij laten zien, dat ik het leuk 
vind om andere mensen iets te mogen leren. In de toekomst hoop ik meer mensen zo 
te mogen helpen.
Professor van der Wilt, beste Gert-Jan, jou wil ik specifiek bedanken voor de mogelijk-
heden, die je me hebt gegeven om me te ontplooien als student en wetenschapper. 
Zonder jouw persoonlijke inzet was het allemaal een stuk moeizamer verlopen. Jouw 
steun is een inspiratie voor me: zonder de kwaliteit uit het oog te verliezen, gaf jij me 
de flexibiliteit die ik nodig had.
Dankwoord
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Dankwoord
Rob Reuzel, vriend en collega, wil ik ook specifiek benoemen. Ik heb in de tijd dat we 
elkaar kennen steeds weer verbaasd mogen staan, hoe makkelijk jij je vak beoefent. 
Ik hoop dat ik dat van je mag leren: al is het maar een beetje. Ook hoop ik dat we in 
de toekomst weer wat meer tijd hebben om ook gewoon weer vrienden te zijn, want 
dat is er de afgelopen jaren wat bij ingeschoten.
Pa en ma van Rossum, daar staat jullie tweede zoon dan toch. Met het nodige vallen 
en opstaan, wat jullie wel van me gewend zijn. Jullie hebben me altijd maar mijn gang 
laten gaan. Dat klinkt misschien niet direct positief, maar er spreek wel jullie onvoor-
waardelijke vertrouwen in mij uit: “het komt wel goed met onze jongen.” Mijn promotie 
is maar een van de blijken daarvan; toch een mooie kroon, ook op jullie werk.
Mijn broer en broertje, Roland en Norman, enerzijds een verschil als dag en nacht en 
anderzijds weer exact gelijk in jullie vertrouwen in mij. Net als pa en ma stralen jullie 
altijd een onvoorwaardelijk vertrouwen uit dat ik het wel zal redden ongeacht wat ik 
heb gedaan of ga doen. Waar ik dat aan verdien is me niet helemaal duidelijk, maar 
daardoor heb ik er zelf ook vertrouwen in.
Ria en Henk, beste schoonma en -pa, ook jullie wil ik bedanken voor al jullie steun, 
interesse en vertrouwen. Maar natuurlijk als allerbelangrijkste voor jullie prachtige 
dochter, mijn vrouw. Zonder haar ben ik niet veel waard en dus maken jullie mij veel 
waard.
Gaby en Eric, in nood leer je je vrienden kennen: dat hebben we over en weer in de 
loop der jaren mogen ervaren. Ik hoop dat we nog heel lang vrienden voor elkaar 
mogen zijn. Jacqueline en Teus, nieuw in mijn leven gekomen via Marjan, maar samen 
met jullie kinderen hebben jullie ondertussen ook een speciaal plekje in mijn hart. 
Het spijt me dat ik niet alle familieleden, vrienden en kennissen kan noemen, die mijn 
leven zo aangenaam maken. Ik prijs me vooral gelukkig, dat ik me moet realiseren dat 
er teveel van jullie zijn om op te noemen.
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Bente, kleine ‘schoepie’, jij bent het zonnetje dat altijd in mijn hart schijnt. Het beste 
van Marjan en mij en zoveel mooier dan de som der delen. Voor jou kan ik de hele 
wereld aan. Ook al vind je jezelf al een hele grote meid, nu ben je nog een beetje te 
klein om echt te beseffen wat dit voor papa betekent. Ik weet niet wat je er van zult 
vinden als je het wel kunt begrijpen: ik ben in ieder geval erg trots en verschrikkelijk 
blij dat jij er ook bij bent.
Marjan ik weet niet hoe ik je moet bedanken. Ik ben geen poëet en woorden schieten 
dan al snel te kort. Ik vind het ongelofelijk hoe jij me altijd weer weet te steunen ook 
al is het de afgelopen jaren soms moeilijk voor je geweest. Jouw weerbaarheid is echt 
onvoorstelbaar en daar heb ik voordeel van en neem ik voorbeeld aan. Ik wil uit de 
grond van mijn hart zeggen, dat ik enorm veel van je hou en dat ik het zonder jou nooit 
had gered.
Dankwoord
I wish I had the voice of Homer
To sing of rectal carcinoma,
Which kills a lot more chaps, in fact,
Than were bumped off when Troy was sacked.
Yet, thanks to modern surgeon’s skills,
It can be killed before it kills
Upon a scientific basis
In nineteen out of twenty cases.
I noticed I was passing blood
(Only a few drops, not a flood).
So pausing on my homeward way
From Tallahassee to Bombay
I asked a doctor, now my friend,
To peer into my hinder end,
To prove or to disprove the rumour
That I had a malignant tumour.
They pumped in BaS04.
Till I could really stand no more,
And, when sufficient had been pressed in,
They photographed my large intestine,
In order to decide the issue
They next scraped out some bits of tissue.
(Before they did so, some good pal
Had knocked me out with pentothal,
Whose action is extremely quick,
And does not leave me feeling sick.)
The microscope returned the answer
That I had certainly got cancer,
So I was wheeled into the theatre
Where holes were made to make me better.
One set is in my perineurn
Where I can feel, but ca not yet see ‘em.
Another made me like a kipper
Or female prey of Jack the Ripper,
Through this incision, I do not doubt,
The neoplasm was taken out,
Along with colon, and lymph nodes
ancer’s a Funny Thing
Where cancer cells might find abodes.
A third much smaller hole is meant
To function as a ventral vent:
So now I am like two-faced Janus
The only* god who sees his anus.
*In India there are several more
With extra faces, up to four,
But both in Brahma and in Shiva
I own myself an unbeliever.
I’ll swear, without the risk of perjury,
It was a snappy bit of surgery.
My rectum is a serious loss to me,
But I’ve a very neat colostomy,
And hope, as soon as I am able,
To make it keep a fixed time-table.
So do not wait for aches and pains
To have a surgeon mend your drains;
If he says “cancer” you’re a dunce
Unless you have it out at once,
For if you wait it’s sure to swell,
And may have progeny as well.
My final word, before I’m done,
Is “Cancer can be rather fun”.
Thanks to the nurses and Nye Bevan
The NHS is quite like heaven
Provided one confronts the tumour
With a sufficient sense of humour.
I know that cancer often kills,
But so do cars and sleeping pills;
And it can hurt one till one sweats,
So can bad teeth and unpaid debts.
A spot of laughter, I am sure,
Often accelerates one’s cure;
So let us patients do our bit
To help the surgeons make us fit.
JBS Haldane, 1964
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